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General Introduction
The German pathologist Siegfried Oberndorfer was in 1907 the first to describe a neu-
roendocrine tumor (NET) in a patient with a tumor in the small intestine and named this 
a “Karzinoide tumor” or carcinoid (1). Although the World Health Organization (WHO) 
has	 replaced	 the	 term	carcinoid	 in	 the	classification	 for	 this	 type	of	 tumor	 (2),	 the	 term	
carcinoid is still frequently used for NETs of the small intestine and the lungs in particular. 
NETs	can	arise	from	neuroendocrine	cells,	which	are	present	throughout	the	whole	body.	
Therefore,	these	tumors	can	develop	anywhere	in	the	body.	NETs	are	a	rare	type	of	cancer.	
The most frequent primary locations are in the gastrointestinal tract and in the lungs (3). 
A commonly used classification is based on their embryonic origin (Figure 1). Foregut 
tumors	 are	 tumors	 from	 the	 respiratory	 tract,	 stomach,	 esophagus,	 proximal	duodenum,	
thymus	and	pancreas.	Midgut	tumors	arise	from	the	distal	duodenum,	small	bowel,	cecum	
(+	appendix),	ascending	colon	and	proximal	2/3	of	the	transverse	colon.	Hindgut	tumors	
originate	from	the	distal	1/3	of	the	transverse	colon,	descending	colon,	sigmoid	and	rec-
tum. Pancreatic NETs are tumors arising from the foregut and they are frequently named 
after	the	hormone	they	produce	in	excess.	
Figure 1. Classification	of	NETs	based	according	to	their	embryonic	origin
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General introduction 
1Neuroendocrine	tumor	cells	have	in	common	that	the	majority	express	somatostatin	recep-
tors on their cell membranes. These receptors are targets for endogenous somatostatin and 
its synthetic analogs. Somatostatin analogs (SSA) are used for symptom control and tumor 
growth	inhibition	(4,5).	Radiolabeled	somatostatin	analogs	can	be	used	for	 imaging	and	
peptide	 receptor	 radionuclide	 therapy	 (PRRT)	 (6,7).	The	 cells	 that	 produce	 endogenous	
somatostatin	are	located	throughout	the	whole	body,	but	especially	in	the	gastrointestinal	
tract.	 In	 the	gastrointestinal	 tract,	 somatostatin	can	 inhibit	different	gastrointestinal	pro-
cesses	 (8).	The	 somatostatin	 receptors	 are	G	protein-coupled	 receptors.	Currently,	 there	
are five known subtypes of this receptor (9). The different commercially available soma-
tostatin analogs have a different affinity for the five subtypes of the receptor. It is known 
that	neuroendocrine	tumor	cells	express	especially	the	high-affinity	subtype	2(a)	receptors	
on	their	surface.	After	binding	of	the	somatostatin	analog	to	the	receptor,	the	peptide-re-
ceptor	complex	internalizes	in	the	cell.	After	internalization,	the	receptor	recycles	to	the	
cell membrane and is again available for peptide binding (Figure 2). With this process of 
internalization,	high	concentrations	of	radiolabeled	somatostatin	analogs	can	enter	the	cell	
and this mechanism is used for receptor imaging and PRRT. 
Figure 2. Internalization of radiolabeled somatostatin analogs
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Epidemiology
Neuroendocrine tumors are a rare type of cancer. The incidence of NETs in The Nether-
lands	was	4.9/100,000	in	2010.	Over	the	past	decades,	the	incidence	has	been	increasing.	
In	1990,	the	incidence	of	NETs	in	the	Netherlands	was	2.1/100,000	(10).	Tumor	grading	
depends	on	the	expression	of	the	Ki67	antigen,	which	can	be	demonstrated	in	tumor	cells	
using	the	MIB-1	antibody	(see	later).	WHO	grade	1-2	gastrointestinal	tumors	(Ki67	index	
<	20%)	are	most	frequently	 localized	in	 the	appendix	and	small	bowel,	followed	by	the	
colon,	rectum	and	pancreas.	In	10-13%	of	NET	patients,	no	primary	tumor	can	be	found	
with	 extensive	 diagnostic	work-up	 (10,11).	However,	 after	 the	 introduction	 of	 the	 new	
Gallium-68	labeled	somatostatin	analogs	for	PET	imaging,	a	primary	tumor	localization	
could	be	found	in	more	than	half	of	these	patients	(12).	Unfortunately,	the	majority	of	NET	
patients	have	metastatic	disease	at	 the	 time	of	diagnosis.	At	 that	point,	curative	 therapy	
is	 generally	 not	 feasible	 anymore,	 since	 the	main	 curative	 option	 is	 surgery.	Metastatic	
disease	is	demonstrated	at	diagnosis	in	24%	of	WHO	grade	1,	35%	of	grade	2	and	61%	
of grade 3 NETs (10). The five-year survival rate is higher for localized and low-grade 
(grade	1-2)	NETs,	then	for	metastasized	or	high-grade	tumors.	After	the	recent	introduc-
tion	of	new	therapeutic	options,	the	five-year	survival	rate	for	all	patients	has	significantly	
improved,	 particularly	 for	 patients	with	metastatic	 disease.	 In	 1990-2000,	 the	 five-year	
survival	rate	was	30%,	this	has	improved	to	47%	between	2001	and	2010	(10).	
Pathologic Classification
Currently,	neuroendocrine	tumors	are	staged	and	graded	according	to	the	WHO	classifi-
cation (2). This system is based on mitotic count and proliferative activity (Ki67) (Table 
1). The WHO presented the most recent classification of NETs of the digestive system in 
2010. Grade 3 tumors are currently named neuroendocrine carcinomas. Grade 3 tumors 
can be divided in large cell neuroendocrine carcinomas and small cell neuroendocrine 
carcinomas. The behavior of these grade 3 carcinomas is much more aggressive than that 
of	low-grade	tumors	and	survival	rates	are	lower.	Recently,	a	new	tumor	category	has	been	
introduced: grade 3 neuroendocrine tumors. These will be included in the new WHO 2017 
classification. 
Grade 1 Grade 2 Grade 3
Ki67 index ≤2 3-20 >20
Mitotic count (MC) <2 2-20 >20
Table 1. 2010 WHO classification of neuroendocrine tumors
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1The ENETS and the AJCC have designed a classification system for gastrointestinal NETs 
based	on	size	and	 invasion	of	 the	primary	 tumor	 (T),	 lymph	node	 involvement	 (N)	and	
distant	metastases	(M)	(Table	2).	Besides,	different	classifications	are	defined	according	to	
the primary localization of the tumor (13). 
Clinical Symptoms
The presence and severity of clinical symptoms depends on the primary localization of the 
tumor	and	its	potency	to	produce	hormones.	 In	general,	all	different	 type	of	 tumors	can	
cause	non-specific	symptoms,	such	as	pain,	weight	loss,	fatigue	and	loss	of	appetite.	
Most neuroendocrine tumors of the small bowel are asymptomatic and are found incidentally. 
Sometimes they can induce obstruction or intussusception of the small intestine. If a midgut 
tumor	produces	hormones	the	carcinoid	syndrome	may	develop,	but	this	usually	only	occurs	
in the presence of distant metastases (see later). Colorectal tumors are most often asymptom-
atic	until	they	cause	obstruction,	leading	to	an	altered	stool	pattern	and	gastrointestinal	bleed-
ing.	Usually	these	tumors	don’t	produce	hormones	(14,15).	The	type	of	symptoms	caused	by	
neuroendocrine tumors of the pancreas depends on the type of hormone they produce. Larger 
tumors	of	the	pancreas	may	cause	obstruction	of	bile	ducts	and,	therefore,	jaundice.
Metastatic disease in the liver can cause hepatomegaly and jaundice as well. A mesenter-
ic	mass,	which	is	often	present	in	patients	with	metastatic	small	bowel	NETs,	can	cause	
retraction	of	the	mesentery,	leading	to	venous	congestion,	or	arterial	obstruction	causing	
edema,	or	ischemia	of	the	bowel.	Bone	metastases	may	cause	localized	pain.	These	metas-
tases	are	especially	found	in	the	axial	skeleton.	
Table 2. ENETS/AJCC	TNM	classification	of	neuroendocrine	tumors
ENETS/AJCC Classification criteria GI NETs
Stage I T1 N0 M0
Stage IIa T2 N0 M0
Stage IIb T3 N0 M0
Stage IIIa T4 N0 M0
Stage IIIb Any T N1 M0
Stage IV Any T Any N M1
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Neuroendocrine	tumors	can	produce	up	to	40	different	bioactive	products,	which	can	lead	
to symptoms (16). The liver inactivates most bioactive products if they are transported 
via the portal circulation. Tumors in the digestive tract that bypass the portal circulation 
are	more	likely	to	cause	endocrine	problems.	Therefore,	tumors	of	the	small	bowel	most	
often produce hormonal symptoms when metastases in the liver are present and bioactive 
products can reach the systemic circulation. The hypersecretion of these bioactive products 
can	result	in	a	carcinoid	syndrome.	This	syndrome	includes	different	symptoms,	such	as	
flushing,	diarrhea	and	carcinoid	heart	syndrome	caused	by	fibrosis	of	the	right	sided	heart	
valves.	If	a	patient	presents	with	the	carcinoid	syndrome,	it	is	very	likely	that	a	metasta-
sized NET of the small intestine (or lungs) will be diagnosed (17). 
A small proportion of pancreatic (or lung) NETs are associated with familiar hereditary 
syndromes.	These	syndromes	include:	multiple	endocrine	neoplasia	type	1	(MEN-1),	von	
Hippel	Lindau	syndrome,	neurofibromatosis	type	1	and	tuberous	sclerosis	(18).	
Biochemical Markers
The	most	 frequently	 used	 biomarkers	 for	NETs	 are	 chromogranin	A	 (CgA),	 5-hydroxy	
indole	acetic	acid	(5-HIAA),	and	neuron	specific	enolase	(NSE).	CgA	is	a	protein	that	is	
located	in	the	neurosecretory	vesicles	of	neuroendocrine	tumor	cells	(19,20).	Its	levels	can	
be	elevated	in	the	blood	of	patients	harboring	all	kinds	of	NETs,	but	also	non-producing	
tumors.	An	 elevated	 level	 of	CgA	 is	 associated	with	 a	more	 extensive	 tumor	 load	 and,	
therefore,	also	with	a	worse	prognosis	(21,22).	CgA	can	be	a	very	useful	marker	for	the	fol-
low-up	of	NETs	during	and	after	therapy	(23).	Unfortunately,	CgA	is	a	non-specific	marker	
and it can be elevated in a variety of other conditions. False-positive results are reported 
with	the	use	of	proton	pump	inhibitors,	atrophic	gastritis	and	renal	and	liver	failure.	CgA	
is,	therefore,	not	useful	as	a	diagnostic	screening	tool	for	NETs.
5-HIAA is a metabolite of serotonin and it is a very specific marker for serotonin-produc-
ing tumors. 5-HIAA is mainly used for detection and follow-up of metastatic midgut tu-
mors and the carcinoid syndrome. Since tumors arising from the foregut and hindgut rarely 
produce	serotonin,	this	diagnostic	test	is	not	useful	for	patients	with	these	kinds	of	tumors	
(24).	Healthy	 persons	 excrete	 5-HIAA’s	 as	well	 in	 their	 urine	 and	 the	 reference	 ranges	
differ between persons and between laboratories. This marker can be elevated in different 
malabsorption	 syndromes	 and	with	 some	 diets.	Also,	 the	 ingestion	 of	 large	 amounts	 of	
tryptophan- or serotonin-rich foods and the use of different kind of drugs may increase the 
urinary	excretion	of	5-HIAA.	It	is	therefore	also	difficult	to	use	the	5-HIAA	excretion	as	
a	diagnostic	tool.	Recently,	a	plasma	5-HIAA	assay	was	introduced.	This	single	measure-
ment	of	the	fasting	plasma	5-HIAA	correlates	with	the	24-hour	urinary	5-HIAA	excretion	
in patients with midgut neuroendocrine tumors (25). 
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1NSE is present in the cytoplasm of neuroendocrine cells. It is mainly elevated in patients 
with	high-grade,	or	poorly	differentiated	tumors	(26).	Due	to	a	poor	sensitivity	of	approx-
imately	 38%	 in	 neuroendocrine	 tumors,	 this	marker	 is	 not	 frequently	 used	 in	 the	 daily	
practice in the follow up of patients with low-grade tumors (27).
Bronchial Carcinoids 
Bronchial carcinoids are NETs of the foregut and include a spectrum of histologically dif-
ferent tumors. These tumors are also classified based on the mitotic count (MC). Typical 
carcinoids have <2 MC per 2 mm2 and show no signs of necrosis. Atypical carcinoids have 
2-10 MC per 2 mm2,	or	foci	of	necrosis.	Poorly	differentiated	tumors	(MC	>10	per	2	mm2 
and	extensive	necrosis)	are	divided	into	large	cell	neuroendocrine	carcinomas	and	small	
cell neuroendocrine tumors (28). The majority of patients with poorly differentiated lung 
tumors have metastatic disease at time of presentation and have a very poor prognosis (10). 
The	incidence	of	bronchial	carcinoids	is	0,2-2	per	100,000	population/year	(29).	Approxi-
mately 25% of all low-grade NETs are localized in the respiratory tract (3). These tumors 
can	develop	in	patients	who	have	never	or	only	incidentally	smoked,	whereas	poorly	dif-
ferentiated tumors are strongly associated with smoking (29). Patients may present with 
non-specific	 symptoms,	 such	 as	 coughing,	 pneumonia	 or	 hemoptysis.	 Bronchial	 carci-
noids	can	be	hormonal	active	and,	therefore,	patients	can	present	with	a	so-called	atypical	 
carcinoid	syndrome	or	Cushing’s	syndrome.	This	atypical	carcinoid	syndrome,	which	in-
cludes	diarrhea	and	flushing,	occurs	in	approximately	8%	of	patients.	Cushing’s	syndrome,	
due	to	the	ectopic	production	of	ACTH,	occurs	in	about	6%	(30).	Up	to	40%	of	patients	
with an ectopic Cushing’s syndrome appears to have a bronchial carcinoid. There is an 
association	between	bronchial	and	thymic	carcinoids	and	the	MEN-1	syndrome.	However,	
the MEN-1 syndrome is diagnosed in less than 5% of patients presenting with a bronchial 
carcinoid.
Radiological Imaging
The majority of patients with NETs have metastatic disease at the time of presentation. 
For	the	detection	of	the	primary	tumor,	mainly	CT	and	MRI	are	used.	NETs	can	be	very	
small	and	multifocal,	so	detection	of	the	primary	tumor	can	be	a	challenge.	Most	tumors	
are	highly	vascularized	and	therefore	best	visible	on	the	arterial	phase	of	the	CT/MRI.	If	
CT	and/or	MRI	don’t	reveal	the	primary	tumor,	nuclear	medicine	imaging	techniques	are	
indicated.	Also	for	optimal	(whole	body)	staging	and	detection	of	recurrent	disease,	nucle-
ar medicine imaging plays a pivotal role (31). 
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A	very	distinguished	feature	of	small	 intestinal	NETs	is	a	mesenterial	mass,	which	may	
cause	a	desmoplastic	reaction,	resulting	in	a	spoke	wheel	phenomenon	due	to	traction	on	
the mesentery. 
Since	the	majority	of	patients	have	metastases	in	the	liver,	the	detection	of	metastases	is	fo-
cused	on	the	liver.	The	vascularity	of	metastases	may	vary,	therefore	it	is	necessary	to	make	
a CT in both the arterial and portovenous contrast phase. The majority of liver metastases 
are	highly	vascularized,	however	the	vascularity	can	differ,	even	within	the	same	patient.	
Besides,	in	a	quarter	of	patients	there	is	some	necrosis	visible	within	the	metastases.	MRI	
can	be	used	for	detection	and	further	characterization	of	liver	metastases,	since	the	sensi-
tivity of MRI is better than that of CT (32). 
Detection of primary tumors in the pancreas can be challenging. These tumors can be 
multifocal and may have some calcifications. The most sensitive method for detection of 
pancreatic	NETs	is	endoscopic	ultrasound	(EUS).	However,	a	disadvantage	of	ultrasound	
is	the	interobserver	variability.	Therefore,	MRI	is	used	for	detection	of	pancreatic	NETs	as	
well,	with	comparable	sensitivity	as	with	EUS.
Nuclear Medicine Imaging
Imaging	with	nuclear	medicine	 techniques	will	be	extensively	described	 in	chapter	2	of	
this thesis. 
Medical Therapy
Somatostatin Analogs 
Somatostatin analogs (SSAs) are used for symptom control and inhibition of tumor growth 
of	NETs	(4,5).	The	literature	on	the	treatment	of	the	different	subtypes	of	NETs	is	emerg-
ing and these SSAs are now used for all kinds of somatostatin receptor-positive tumors. 
Synthetic	SSAs	can	inhibit	the	secretion	of	bioactive	products	and,	therefore,	therapy	with	
these	pharmaceuticals	can	completely,	or	partially	inhibit	the	symptoms	of	the	carcinoid	
syndrome. The most important studies that have demonstrated that SSAs can prolong time 
to progression (TTP) and progression free survival (PFS) are the PROMID and CLARI-
NET trials. The PROMID study investigated the effect of octreotide LAR in patients with 
metastatic	midgut	NETs.	TTP	was	14.3	months	with	octreotide	LAR	30	mg	/	month	versus	
6 months for placebo (4). The other large randomized study was the CLARINET study. 
Comparison	between	120	mg	lanreotide	autogel	/	month	and	placebo	in	patients	with	ad-
vanced	GEP	and	pulmonary	NETs	was	made.	At	 the	 end	of	 this	 study,	 the	PFS	 for	 the	
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1lanreotide autogel group was not reached and it was 18 months for the placebo group (5). 
These different PFS data in the control groups of both studies also demonstrate the differ-
ences	between	study	groups	used	for	clinical	trials	and,	therefore,	the	need	for	controlled	
studies.	The	recent	results	of	the	NETTER-1	trial,	comparing	high	dose	octreotide	LAR	
therapy	(60	mg	/	month)	to	4	cycles	of	177Lu-DOTATATE in combination with octreotide 
LAR	30	mg	/	month,	have	demonstrated	the	superiority	of	PRRT	with	177Lu-DOTATATE 
as compared to high dose octreotide therapy (33). 
Molecular Targeted Therapy 
Everolimus and Sunitinib are approved by the US Food & Drug Administration (FDA) and 
European Medicines Agency (EMA) for the treatment of patients with advanced low-grade 
pancreatic NETs. Everolimus is also approved for the treatment of other GEP-NETs and 
bronchial NETs. Everolimus is an inhibitor of the mammalian target of rapamycin (mTOR) 
and sunitinib is a receptor tyrosine kinase (RTK) inhibitor. The RADIANT-3 and 4 studies 
have compared everolimus to placebo in a group of patients with NETs of the pancreas 
and	the	lungs,	or	gastrointestinal	tract,	respectively.	The	PFS	in	the	groups	receiving	10	
mg everolimus daily was 11 months. This was better as compared to the placebo group 
with a PFS of 4.6 months for pancreatic NETs and 3.9 months for lung and gastrointestinal 
NETs	(34,35).	The	other	targeted	pharmaceutical	is	sunitinib.	The	SUN-1	study,	studying	
patients	with	advanced,	progressive	pancreatic	NETs	treated	with	37.5	mg	sunitinib	daily,	 
demonstrated a PFS of 11.4 months as compared to a PFS of 5.5 months in the placebo 
group (36). 
Chemotherapy / Interferon-Alpha
In	oncology,	chemotherapy	is	the	cornerstone	in	the	treatment	of	patients	with	metastat-
ic	 cancer.	However,	 for	 low	grade	NETs	 the	 role	of	 chemotherapy	 is	 limited.	The	most	
frequently used chemotherapy regimen for metastatic inoperable pancreatic NETs is the 
combination of Streptozotocin (STZ) and 5-Fluorouracil (5-FU). This combination demon-
strated	an	objective	 response	of	approximately	16%	with	a	PFS	of	5	months	 (37).	Also	
the	combination	Temozolomide/Capecitabine,	or	Temozolomide	monotherapy	can	be	used	
as a fist line treatment for pancreatic low grade NETs. A recent meta-analysis did not 
demonstrate	any	difference	in	PFS,	or	OS	when	comparing	STZ/5-FU	to	Interferon-Alpha	
(IFN-alpha),	or	other	chemotherapeutic	regimes	(38).	IFN-alpha	treatment	was	associated	
with	higher	hematological	toxicity	and	less	renal	toxicity.	Currently,	no	large	randomized	
studies	are	available	comparing	different	chemotherapeuticals	and	SSAs,	or	targeted	thera-
pies.	IFN-alpha	can	be	used	as	a	second	line	therapy	for	patients	who	can’t	tolerate	SSAs,	
or	who	are	refractory	to	SSAs.	Besides,	it	can	be	used	for	the	treatment	of	somatostatin	
receptor-negative	tumors.	Interferon	receptors	can	be	expressed	on	NETs	and	are,	there-
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fore,	a	potential	target	for	therapy	with	IFN-alpha.	Due	to	more	and	severe	side-effects	this	
therapy is not frequently used in daily practice (39).
For	high	grade	NEC,	chemotherapy	with	the	combination	of	Cisplatin	and	Etoposide	is	the	
therapy	of	first	choice.	For	low-grade	tumors	this	regimen	is	not	indicated,	due	to	a	limited	
effect and severe side-effects. 
PRRT
Peptide	 receptor	 radionuclide	 therapy	will	 be	 extensively	described	 in	 chapter	4	of	 this	
thesis. 
Other (Liver-Directed) Therapeutic Options
External	beam	radiotherapy	(EBRT)	of	liver	metastases	or	other	liver-directed	therapies,	
such	as	radiofrequency	ablation	(RFA),	are	not	frequently	used	for	therapy	of	liver	metas-
tases. In most patients these metastases are multiple and distributed throughout the whole 
liver	and,	 therefore,	 these	specific	 localized	 therapies	are	not	very	useful.	EBRT	can	be	
helpful	as	pain	relief	in	patients	with	bone	metastases,	or	to	lower	the	risk	of	pathological	
fractures. It is also used for treatment of brain metastases. 
New therapies with microspheres made of glass or resin filled with Yttrium-90 adminis-
tered directly in a hepatic artery are a good treatment option for patients with dominant 
disease in the liver. A recent meta-analysis reported an objective response rate of 50% 
(95% CI 38-62%) in patients with liver-dominant metastatic neuroendocrine tumors (40). 
Unfortunately,	this	is	not	a	therapeutic	option	for	patients	with	extra-hepatic	disease.			
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1Aims and Outlines of this Thesis
The aims of the studies presented in this thesis are to:
1. Evaluate	 the	 efficacy	 and	 toxicity	 of	 177Lu-DOTATATE in patients with inoperable 
and/or	metastatic	GEP	and	bronchial	NETs
2. Identify several pitfalls in imaging and therapy of patients with NETs
3. Evaluate the best way to detect progression after PRRT with 177Lu-DOTATATE
Chapter	2	gives	an	overview	on	the	nuclear	medicine	imaging	techniques,	which	are	cur-
rently	 used	 for	 the	 imaging	 of	 neuroendocrine	 tumors.	 In	 chapter	 3,	 the	 incidence	 and	
mechanism of physiological uptake in the pancreatic head on scintigraphy with 111In- 
DTPA-octreotide are described. Chapter 4 gives an overview on the current literature on 
PRRT	in	patients.	Chapter	5	describes	a	large	prospective	study,	which	evaluates	the	effect	
of 177Lu-DOTATATE	in	patients	with	inoperable	and/or	metastatic	GEP	and	bronchial	NETs	
In the same chapter different factors that can predict the overall survival are discussed. 
In	chapter	6,	several	pitfalls	which	can	occur	during	and	direct	after	therapy	with	177Lu- 
DOTATATE are identified. Pitfalls in biochemical markers and imaging are discussed. 
Chapter 7 describes different ways to detect progression after PRRT with 177Lu-DOTATATE 
and evaluates the best way to detect progressive disease. 
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Abstract 
An important role is reserved for nuclear imaging techniques in the imaging of neuroen-
docrine tumors (NETs). Somatostatin receptor scintigraphy (SRS) with 111In-DTPA-oct-
reotide	 is	currently	 the	most	 important	 tracer	 in	 the	diagnosis,	 staging	and	selection	 for	
peptide	receptor	radionuclide	therapy	(PRRT).	In	the	past	decade,	different	positron-emit-
ting tomography (PET) tracers have been developed.
The largest group is the 68Gallium-labeled somatostatin analogs (68Ga-SSA). Several stud-
ies have demonstrated their superiority compared to SRS in sensitivity and specificity. 
Furthermore,	patient	comfort	and	effective	dose	are	 favorable	 for	 68Ga-SSA. Other PET 
targets	like	β-[11C]-5-hydroxy-	L	-tryptophan	(11C-5-HTP) and 6-18F-L-3,4-dihydroxyphe-
nylalanine (18F-DOPA)	were	developed	recently.	For	insulinomas,	glucagon-like	peptide-1	
receptor imaging is a promising new technique. The evaluation of response after PRRT 
and	other	therapies	is	a	challenge.	Currently,	the	official	follow-up	is	performed	with	ra-
diological imaging techniques. The role of nuclear medicine may increase with the newest 
tracers	for	PET.	In	this	review,	the	different	nuclear	imaging	techniques	and	tracers	for	the	
imaging of NETs will be discussed.
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Introduction 
Nuclear imaging techniques play a pivotal role in the diagnosis and staging of neuroendo-
crine	tumors	(NETs).	Furthermore,	selection	of	patients	for	peptide	receptor	radionuclide	
therapy (PRRT) can only be done by scintigraphy with radiolabeled somatostatin analogs. 
Besides	the	above-mentioned	indications,	nuclear	imaging	can	play	an	important	role	in	
follow-up after therapy and in the evaluation of therapy response.
In	general,	two	different	imaging	modalities	in	nuclear	medicine	are	used	to	image	NETs.	
With	the	gamma	camera,	both	planar	(two-dimensional)	and	single-photon	emission	com-
puted tomography (SPECT; three-dimensional) images can be made. A relative new image 
modality,	the	positron	emission	tomography	(PET)	camera	can	be	used	after	the	injection	
of a positron-emitting radionuclide-based tracer. The emitted positrons annihilate with a 
surrounding	electron	 in	 the	 tumor	or	normal	 tissue,	 two	gamma	 rays	with	 an	energy	of	
511	KeV	in	opposite	directions.	In	this	way,	imaging	with	a	PET	camera	ensures	a	better	
sensitivity	and	higher	spatial	resolution	compared	to	the	gamma	camera.	Currently,	most	
PET	cameras	are	combined	with	computed	tomography	(CT),	allowing	hybrid	imaging	in	
a single imaging procedure.
The	CT	is	used	for	attenuation	correction,	which	improves	the	image	quality.	Furthermore,	
the CT can be used for anatomical correlation. This will improve the accuracy and makes 
it	possible	to	distinguish	between	physiological	and	pathological	activity,	resulting	in	less	
false-positive	findings	(1,	2).	This	review	will	focus	on	the	different	imaging	modalities	
which	nuclear	medicine	has	to	offer	for	the	diagnosis	and	staging	of	NETs.	Furthermore,	
selection for PRRT and the imaging options for the evaluation of therapy response will be 
discussed.
Imaging of Neuroendocrine Tumors
NETs	are	a	heterogeneous	group	of	tumors	that	can	differ	in	location,	function	and	growth.	
Variations	in	these	characteristics	make	the	presentation	of	a	NET	diverse	and,	therefore,	
the optimal diagnostic path for patients may be different. In order to perform the right type 
of	diagnostic	imaging,	knowledge	of	the	most	recent	World	Health	Organization	(WHO)	
classification	of	gastroenteropancreatic	NETs,	as	published	in	2010	(3),	is	essential.	This	
classification	defines	three	tumor	categories	or	grades,	irrespective	of	their	site	of	origin,	
based on the mitotic count (MC) and the number of cells positively staining with the prolif-
eration	marker	Ki-67:	low-grade	(grade	1;	G1)	NETs	with	<2	mitoses/10	HPF	(high-power	
field)	and	Ki-67	<3%;	intermediate	(grade	2;	G2)	NETs	with	2–20	mitoses/10	HPF	or	Ki-
67	3–20%,	and	highgrade	(grade	3;	G3)	neuroendocrine	carcinomas	with	>20	mitoses/10	
HPF or Ki-67 >20%. This grading is important since there is an inverse association be-
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tween	grade	and	prognosis	(4).	Besides	the	prognosis,	the	classification	plays	a	role	in	the	
choice	of	imaging	and/or	subsequent	therapy.
Somatostatin Receptor-Based Imaging
One	of	the	characteristics	of	NETs	is	that	they	may	express	somatostatin	receptors	(SSTRs)	
on the cell surface. This receptor can be used to image tumors by using radiolabeled so-
matostatin analogs. In vivo visualization of somatostatin-positive tumors with radioiodine- 
labeled	somatostatin	analogs	was	first	described	in	1989	(5).		In	the	following	years,	so-
matostatin analogs labeled with different radionuclides were developed. These compounds 
have different affinities for the five subtypes of the SSTR (table 1) (6). 
Most	radiolabeled	somatostatin	analogs,	which	are	currently	available	for	imaging,	have	
good	affinity	for	the	subtype	2	receptor,	which	is	most	frequently	expressed	by	NETs.	In	
SSTR-positive	NETs,	unlabeled	somatostatin	analogs	(e.g.	octreotide	or	lanreotide)	can	be	
used	for	therapy.	In	case	patients	have	NETs	that	produce	hormones,	which	lead	to	specific	
symptoms	or	syndromes	(e.g.	carcinoid	syndrome),	 treatment	with	somatostatin	analogs	
results	in	a	reduction	of	hormonal	overproduction	and,	therefore,	relief	of	these	symptoms.	
Furthermore,	it	can	lengthen	the	time	to	tumor	progression	compared	to	placebo	in	patients	
with	midgut	NETs	 (7).	Currently,	many	patients	with	NETs	are	 treated	with	 somatosta-
tin analogs. This cold octreotide can compete for binding to the SSTR with the radiola-
beled somatostatin analogs. This may influence the sensitivity of the imaging and effect of 
PRRT.	To	obtain	the	best	quality	of	imaging,	it	is	therefore	advised	to	discontinue	soma-
tostatin analogs before SSTR-based imaging and PRRT. With the proper patient prepara-
hsst1 hsst2 hsst3 hsst4 hsst5
SS-28 5.2±0.3 2.7±0.3 7.7±0.9 5.6±0.4 4.0±0.3
Octreotide >10,000 2.0±0.7 187±55 >1,000 22±6
DTPA-octreotide >10,000 12±2 376±84 >1,000 299±50 
In-DTPA-octreotide >10,000 22±3.6 182±13 >1,000 237±52
DOTA-TOC >10,000 14±2.6 880±324 >1,000 393±84 
Ga-DOTA-TOC >10,000 2.5±0.5 613±140 >1,000 73±21
In-DTPA-octreotate >10,000 1.3 ±0.2 >10,000 433 ±16 >1,000
Ga-DOTATATE >10,000 0.2±0.04 >1,000 300±140 377±18
Table 1. Affinity	profiles	(IC50)	for	human	sst1-sst5	receptors	of	a	series	of	somatostatin	analogs
All values are IC50±SEM in nM.
Modified	from	Reubi	et	al.	(5)
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tion and imaging acquisition SSTR imaging is very helpful in the optimal staging of the 
patient.
[111In-DTPA0]octreotide
Currently,	 the	 only	 registered	 radiopharmaceutical	 for	 SSTR	 scintigraphy	 (SRS)	 is	
[111In-DTPA0]octreotide	 (OctreoScan;	 Covidien,	 Petten,	 The	 Netherlands).	 The	 SNM	
guideline	(8)	recommends	an	administered	activity	of	222	MBq	and	10	μg	of	pentetreotide.	
Furthermore,	SPECT(-CT)	of	at	least	the	upper	abdomen	is	mandatory	for	optimal	imaging	
and	staging.	Due	to	a	relative	long	half-life	of	2.8	days,	it	is	possible	to	image	at	24	h	and	
an	optional	48	h	after	injection.	Normal	tissues,	such	as	thyroid,	spleen	and	the	pituitary	
gland,	express	SSTR.	Furthermore,	the	liver	and	kidneys	excrete	the	tracer,	so	accumula-
tion	of	radioactivity	is	seen	in	these	organs	as	well	(9).	More	specifically,	approximately	
2%	of	the	administered	dose	leaves	the	body	by	hepatobiliary	excretion.	Therefore,	lax-
atives	should	be	considered	when	visualizing	tumors	in	the	abdomen.	In	the	last	decade,	
many studies have evaluated the sensitivity and specificity of 111In-DTPA-octreotide for 
the	detection	of	NETs,	and	the	results	vary	considerably	due	to	variations	in	the	size	and	
location	of	the	tumor	and	different	acquisition	protocols.	A	large	review	of	1,200	patients	
with gastrointestinal NETs showed a median detection rate of 89% (range 67–100%) and 
sensitivity of 84% (range 57–93%) (10). Besides the presence of unlabeled somatostatin 
or	therapeutic	use	of	somatostatin	analogs	blocking	the	SSTR,	SRS	can	have	a	negative	
result	 due	 to	 high	 glucocorticoid	 levels,	which	 has	 a	 downregulatory	 effect	 on	 tumoral	
SSTR	expression.	De	Bruin	et	al.	(11)	described	2	patients	with	a	negative	SRS	caused	by	
hypercortisolism due to ectopic ACTH secretion. After treatment with the glucocorticoid 
receptor	antagonist	mifepristone,	the	SRS	pointed	towards	the	diagnosis	of	an	ACTH-pro-
ducing bronchial carcinoid in both patients.
Furthermore,	 imaging	of	NETs	with	 111In-DTPA-octreotide is used to select patients for 
PRRT.	PRRT	is	performed	with	somatostatin	analogs	labeled	with	a	β-emitting	radionu-
clide such as Yttrium-90 or Lutetium-177 (e.g. [90Y-DOTA0,Tyr3]octreotide and [177Lu-
DOTA0,Tyr3]octreotate). The level of accumulation in the tumor on the pretherapeutic SRS 
is	an	important	prognostic	factor	for	the	prediction	of	tumor	regression.	The	uptake	is	ex-
pressed	using	a	semiquantitative	score,	comparing	the	accumulation	in	the	tumor	to	phys-
iological	accumulation	in	the	liver	and	kidneys/spleen.	In	general,	a	high	accumulation	in	
the tumor will result in a good response to therapy (12).
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99mTc-Labeled Somatostatin Analogs
As an alternative to 111In-DTPA-octreotide,	 somatostatin	 analogs	 can	 be	 labeled	 with	
99mTechnetium (99mTc).	 Currently,	 the	 most	 commonly	 used	 99mTc-labeled somatostatin 
analogs are 99mTc-depreotide and 99mTc-EDDA/HYNIC-Tyr3-octreotide (99mTc-EDDA/ 
HYNIC-TOC). The latter is available under the commercial name 99mTc-Tektrotyd and 
most frequently used in (Eastern) Europe. The main advantage of 99mTc-labeled somatosta-
tin analogs is the wide availability of 99mTc,	which	 can	be	 produced	by	 the	majority	 of	
nuclear medicine departments with the use of a 99mTc generator. This makes the production 
of	this	radionuclide	relatively	inexpensive.	Another	advantage	is	that	the	radiation	burden	
is	lower	(13).	However,	a	disadvantage	of	99mTc is the short half-life of 6 h. Because of this 
short	half-life,	it	is	not	possible	to	image	at	24	h	after	injection.	On	the	other	hand,	imaging	
can be performed on the day of the administration of the tracer and therefore disturbing 
bowel	uptake	 is	 less	of	an	 issue.	Still,	 it	 is	 recommended	that	an	 imaging	protocol	with	
99mTc-EDDA/HYNIC-TOC	should	include	acquisitions	2	and	4	h	after	injection,	comple-
mented	with	SPECT(-CT)	of	the	upper	abdomen.	Using	this	protocol,	a	sensitivity	of	80%	
and specificity of 94% could be achieved in 88 patients with NETs of the gastroenteropan-
creatic tract (14). In a direct comparison between 111In-DTPA-octreotide and 99mTc-EDDA/
HYNIC-TOC	SRS,	both	modalities	performed	similarly,	with	a	slightly	higher	sensitivity	
for 99mTc-EDDA/HYNIC-TOC.	However,	the	latter	showed	more	false-positive	results	due	
to	nonspecific	 abdominal	 tracer	 accumulation	 (15).	 In	 summary,	 although	 99mTc-EDDA/
HYNIC-TOC	is	not	widely	used	and	only	few	studies	have	been	performed	with	this	tracer,	
somatostatin scintigraphy with 99mTc-EDDA/HYNIC-TOC	seems	a	reasonable	alternative	
for 111In-DTPA-octreotide.
Somatostatin Receptor PET/CT
Imaging with a positron-emitting radionuclide-labeled compound allows imaging with a 
PET	camera,	which	results	in	a	better	image	quality	compared	to	imaging	with	a	gamma	
camera	including	SPECT.	To	image	NETs	with	PET,	most	somatostatin	analogs	are	labeled	
with the positron emitter Gallium-68 (68Ga). The most commonly used somatostatin ana-
logs labeled with 68Ga are [68Ga-DOTA0,Tyr3]octreotide (68Ga-DOTATOC),	[68Ga-DOTA, 
1-nal3]octreotide (68Ga-DOTANOC) and [68Ga-DOTA0,Tyr3]octreotate (68Ga-DOTATATE). 
These 68Ga-labeled somatostatin analogs (68Ga-SSA) all have a different affinity profile 
for	 the	different	 subtypes	of	 the	SSTR,	but	have	 in	 common	 that	 each	analog	can	bind	
to SSTR2. 68Ga-DOTATATE has the highest affinity for SSTR2. Despite the differenc-
es	 in	 the	 affinity	 profile,	 the	 different	 68Ga-SSAs perform similarly with regard to sen-
sitivity	 and	 specificity	 (16).	 Recently,	 the	 European	Association	 of	 Nuclear	 Medicine	 
(EANM) published the first guideline for imaging with 68Ga-labeled somatostatin analogs. 
In	order	to	obtain	the	best	imaging	quality,	an	administered	activity	of	at	least	100	MBq	
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and	less	than	50	μg	of	68Ga-DOTA-conjugated peptide is recommended. Image acquisition 
shouldbe done at 60 min after injection (17). A recent meta-analysis in which studies were 
included using various somatostatin analogs labeled mainly with 68Ga	with	a	total	of	2,105	
patients	with	NETs	 in	 the	 thorax	and	abdomen	showed	a	pooled	sensitivity	of	93%	and	
specificity	of	91%	(16).	It	is	to	be	expected	that	the	68Ga-labeled somatostatin analogs will 
become more widely available in the near future.
Comparison between 68Ga-SSA and non-PET SRS 
Several studies have compared 68Ga-SSA	 to	 SRS,	 including	 111In-DTPA-octreotide,	
111In-DOTATOC and 99mTc-EDDA/HYNIC-TOC	 [18–20].	Overall,	 68Ga-SSA have many 
advantages	over	non-PET	SRS.	Firstly,	as	mentioned	before,	 68Ga is a positron emitting 
radionuclide,	which	ensures	a	higher	spatial	resolution	with	PET	imaging.	Therefore,	it	is	
not	surprising	that,	in	a	direct	comparison,	68Ga-SSA imaging shows a significantly higher 
detection rate compared to non-PET SRS [18]. Especially for the detection of metastatic 
lesions	in	the	bones	and	lungs,	68Ga-SSA is superior to 111In-DTPA-octreotide (19). Due to 
the	higher	detection	rate,	the	clinical	management	can	change.	Secondly,	imaging	with	a	
68Ga-SSA is performed 60 min after injection in contrast to imaging with 111In-DTPA-oc-
treotide after 24 h. Due to the short time between injection and image acquisition it is not 
necessary	 to	use	 laxatives	when	performing	PET	with	 68Ga-SSA,	which	is	an	advantage	
as	patients	often	experience	the	use	of	 these	laxatives	as	burdensome.	Other	advantages	
are that 68Ga-SSA	is	performed	in	1	day,	and	the	radiation	burden	for	a	whole-body	scan	
is lower compared to 111In-DTPA-octreotide	(21).	For	these	reasons,	the	68Ga-SSA is bet-
ter tolerated by the patients than 111In-DTPA-octreotide	(20).	Furthermore,	one	cost-effec-
tiveness study comparing 68Ga-DOTATOC and 111In-DTPA-octreotide demonstrated that 
68Ga-DOTATOC	was	 less	 expensive	with	 respect	 to	materials	 and	personnel	 costs	 (22).	
Due	to	the	higher	sensitivity	and	specificity	fewer	additional	examinations	were	needed.	
A disadvantage of 68 Ga-SSA is the increase in false-positive results especially due to find-
ings	of	high	uptake	in	the	pancreatic	head	(18,	23),	which	can	be	explained	by	the	higher	
density of SSTRs in this area of the pancreas (24). These false positive findings did not 
occur with 111In-DTPA-octreotide,	probably	because	of	the	lower	sensitivity	and	resolution	
of the gamma camera. Another disadvantage remains the limited availability of 68Ga-SSA. 
Currently,	 the	 most	 frequently	 used	 radiopharmaceutical	 for	 imaging	 of	 NETs	 is	 111In- 
DTPA-octreotide. This tracer is available in almost every nuclear medicine department and 
there	is	considerable	shared	experience	with	the	interpretation	of	 the	images.	Moreover,	
most literature is based on SRS with 111In-DTPA-octreotide.	Currently,	the	uptake	on	SRS	
can be used to assess whether a patient is eligible for PRRT. If the tumor shows less uptake 
than	the	physiological	 liver	uptake	on	the	SRS	(grade	1	uptake),	PRRT	is	not	a	suitable	
therapy. Such a scale is not available for 68Ga-SSA and further studies are needed to trans-
late the semiquantitative ‘Krenning’ score on SRS to quantitative uptake on a PET scan 
with 68 Ga-SSA. 
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In	summary,	PET	imaging	with	 68Ga-SSA performs better with regard to sensitivity and 
detection rate than 111In-DTPA-octreotide.	The	discomfort	 for	patients	 is	 lower,	due	 to	a	
1-day	protocol	and	there	being	no	need	to	use	laxatives.	However,	SRS	has	the	advantage	
of	better	availability	and	larger	clinical	experience.	It	is	expected	that	68 Ga-SSA PET im-
aging will replace SRS in the daily practice of imaging NETs.
Other Imaging Modalities
123I-Metaiodobenzylguanidine
Metaiodobenzylguanidine (MIBG) labeled with radioactive iodine (123 I) can be used to 
image	NETs	with	planar	and/or	with	SPECT(-CT)	imaging.	MIBG	is	structurally	similar	
to norepinephrine and therefore utilizes the vesicular monoamine transporters and is incor-
porated into vesicles or neurosecretory granules in the cytoplasm of neuroendocrine cells 
(25).	For	imaging	of	pheochromocytoma	and	paraganglioma,	123I-MIBG scintigraphy has 
been	the	investigation	of	first	choice	with	a	high	sensitivity	and	specificity	of	87	and	99%,	
respectively	(26).	However,	new	PET	tracers	(e.g. 18F-DOPA),	which	will	be	discussed	in	
the	next	paragraphs,	may	perform	better	in	sensitivity	and	specificity,	but	their	availability	
is	limited.	For	the	detection	of	NETs,	the	sensitivity	of	MIBG	scintigraphy	is	lower	than	
SRS with 111In-DTPA-octreotide.	In	a	large	review,	the	median	detection	rate	was	50%	and	
the	sensitivity	76%	(27).	Therefore,	MIBG	has	a	 limited	 role	 in	 the	diagnosis	of	NETs.	
However, 123I-MIBG scintigraphy can be used when other imaging modalities fail to detect 
the tumor and for the selection of therapy with 131I-MIBG.
Figure 1. Patient with liver and mes-
enteric lymph node metastases from 
a small bowel neuroendocrine tumor 
grade	1.	A.	Maximum	intensity	pro-
jection of whole body 18F-DOPA PET 
showing multiple liver lesions and me-
tastases in the mesenterium. Physiolog-
ic uptake is seen in the striata. Physio-
logical	excretion	is	via	the	kidneys	and	
ureters to the bladder. B. Abdominal 
CT showing large and smaller (white 
arrows) malignant mesenteric lymph 
nodes. C. On the 111In-DTPA-octreotide 
SPECT scan 24 h after injection only 
the large mesenteric lymph node could 
be visualized (grey arrow).
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18F-Fluorodeoxyglucose
18F-fluorodeoxyglucose	 (18 F-FDG) is the most frequently used PET tracer in oncology. 
FDG	is	a	glucose	analog	that	accumulates	in	tumor	cells	with	a	high	expression	of	glucose	
transporters.	The	FDG	undergoes	phosphorylation	by	hexokinase	and	is	trapped	intracel-
lularly.	However,	in	contrast	to	the	wide	use	of	18 F-FDG	in	numerous	types	of	tumors,	it	
has a limited role in the imaging of NETs. Poorly differentiated tumors (G3) with a high 
proliferative activity have an increased glucose metabolism (28). The majority of the more 
differentiated	tumors	(G1/G2)	have	a	normal	or	slightly	increased	glucose	metabolism.	For	
these	tumors,	imaging	with	18F-FDG should not be the first choice of imaging technique 
for	 staging.	 However,	 some	G2	 tumors	 do	 have	 an	 increased	 glucose	metabolism.	 For	
these	tumors,	the	uptake	on	18 F-FDG	PET	can	predict	the	prognosis.	Overall,	a	high	FDG	
uptake	predicts	a	poorer	prognosis	(29,	30).	Only	a	few	studies	have	compared	18F-FDG 
to 68Ga-SSA	(31,	32).	Kayani	 et	 al.	 (31)	 found	a	 significant	 correlation	between	uptake	
of 68Ga-DOTATATE and 18F-FDG and tumor grade on histology. Low-grade tumors had 
a higher accumulation of 68Ga-DOTATATE than 18F-FDG. The reverse was true in high-
grade tumors. The overall sensitivity in this study for 68Ga-DOTATATE	was	82%,	and	for	
18F-FDG was 66%. The highest sensitivity of 92% was achieved when combining these two 
different PET tracers (31). SSTR imaging and glucose metabolism imaging seem to have 
a complementary role (32). Although 18F-FDG-PET seems to have no additional value for 
the	staging	of	patients	with	low-grade	tumors	(G1/G2),	positive	findings	on	an	18F-FDG 
PET	might	define	specific	NET	subgroups.	However,	it	is	currently	not	common	practice	
to perform both imaging modalities for staging or to use this functional or metabolic in-
formation as a guidance before starting the therapy. Additional clinical studies have to be 
performed to gain more insight.
1 8F-L-3,4-Dihydroxyphenylalanine
The radiopharmaceutical 6-18F-L-3,4-dihydroxyphenylalanine	 (18F-DOPA) is one of the 
PET tracers for imaging NETs which makes use of the capability of neuroendocrine (tumor) 
cells	to	synthesize	various	hormones	via	amine	precursor	uptake	and	decarboxylation.	In	
the	catecholamine	pathway,	active	in	many	NETs,	phenylalanine	and	intermediate	products	
such as L -DOPA are taken up via system L large amino acid transporters. Once inside the 
cell,	decarboxylation	to	dopamine	takes	place	via	the	enzyme	AADC	(aromatic	amino	acid	
decarboxylase).	Dopamine	 is	 then	 transported	 into	 intracellular	storage	vesicles	 through	
the	vesicular	monoamine	transporter.	From	these	vesicles,	the	resulting	end	products	can	
be	released	in	the	extracellular	environment.	Nowadays,	more	and	more	PET	centers	are	
capable of producing 18F-DOPA,	 and	 it	 is	 commercially	 available	 in	 several	 European	
countries.	Usually,	 images	 are	made	60–90	min	 after	 injection,	 although	 earlier	 images	
are	advocated	for	some	indications	(33,	34).	Physiological	variants	and	pitfalls	have	been	
described	 (34,	 35).	Practices	differ	 regarding	premedicating	patients	with	 carbidopa	 for	
NET	imaging.	Carbidopa	is	an	inhibitor	of	AADC,	and	it	prevents	early	decarboxylation	of	
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18F-DOPA to    18F-dopamine	outside	the	brain.	This	results	in	decreased	renal	excretion	and	
increased 18F-DOPA	uptake	in	NET	cells,	thus	increasing	image	quality	and	sensitivity	(36,	
37).	However,	carbidopa	pretreatment	is	not	recommended	for	the	evaluation	of	pancreatic	
pathology,	such	as	congenital	hyperinsulinism/nesidioblastosis	or	insulinomas	(38,	39).
Most studies with 18F-DOPA PET have been performed for diagnosing and the (re-)staging 
of	NET	patients.	 Its	 superior	 role	has	been	 established	 in	 the	 following,	more	 common	
subtypes	of	NETs:	well-differentiated	NETs	of	midgut	origin,	 pheochromocytoma/para-
ganglioma	and	medullary	thyroid	carcinoma.	In	these	NET	types,	18F-DOPA	PET/CT	can	
serve	as	the	initial	imaging	technique,	provided	that	it	is	available	(40).	In	well-differenti-
ated	NETs	of	midgut	origin,	overall	(n	=	76	patients)	patient-	and	lesion-based	sensitivity	
for 18F-DOPA is 89 and 97%. This is significantly higher when compared to SRS with 
111In-DTPA-octreotide	 (80	and	49%,	 respectively;	 fig.	1),	 and	 is	equal	compared	 to	CT/
MRI	 (89%	patient	 based)	 or	 higher	 (65%	 lesion	 based)	 (40).	 Furthermore,	 in	 these	 pa-
tients,	 the	extension	of	 18F-DOPA uptake on the whole-body PET scan reflects the total 
tumor	load,	and	was	correlated	with	various	urinary	and	plasma	hormonal	products,	but	
not	with	serum	chromogranin	A	(41).	Thus	far,	patient	series	directly	comparing	18F-DOPA 
and 68Ga-SSA in NET patients are small. Preliminary results suggest that they perform 
equally	well	(40).	An	example	is	given	in	figure	2.	There	are	differences	of	opinion	as	to	
whether or not 18F-DOPA should be advised as a first-choice functional imaging technique 
in patients with pancreatic NETs. Other functional imaging techniques such as 111In-DTPA- 
ocetreotide	SRS,	68Ga-SSA PET or 11C-5-HTP	PET	may	be	considered	as	well	(35,	39,	40,	
42).
β-[11C]-5-Hydroxy-L-Tryptophan
PET	imaging	with	β-[11C]-5-hydroxy-L-tryptophan (11C-5-HTP) PET can visualize the se-
rotonin	pathway,	which	is	active	in	many	NETs.	The	precursors	tryptophan	and	5-HTP	are	
taken up via the L-amino	acid	transporter,	and	subsequently	decarboxylated	by	aromatic	 
Figure 2.  Patient with paragan-
glioma with widespread (bone) 
metastases.	A.	Maximum	intensity	
projection (MIP) of whole body 
68Ga-DOTATATE PET B. MIP of 
whole body 18F-DOPA PET. Note 
the similarity of uptake of 68Ga-DO-
TATATE and 18F-DOPA in the 
lesions. Only some lesions only take 
up 68Ga-DOTATATE	(e.g.	axillary	
regions),	but	this	might	be	due	to	
progressive disease (the acquisition 
6 months after the 18F-DOPA PET).
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L-amino	 acid	 decarboxylase	 (DOPA	 decarboxylase,	 tryptophan	 decarboxylase)	ADCC.	
This	results	in	serotonin,	which	is	then	also	stored	in	vesicles	through	the	vesicular	mono-
amine	transporter.	When	released	into	the	extracellular	environment,	serotonin	is	thereafter	
degraded	and	eventually	excreted	as	urinary	5-hydroxyindole	acetic	acid	(5-HIAA).
11C-5-HTP	is	produced	in	only	a	few	centers	worldwide,	since	the	tracer	synthesis	is	very	
complex.	It	 is	advised	for	 the	pretreatment	of	patients	with	carbidopa	(43).	Whole-body	
imaging usually starts 10–20 min after injection of the tracer. Based on the limited studies 
that	have	been	published,	it	can	be	concluded	that	11C-5-HTP is a universal NET tracer for 
all	tumors	arising	from	the	fore-	to	hindgut	(44,	45).	It	has	been	suggested	that	11C-5-HTP 
performs better compared to 18F-DOPA,	especially	 in	foregut	(e.g.	bronchial)	NETs,	but	
this	 needs	 further	 confirmation	 (33).	 In	 a	 recent	 study,	Orlefors	 et	 al.	 (46)	 reported	 for	
11C-5-HTP PET a sensitivity of 83% and specificity of 100% in 38 patients with abdominal 
NETs,	confirmed	by	surgery	and	histopathology	results.	An	example	of	a	11C-5-HTP PET 
is	given	in	figure	3.	Based	on	a	study	by	Koopmans	et	al.	(47),	it	was	concluded	that	11C-5-
HTP PET outperforms 18F-DOPA PET both in a patient- and a tumor lesion-based analysis 
in	patients	with	predominantly	advanced	pancreatic	islet	cell	tumors.	However,	as	stated	
earlier,	there	are	different	opinions	regarding	the	choice	for	a	functional	imaging	PET	trac-
er	in	this	patient	group.	Not	only	for	pancreatic	NETs,	but	also	for	other	(subsets)	of	NETs,	
further research is needed to define more precisely the role of both metabolic pathway 
Figure 3.	Patient	with	insulinoma	grade	2	of	the	pancreas,	pT3N1M1.	A.	Maximum	intensity	
projection of whole body 11C-5-HTP PET before surgery. The primary tumor is seen in the head 
of	the	pancreas.	Also,	a	liver	metastasis	(black	arrow)	and	a	locoregional	lymph	node	metastasis	
were detected. All were surgically removed. Physiological uptake is seen in salivary and mammary 
glands,	mucosa	of	the	oesophagus	and	bone	marrow.	Physiological	excretion	is	via	the	kidneys	and	
ureters	to	the	bladder.	B.	Six	months	later	during	follow-up	with	11C-5-HTP PET and a diagnostic 
CT	of	the	abdomen,	two	small	new	locoregional	metastatic	lymph	nodes	were	detected.	C.	Trans-
verse slices of 11C-5-HTP	PET/CT	showing	the	two	new	lesions,	para-aortic	right	and	left-sided.	D.	
Transverse	slices	of	the	diagnostic	CT	of	the	abdomen	(venous	phase),	also	showing	the	two	new	
lymph node metastases. E. A follow-up 111In-DTPA-octreotide SPECT scan (transverse slice) failed 
to detect these small metastases.
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tracers,	18F-DOPA and 11C-5-HTP,	also	in	relation	to	other	new	functional	PET	tracers	that	
are currently being developed or are already in use.
Glucagon-Like Peptide-1 Receptor
A rare type of NET is the insulinoma. The great majority (more than 90%) of insulinomas 
are	benign,	but	they	can	be	life	threatening	due	to	increased	excretion	of	insulin	and	in-
duction	of	episodes	of	hypoglycemia.	Approximately	10%	of	the	insulinomas	are	multiple,	
mainly in genetic polyendocrine syndromes. Insulinomas are the most common cause of 
endogenous	 hyperinsulinemic	 hypoglycemia	 in	 adults.	Virtually	 all	 insulinomas	 are	 lo-
cated	in	the	pancreas,	but	10–27%	remain	undetected	even	after	surgery	(48).	Preopera-
tive localization is therefore essential to facilitate and optimize surgery. The sensitivity of 
111In-DTPA-octreotide for detection of insulinomas is only 50–60% (49). Because of this 
relatively	poor	sensitivity,	other	imaging	targets	such	as	the	glucagon-like	peptide-1	recep-
tor	(GLP-1R)	have	been	recently	developed.	GLP-1R	is	expressed	at	very	high	density	in	
almost all benign insulinomas (50). The first studies with GLP-1R agonists demonstrated 
very	promising	results	(51,	52)	with	a	high	detection	rate	compared	to	conventional	imag-
ing.	However,	 these	agonists	are	not	commercially	available.	Unlike	benign	insulinoma,	
malignant	 insulinomas	often	 lack	GLP1-R.	 In	contrast,	 the	malignant	 insulinomas	often	
express	SSTR	type	2,	which	can	be	visualized	by	SRS	(53).
Imaging Response after Therapy
Adequate assessment of response after therapy is important in NET patients. Not only will 
it	predict	 the	prognosis	of	 the	patient,	but	 it	will	also	influence	the	decision	to	continue	
the current therapy or to switch to other alternative therapies. The most frequently used 
assessment method during follow-up is the response evaluation criteria in solid tumors 
(RECIST). This assessment is based on the number and size of the lesions measured on CT 
and,	in	certain	situations,	MRI	or	chest	X-ray.	The	latest	guideline	version	was	published	
in 2009 (54). A partial response (PR) is defined as a decrease of at least 30% in the sum of 
the diameters of target lesions. Progressive disease (PD) is defined as a 20% increase in the 
sum of the diameters of target lesions. Stable disease is every change that is not sufficient 
for PD or PR. Another response evaluation assessment method is the Southwest Oncology 
Group (SWOG) solid tumor response criteria. The SWOG criteria use a slightly different 
method for tumor measuring and different definitions for PD and PR. In a direct compar-
ison between the RECIST and SWOG criteria in patients treated with [177Lu-DOTA0,Tyr3]
octreotate,	 there	were	 no	 significant	 differences	 in	 the	 evaluation	 of	 responses	 (55).	 In	
general,	NETs	are	 slow-growing	 tumors	and	most	 therapies	do	not	 lead	 to	 shrinkage	of	
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tumors,	 but	 stable	 disease	 instead.	Therefore,	 the	RECIST	 criteria	 using	morphological	
volume characteristics may not be the ideal response criteria for relatively slow-grow-
ing	NETs	 (i.e.	 G1/G2	 tumors).	 Different	 groups	 have	 tried	 to	 develop	 new	 criteria	 for	
response evaluation based on nuclear imaging techniques. A small study with 4 patients 
found	a	more	appropriate	evaluation	with	the	tumor-to-nontumor	ratio	(T/nT)	on	SRS	with	
99mTc-EDDA/HYNIC-TOC	 in	 combination	with	volume	 and	 attenuation	 changes	on	CT	
(56). With the newest 68 Ga-SSA,	it	is	easier	to	measure	the	change	in	standardized	uptake	
value	(SUV).	Haug	et	al.	(57)	measured	the	tumor-to-spleen	SUV	ratio	and	maximum	SUV	
ratio at baseline and 3 months after the first cycle of PRRT. They found a significant cor-
relation	with	improvement	in	clinical	symptoms.	Moreover,	the	decrease	in	tumor	uptake	
predicted	a	longer	time	to	progression.	On	the	other	hand,	Gabriel	et	al.	(58)	found	that	an	
SUV	analysis	of	individual	lesions	did	not	have	an	additional	value	in	the	prediction	of	in-
dividual responses to therapy compared with conventional anatomical imaging with CT. It 
is clear that further investigation is needed. A disadvantage of somatostatin-based imaging 
is	that	NETs	may	lose	their	receptors	and	become	negative	on	these	images.	Therefore,	it	
would be very interesting to measure the response with metabolic tracers like 18F-DOPA 
or 11C-	5-HTP,	which	demonstrate	metabolism	within	the	tumor	rather	than	expression	of	
receptors.	Unfortunately,	there	are	so	far	no	data	available	on	the	use	of	these	tracers	for	
response	evaluation,	but	 this	 type	of	response	evaluation	will	become	paramount	within	
the	next	decade.
Conclusion
The initial diagnosis of NETs is made with radiological and histological methods.
Nuclear	imaging	techniques	are	essential	to	estimate	the	total	disease	burden.	Currently,	
the gold standard for the imaging of NETs is SRS with 111In-DTPA-octreotide. It is almost 
certain that in the near future this will be replaced by 68Ga-SSA PET imaging. 18F-FDG 
PET	has	a	limited	role	in	the	imaging	of	NETs,	but	may	play	a	role	in	predicting	the	prog-
nosis	in	G2/G3	tumor	patients.	11C-5-HTP and 18F-DOPA PET show very promising results 
but	are	more	difficult	to	produce	and/or	not	widely	available.	18F-DOPA is commercially 
available in several European countries and its use may increase in the coming years. Be-
sides,	18F-DOPA	has	broader	imaging	applications	than	only	NETs.	Currently,	selection	for	
PRRT is based on SRS; further research needs to be done to translate the uptake on SRS 
to accumulation in the tumor on 68Ga-SSA	imaging.	Subsequently,	changes	in	tumor	accu-
mulation	after	therapy	using	metabolic	tracers	can	have	an	additional	value	to	the	existing	
response	criteria	based	on	CT/MRI.
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Abstract 
Purpose 
Physiological uptake in the uncinate process or pancreatic head has been described with 
68Ga-labeled PET tracers for somatostatin receptor imaging. 111In-DTPA-octreotide is the 
only registered radiopharmaceutical for the imaging of neuroendocrine tumors. We studied 
the uptake in this region of the pancreatic head on somatostatin receptor scintigraphy (SRS) 
using 111In-DTPA-octreotide	in	a	large	group	of	patients.	Furthermore,	known	physiolog-
ical and clinical characteristics are discussed in an attempt to elucidate this phenomenon.
Methods
Four hundred seven patients underwent SRS using 111In-DTPAoctreotide in our department 
in	2014.	After	excluding	patients	with	a	known	malignancy	in	or	close	to	the	pancreas,	as	
well	as	all	scans	without	SPECT/CT	of	the	upper	abdomen,	we	reviewed	178	scans	in	total.	
The uptake was graded on a 4-point scale that correlates the uptake in the pancreatic head 
to physiological uptake in the liver.
Results
Uptake	in	the	region	of	the	pancreatic	head,	including	the	uncinate	process,	was	seen	in	
46	(26%)	of	178	patients	on	SPECT/CT	and	in	12	patients	(7%)	on	planar	 imaging.	On	
SPECT/CT,	uptake	was	lower	than	the	liver	in	26	patients	(15%),	equal	to	the	liver	in	17	
patients	(10%),	and	higher	than	the	liver	in	3	patients	(2%).	In	patients	with	diabetes	melli-
tus	(DM),	the	incidence	of	uptake	in	the	pancreatic	head	was	50%	on	SPECT/CT.
Conclusions 
Physiological	 uptake	 in	 the	 pancreatic	 head	 is	 seen	on	SPECT/CT	with	 111In-DTPA-oc-
treotide	 in	26%	of	patients,	and	 the	 incidence	 is	doubled	 in	patients	with	DM.	Previous	
case reports showed uptake in the pancreatic head due to histologically proven pancreatic 
polypeptide	(PP)	cell	hyperplasia.	Also,	patients	with	DM	have	elevated	serum	PP	concen-
trations,	which	is	likely	due	to	PP	cell	hyperplasia.	Because	90%	of	PP	cells	are	present	in	
the	pancreatic	head,	PP	cell	hyperplasia	is	the	most	likely	explanation	for	visualization	of	
the pancreatic head on SRS in a substantial number of patients.
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Introduction
Neuroendocrine	tumors	(NETs)	are	heterogeneous.	However,	these	tumors	have	in	com-
mon	that	in	the	vast	majority	the	somatostatin	receptor	(SSTR)	is	overexpressed	on	their	
cell surface. This receptor can be used for imaging with radiolabeled somatostatin ana-
logs. This type of imaging was first described in humans in 1989 (1). Although different 
somatostatin	analogs	linked	to	different	radionuclides	have	been	used	in	the	past	decades,	
the only registered radiopharmaceutical for SSTR scintigraphy (SRS) is [111In-DTPA]oc-
treotide	(OctreoScan;	Covidien,	Petten,	the	Netherlands).	Currently,	SRS	plays	a	pivotal	
role	in	the	diagnosis	and	staging	of	patients	with	NETs.	Besides,	it	is	the	only	validated	
imaging method to select patients for peptide receptor radionuclide therapy. Neuroendo-
crine	tumors	are	not	the	only	malignant	tumors	that	overexpress	the	SSTR,	and	therefore	
other	malignant	diseases	can	be	detected	with	SRS.	Furthermore,	non	neoplastic	diseases,	
such	 as	 autoimmune	diseases,	 granulomas,	 and	 infections,	 can	 be	 visualized	with	SRS.	
False-positive	findings	have	been	described	in	patients	with	gastritis,	splenosis,	radiation	
fibrosis,	and	inflammatory	bowel	disease	(2–4).	This	nonspecific	uptake	can	be	difficult	to	
distinguish from tumor-related pathology but is important knowledge for optimal reading.
Although	 new	 PET	 tracers	 have	 become	 available	 in	 the	 past	 years,	 SRS	 using	 111In- 
DTPA-octreotide is most widely available and frequently used for imaging of NETs. How-
ever,	 the	new	 68Ga-labeled	 somatostatin	 analogs	 that	 are	used	 in	PET/CT	 imaging	have	
many	 advantages	 over	 SRS,	 such	 as	 better	 image	 quality,	 patient	 comfort,	 and	 a	 lower	
radiation	dose.	A	disadvantage	is	 the	uptake	by	the	pancreatic	head	or	uncinate	process,	
which can lead to false-positive findings. This physiological uptake in the region of the 
pancreatic head has been described for [68Ga-DOTA0,	Tyr3]octreotide (68Ga-DOTATOC),	
[68Ga-DOTA,1-nal3]octreotide (68Ga-DOTANOC),	 and	 [68Ga-DOTA0,	 Tyr3]octreotate 
(68Ga-DOTATATE) (5–10) (Table 1). These 3 tracers all have a different affinity for the 
Reference Ligand Imaging  
modality 
Localisation Incidence  
Al-Ibraheem et al (2011) (5) 68Ga-DOTATOC PET/CT Pancreatic head 20/43	(47%)
Castellucci et al (2011) (6) 68Ga-DOTANOC PET/CT Pancreatic head 31/100	(31%)
Kunikowska et al (2012) (7) 68Ga-DOTATATE PET/CT Uncinate process 41/250	(16%)
Jacobssen et al (2012) (8) 68Ga-DOTATOC PET/CT Uncinate process 35/50	(70%)
Krausz et al (2012) (9) 68Ga-DOTANOC PET/CT Head/uncinate	
process/body	
38/103	(37%)
Mapelli et al (2014) (10) 68Ga-DOTATATE PET/CT Head/uncinate	
process 
10/38	(26%)
Yamaga et al (2015) (13) 99mTc-HYNIC-TOC SPECT/CT Uncinate process 7/36	(19%)
Table 1. Frequency of visualization of physiological uptake in the pancreas. 
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5	known	subtypes	of	the	SSTR,	but	have	in	common	a	high	affinity	for	the	subtype	2	re-
ceptor.	It	is	known	that	SSTR	subtypes	1,	2,	3,	and	5	are	present	in	the	endocrine	pancreas	
(12). 111In-DTPA-octreotide	also	has	a	high	affinity	 for	 the	subtype	2	 receptor,	 followed	
by	subtypes	3	and	5.	Therefore,	 also	with	 111In-DTPA-octreotide	 imaging,	uptake	 in	 the	
pancreatic	head	in	some	patients	can	be	expected.
Materials and Methods 
Patients
This retrospective study included a total of 407 consecutive 111In-DTPA-octreotide imaging 
studies that were obtained in our department in 2014. Imaging was performed for diagnostic 
workup,	staging,	or	follow-up.	Patients	without	an	SPECT/CT	of	the	upper	abdomen	or	with	
a	known	NET	in	the	pancreas	were	excluded	from	analysis.	Other	exclusion	criteria	were	pri-
or	surgery	of	the	pancreas	and	lymph	node	metastases	close	to	the	pancreas	(eg,	lymph	nodes	
in the hilum of the liver or retroperitoneal metastases of paragangliomas) to minimize the 
possibility of false-positive uptake in the pancreatic head. If a patient had multiple imaging 
studies	in	2014,	only	the	first	was	included.	All	patients	who	did	have	uptake	in	the	pancreas,	
but	had	no	contrast	enhanced	CTor	MRI	to	correlate	with,	were	excluded	as	well.	After	exclu-
sion,	178	patients	were	available	for	analysis.	The	indications	for	SRS	are	listed	in	Table	2.
Image Acquisition and Analysis
Patients	were	 injected	 intravenously	with	a	mean	activity	of	225	MBq	 (range,	203–241	
MBq) 111In-DTPA-octreotide. Patients were prepared according to the European Associa-
tion of Nuclear Medicine guidelines (13). Somatostatin analog therapy was discontinued 
if	 clinically	 feasible.	 Oral	 laxatives	were	 administered	 on	 the	 day	 before	 and	 after	 the	
injection. Images were acquired 24 hours after injection using a Siemens Symbia T16 
SPECT/CT	scanner	(Siemens	Healthcare,	Erlangen,	Germany).	Spotviews	of	the	head,	tho-
rax,	upper	abdomen,	and	pelvis	were	made	15	minutes	per	view	(256x256	matrix,	MELP	
collimator),	followed	by	an	SPECT/CT	of	the	upper	abdomen.	A	low-dose	CTwas	acquired	
for attenuation correction and anatomical localization. The CT parameters were as follows: 
110	kV,	40	mAs,	a	0.6-second	tube	rotation,	and	a	5-mm	slice	thickness.	SPECT	parame-
ters	were	128x128	matrix,	60	views/detector,	30-second	time	per	view.	If	indicated,	extra	
images of the abdomen 48 hours after injection were made. A nuclear medicine physician 
examined	the	images	without	knowledge	of	the	medical	history.	Uptake	in	the	pancreatic	
head	was	graded	on	a	4-point	scale:	0,	no	uptake;	1,	intensity	less	than	the	physiological	
uptake	in	the	liver;	2,	intensity	identical	to	the	liver;	and	3,	intensity	greater	than	the	liver.	
Uptake	was	scored	both	on	planar	and	SPECT/CT	imaging.	Positive	findings	were	com-
pared with diagnostic abdominal CT or MRI obtained within 12 months of SRS.
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Results 
In	46	(26%)	of	178	patients,	uptake	in	the	pancreatic	head	was	found	on	SPECT/CT.	Twelve	
patients	(7%)	also	demonstrated	uptake	on	the	planar	imaging.	On	planar	imaging,	uptake	
was lower than the physiological uptake in the liver in 7 patients (4%) and equal to the liver 
in	5	patients	(3%).	On	SPECT/CT,	uptake	was	lower	than	the	liver	in	26	patients	(15%),	
equal	to	the	liver	in	17	patients	(10%),	and	higher	than	the	liver	in	3	patients	(2%)	(Table	
3).	An	example	of	a	patient	with	uptake	grade	3	in	the	pancreatic	head	is	given	in	Figure	1.	
Of	the	178	patients,	20	patients	were	on	antidiabetic	drugs	(metformin,	glimepiride,	and/
Indication Number of patients
NET   - Small intestine 107
          - Rectum 12
          - Unknown primary 11
          - Bronchus 9
          - Ovarian 4
          - Kidney 2
										-	Stomach	/	esophagus	 2
										-	Appendix 1
          - Clinical suspicion 3
Paraganglioma 17
Common	variable	immunodeficiency 3
Pheochromocytoma 2
Cushing’s syndrome 1
Meningioma 1
Hurthle cell carcinoma 1
Castleman’s disease 1
Malignant lymphoma 1
Total 178
Table 2. Indications for 111In-DTPA-octreotide	imaging	including	planar	imaging	and	SPECT/CT	
of the upper abdomen.
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or	insulin),	as	evidenced	by	their	medical	history	in	patient	files.	Of	these	20	patients,	10	
had	uptake	in	the	pancreatic	head	(50%),	whereas	in	the	patients	without	known	diabetes,	
36 (23%) of 158 had uptake in this area. The correlating diagnostic CT or MRI that was 
performed within 12 months after 111In-DTPA-octreotide did not show any pathology in 
this area. 
Discussion 
In patients imaged with PET-CT with 68Ga-labeled somatostatin analogs (68Ga-SSA),	up-
take in the area of the pancreatic head or uncinate process is a known pitfall and can result 
in	false-positive	findings.	In	the	era	before	the	availability	of	SPECT/CT,	uptake	in	the	up-
per	abdomen	was	mostly	attributed	to	physiological	activity	in	the	intestine.	However,	with	
the	use	of	SPECT/CT,	it	 is	possible	to	localize	the	exact	anatomical	structure	and	prove	
that this activity is located in the pancreatic head. It has been postulated that detection of 
uptake in the pancreatic head with 68Ga-SSA	PET/CT	imaging	is	due	to	the	higher	imaging	
quality and spatial resolution of this type of imaging. We retrospectively demonstrated 
that the pancreatic head is visible on SRS using 111In-DTPA-octreotide as well. A previous 
report on SRS with 99mTc-HYNIC-TOC showed similar results of uptake in the uncinate 
process	on	SPECT/CT	in	19%	of	studies	without	any	evidence	of	a	malignancy	on	the	CT	
or	MRI	(11).	In	previous	reports,	it	was	postulated	that	physiological	uptake	in	the	uncinate	
process	was	due	to	the	presence	of	SSTR	subtypes	2,	3,	and	5	on	islet	cells,	and	therefore	
a	higher	density	of	islet	cells	in	this	area	was	suggested.	However,	Ionescu-Tirgoviste	et	
al (14) showed that the numbers of islets found in the head of the pancreas are similar or 
less	compared	with	other	parts	of	the	pancreas.	Also,	the	total	islet	volume	is	lower	in	the	
head of the pancreas compared with the body and tail. Wang et al (15) demonstrated that 
the	pancreatic	head,	 or	more	 specifically	 the	uncinate	 region,	 is	 very	 rich	 in	pancreatic	
polypeptide	(PP)	cells.	Moreover,	 the	vast	majority	of	PP	cells	(90%)	are	 located	in	 the	
uncinate	process	of	 the	pancreas,	whereas	 the	number	of	α	and	β	cells	are	 significantly	
decreased	in	this	area	of	the	pancreas.	The	PP	cells	express	SSTR	subtypes	1	to	4	on	their	
surface and can therefore be visualized on SRS (Fig. 2). Because of a lack of histological 
Uptake grade Planar SPECT/CT
0 166 (93%) 132 (74%)
1 7 (4%) 26 (15%)
2 5 (3%) 17 (10%)
3 0 (0%) 3 (2%)
Table 3. Number of patients with uptake in the pancreatic head.
Uptake	grade:	0,	no	uptake;	1,	intensity	less	than	physiological	uptake	in	the	normal	liver	paren-
chyma;	2,	intensity	identical	to	the	liver	and	3,	intensity	greater	than	the	liver
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confirmation	in	our	study,	it	is	difficult	to	prove	that	the	high	number	of	PP	cells	in	the	un-
cinate	region	attributes	to	the	demonstrated	uptake	in	this	area.	On	the	other	hand,	there	are	
2 case reports in which high uptake in the posterior part of the pancreatic head on 111In-DT-
PA-octreotide scintigraphy was demonstrated because of histologically proven hyperplasia 
of	the	PP	cells	(16,17).	This	may	suggest	that	the	PP	cells	are	responsible	for	the	uptake	in	
the	pancreatic	head	in	our	study.	Interestingly,	we	found	a	significantly	higher	percentage	
of physiological uptake in the head of the pancreas in patients who were on antidiabetic 
drugs. It is known that the number and distribution of islet cells change in patients with 
diabetes mellitus (DM).
The	number	of	β	cells	decreases,	and	the	α	cells	show	an	increase	in	number	(18).	Further-
more,	the	total	islet	tissue	mass	is	lower	in	patients	with	DM	compared	with	patients	with	
no DM. It was reported in several studies that the level of serum PP is higher in patients 
with	DM	compared	with	patients	with	no	DM	(19,20).	Such	higher	serum	concentrations	
of PP might be due to hyperplasia of the PP cells in the pancreatic head. Studies that quan-
tified the changes in PP cell population in patients with DM have produced conflicting re-
ports of increased or unaltered numbers (21–24). It seems likely that the reported elevated 
serum concentration of PP in patients with DM is due to PP cell hyperplasia. This PP cell 
hyperplasia	as	such	would	then	explain	the	higher	frequency	of	visualization	of	the	pan-
creatic head on SRS in patients with DM. The elevation of serum PP levels is not specific 
for	DM.	It	has	been	described	in	other	disease	states,	such	as	infections	and	inflammatory	
disorders (25). Because some patients with (a suspected) inflammatory disorder or infec-
tion	undergo	SRS	at	our	department,	this	may	be	the	explanation	for	the	uptake	in	patients	
with	no	DM.	Alternatively,	PP	cell	hyperplasia	may	be	present	in	such	patients	and	signify	
a prodromal phase of diabetes. 
Figure 1. Planar	imaging	of	the	abdomen	(left	image)	and	axial	slice	of	the	SPECT/CT	of	the	upper	
abdomen (right image). The patient was diagnosed with a NET of the small intestine and multiple 
metastases	in	the	liver.	Images	show	an	intense,	focal	uptake	in	the	pancreatic	head	(red	arrow).	
The contrast enhanced CT that was made in the same period did not demonstrate any evidence of a 
malignancy in this area. 
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A	different	explanation	for	the	increased	frequency	of	visualization	of	the	uncinate	process	
in patients with DM might be the infiltration of lymphocytes in the diabetic pancreas. 
Previous analyses demonstrated that CD4+ and CD8+ T cells were more frequent in the 
islets	of	patients	with	DM	compared	with	healthy	donors	(26,27).	Also,	the	proportion	of	
B lymphocytes was significantly elevated in patients with DM type 2 (28). Both T and B 
lymphocytes	 in	 the	peripheral	blood	express	SSTR	subtype	3.	Upon	stimulation,	mono-
cytes	 express	SSTR	subtype	2a	 as	well	 (29).	These	 subtypes	 can	be	visualized	by	SRS	
and	therefore	may	lead	to	a	higher	uptake	during	SRS	in	patients	with	DM.	However,	the	
infiltration	of	lymphocytes	is	not	limited	to	the	pancreatic	head.	Therefore,	this	hypothesis	
cannot	explain	our	findings	on	SRS.
Figure 2. Diagram illustrating the proposed role of the PP-cell in visualization of the pancreatic 
head on SRS. The head of the pancreas has a high density of pancreatic polypeptide cells. These 
PP-cells	express	the	somatostatin	receptor,	which	is	a	member	of	the	family	of	G-protein-coupled	
receptor and can bind 111In-DTPA-octreotide.
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The	main	limitation	of	this	study	is	the	lack	of	a	criterion	standard,	which	is	histological	
confirmation of the state of the pancreatic head. None of the patients had a biopsy or 
surgery	in	the	area	of	high	uptake	on	SRS.	We	think,	however,	 that	we	well	argued	and	
discussed	the	likely	role	of	PP	cell	hyperplasia	as	mechanism	to	explain	the	visualization	of	
the	pancreatic	head	in	approximately	a	quarter	of	patients	undergoing	SRS	with	111In-DT-
PA-octreotide.
Conclusions 
In	this	study,	visualization	of	physiological	uptake	in	the	area	of	 the	pancreatic	head	on	
111In-DTPA-octreotide	SPECT/CT	was	demonstrated	in	26%	of	patients	without	any	evi-
dence of a malignancy on CT or MRI. These results are consistent with previous studies 
using 68Ga-SSA	in	PET/CT	and	99mTc-HYNIC-TOC scintigraphy. The uptake can vary be-
tween patients from very low to higher than the uptake in normal liver parenchyma. The 
uptake is seen more frequently in patients with DM. Previous case reports showed uptake 
in	the	pancreatic	head	due	to	histologically	proven	PP	cell	hyperplasia.	Also,	patients	with	
DM	have	elevated	 serum	PP	concentrations,	which	 is	 likely	due	 to	PP	cell	hyperplasia.	
Because	90%	of	PP	cells	are	present	in	the	pancreatic	head,	PP	cell	hyperplasia	is	the	most	
likely	explanation	for	visualization	of	the	pancreatic	head	on	SRS	in	a	substantial	number	
of patients. Awareness of the possibility of this physiological uptake in the pancreatic head 
should be taken into account when evaluating and reporting SRS with 111In-DTPA-oct-
reotide.
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Abstract
In	the	past	decades,	the	number	of	neuroendocrine	tumors	that	are	detected	is	increasing.	
A relative new and promising therapy for patients with metastasized or inoperable dis-
ease is peptide receptor radionuclide therapy (PRRT). This therapy involves an infusion of 
somatostatin analogs linked to radionuclides like Yttrium-90 or Lutetium-177. Objective 
response rates are reported in 15-35%. Response rates may vary between type of tumor 
and	radionuclide.	Besides	the	objective	response	rate,	overall	survival	and	progression	free	
survival	increase	significantly.	Also,	the	quality	of	life	improves	as	well.	Serious	side-af-
fects	are	rare.	PRRT	is	usually	well	tolerated,	also	in	patients	with	extensive	metastasized	
disease.	Recent	studies	combined	PRRT	with	other	types	of	therapies.	Unfortunately,	no	
randomized	trials	comparing	these	strategies	are	available.	In	the	future,	more	research	is	
needed to evaluate the best therapy combinations or sequence of therapies.
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Introduction 
Neuroendocrine tumors (NETs) are a heterogeneous group of tumors. These tumors can 
induce a number of symptoms (e.g. carcinoid syndrome) or can be asymptomatic for a 
long	time.	Unfortunately,	more	than	50%	of	the	patients	have	metastatic	disease	at	 time	
of	presentation.	When	NETs	are	metastasized,	no	curative	 treatment	option	 is	available.	
Surgery,	the	only	therapeutic	option	with	a	curative	intent,	is	reserved	for	limited	disease	
(no or few metastases). For the large group of patients with metastatic disease different 
types of treatment were developed in the last decades. One of the most promising is Peptide 
Receptor Radionuclide Therapy (PRRT). This therapy is based on the fact that the major-
ity	of	neuroendocrine	tumors	express	the	somatostatin	receptor	(SSTR)	on	their	surface.	
This	receptor	is	the	target	for	somatostatin	analogs	(SSA),	which	is	an	effective	first	line	
treatment for especially midgut NETs in terms of time to progression (1). In the nineties 
of	 the	past	century,	 the	 first	 research	groups	started	with	PRRT	using	SSA	labeled	with	
Indium-111 (111In-DTPA-Octreotide)	(2,3).	This	radiopharmaceutical,	which	emits	y-rays,	
can	be	used	for	imaging	of	neuroendocrine	tumors.	It	also	emits	Auger	electrons,	which	
can be used for therapy. The results of PRRT with 111In-DTPA-Octreotide	were	reasonable,	
however	 the	number	of	patients	with	a	complete	or	partial	 response	 (CR,	PR)	was	 low.	
In	the	following	years,	radiolabeled	somatostatin	analog	therapy	became	more	advanced,	
with	the	introduction	of	PRRT	with	analogs	labeled	with	the	β-emitting	radionuclides	Lu-
tetium-177	or	Yttrium-90.	In	general,	PRRT	with	radiolabeled	somatostatin	analogs	is	used	
mostly	for	NETs,	but	can	also	be	used	for	other	somatostatin	receptor	positive	disease	such	
as	paragangliomas,	meningiomas	and	iodine	refractory	thyroid	cancer	(4-6).	
Efficacy in vivo stability of the radiolabeled peptide is an important factor that contrib-
utes	 to	 its	 success.	 For	 the	Yttrium-90	 and	Lutetium-177	 based	PRRT,	 the	 stable	 bind-
ing of the somatostatin analogs linked to the radionuclide is established via the chela-
tor	 1,4,7,10-tetraazacyclotetradecane-1,4,7,10-tetraacetic	 acid	 (DOTA).	With	 the	 use	 of	
DOTA,	these	radionuclides	can	bind	to	different	somatostatin	analogs,	such	as	octreotide	
or octreotate.
The	results	of	several	phase	1/2	studies	have	been	published	in	the	last	decade.	Different	so-
matostatin analogs with different affinity profiles to the five known subtypes were labeled 
with Yttrium-90 or Lutetium-177. Although in most studies Yttrium-90 is linked to the 
analog [Tyr3]octreotide and Lutetium-177 to the analog [Tyr3]octreotate,	different	combi-
nations	of	analogs	and	chelators	have	also	been	tested.	Considering	the	radionuclides	used,	
there are some differences in physical properties between Yttrium-90 and Lutetium-177. 
The	half-life	of	Lutetium-177	is	6.7	days	versus	2.7	days	for	Yttrium-90.	Furthermore,	the	
tissue penetration of Yttrium-90 is 12 mm and of Lutetium-177 is 2 mm. This longer tissue 
penetration of Yttrium-90 is especially beneficial in tumors with a heterogeneous receptor 
expression.	The	shorter	tissue	penetration	of	Lutetium-177	makes	this	radionuclide	prob-
ably	more	suitable	to	treat	also	smaller	tumors	(7).	Besides	beta-emission,	Lutetium-177	
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also	emits	y-rays	that	can	be	used	for	imaging	in	the	days	after	therapy.	Therefore,	these	
images can be used to verify the targeted delivery of the radiopharmaceutical and to calcu-
late	absorbed	dose	in	organs/tissues	and	SSTR	positive	tumors.
Yttrium-90
One of the first studies with PRRT other than 111In-DTPA-Octreotide was published in 
2001 by Waldherr et al. (8). Patients with gastroenteropancreatic (GEP-NETs) and bron-
chial NETs were included and treated with [90Y-DOTA0,Tyr3]Octreotide (90Y-DOTATOC). 
The overall response (complete and partial remission) was 24%. For pancreatic NETs the 
response was 36%. Since then numerous reports from several research groups involved 
in PRRT were published (Table 1). The number and type of SSRT positive tumors that 
were	treated	varied	between	the	studies.	Therefore,	interstudy	comparison	of	the	outcome	
reported within these studies remains difficult. The largest group of patients studied (9) 
(1109	patients)	showed	a	morphological	response	in	34%	of	patients.	However,	it	was	a	
mixed	group	with	different	types	of	SSTR	positive	tumors	and	patients	were	treated	with	
different amounts of radioactivity and different kinds of radiolabeled SSA. Cwikla et al. 
(10) treated 60 patients with GEPNETs with 90Y-DOTATATE. An objective tumor response 
was observed in 23% and stable disease (SD) in the remaining 77%. Other studies with 
90Y-DOTATOC showed comparable results (Table 1).
Lutetium-177
Kwekkeboom et al. were the first to describe PRRT with [177Lu-DOTA0,Tyr3]Octreotate 
(177Lu-DOTATATE) in 2003 (11) and reported the outcome of PRRT in a large group of 
patients in 2005 (12). The reported 131 patients were treated with a cumulative dose of 
22.2-29.6	GBq	(600-800	mCi).	Complete	response	was	reported	in	2%	of	the	patients,	PR	
in 26% and minor response (MR) in 19%. Overall the tumor response rate for pancreatic 
tumors was higher than for other types of SSTR positive tumors. 
Figure 1 shows a patient with a good result after PRRT with 177Lu-DOTATATE. Like with 
90Y-based	PRRT,	the	published	clinical	studies	on	177Lu-based therapies were conducted in 
patients with different types of SSTR tumors (see Table 1). Although a randomized trial 
comparing 90Y- and 177Lu-based	PRRT	is	 lacking,	 it	 is	generally	accepted	that	 the	 tumor	
responses	are	more	or	less	similar.	Unfortunately,	a	direct	randomized	comparison	between	
Yttrium-90 and Lutetium-177 is currently not available. Only one non-randomized study 
compared PRRT with 90Y-DOTATOC and 177Lu-DOTATOC,	and	no	significant	difference	
in median overall survival was found with either radiolabeled peptide (13). One important 
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Figure 1. A 60-year-old patient with an insulinoma and liver metastases. A. Upper row: Trans-
verse	slices	of	the	diagnostic	CT	of	the	abdomen	at	baseline	and	12	months	after	therapy,	showing	
a large tumor in the pancreas (grew arrow) and liver metastases. Lower row: Planar scintigraphy 
performed 24 hour postinjection demonstrated high uptake in the pancreatic tumor and liver me-
tastases.	During	treatment,	the	intensity	in	the	tumor	decreases,	indicating	tumor	response.	B.	Plot	
depicts	serum	chromogranine	A	(CgA)	at	baseline,	6	weeks	after	each	administration	of	PRRT	and	
during	follow-up.	After	therapy,	the	patient	was	without	any	hypoglycemic	episodes.	
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difference	between	 the	 two	studied	groups	of	 advanced	NET	patients,	was	 that	patients	
treated with 177Lu-DOTATOC	suffered	from	less	hematological	toxicity	during	follow-up.	
Other	 outcome	measures,	 such	 as	 progression	 free	 survival	 (PFS)	 and	 overall	 survival	
(OS),	are	only	reported	in	a	limited	number	of	studies.	Median	PFS	varied	from	16	to	33	
months and median OS varied from 22 to 53 months (Table 2).
Comparison with the effectiveness of unlabeled SSA is logical since most patients with 
symptoms of the hormone producing tumors are treated already with unlabeled somatosta-
tin	analogs	(e.g.	octreotide	or	lanreotide).	Besides	symptomatic	relief,	these	‘cold’	analogs	
can lengthen the time to tumor progression compared to placebo in patients with mid-
gut NETs as well (1). A large randomized study comparing PRRT (177Lu-DOTATATE) to 
high-dose Sandostatin LAR in patients with progressive inoperable or metastasized midgut 
NETs (NETTER-1) was recently concluded in Europe and the USA. The outcome of this 
unique phase 3 randomized clinical trial is anticipated in the fall of 2015 and will be used 
to determine the position of PRRT with 177Lu-DOTATATE more clearly in the therapeutic 
algorithm for this specific patient category. Several clinical factors can predict whether 
a tumor will respond after therapy with 177Lu-DOTATATE. High uptake on the prethera-
peutic somatostatin receptor scintigraphy with 111In-DTPA-octreotide is associated with a 
good	response	after	therapy.	Also,	patients	without	extensive	metastases	in	the	liver	will	
respond	better	than	patients	with	extensive	liver	metastasis.	Conversely,	an	extensive	tu-
mor load and a poor clinical condition are associated with a higher chance of progressive 
disease (14). PRRT with 177Lu-DOTATATE	is	mainly	used	for	GEP-	NETS,	but	can	be	used	
to	treat	other	somatostatin	receptor	positive	tumors	as	well,	such	as	paragangliomas,	me-
ningiomas and well-differentiated thyroid carcinoma. A limited number of studies showed 
that	the	therapy	can	be	effective	in	such	patients.	However,	the	number	of	patients	studied	
Reference
No. of  
patients
Tumor 
type
Median PFS 
(months)
Median OS 
(months)
[90Y-DOTA0,Tyr3]octreotide
Valkema	et	al	2006	(51) 58 GEP-NET 29 37
Bushnell et al 2010 (53) 90 GEP-NET 16 27
[90Y-DOTA0,Tyr3]octreotate
Cwikla et al 2010 (10) 58 GEP-NET 17 22
[177Lu-DOTA0,Tyr3]octreotate
Kwekkeboom et al. 2008 (14) 310 GEP-NET 33 46
Ezziddin et al 2014 (55) 68 pNET 34 53
Sabet et al 2015 (56) 61 Midgut NET 33 61
Table 2. Survival after PRRT
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was limited and therefore further research is needed to evaluate the effectiveness in these 
tumors (4-6). 
Quality of life
Treatment	with	PRRT	is	very	encouraging	in	terms	of	tumor	shrinkage,	progression	free	
survival	 and	overall	 survival,	 but	 improvement	of	quality	of	 life	 (QOL)	may	be	 just	 as	
important	 in	patients	with	extensive	metastatic	disease.	A	group	of	Dutch	patients	com-
pleted	different	questionnaires	before	and	6	weeks	after	the	last	cycle	of	PRRT,	unaware	
of treatment outcome. After therapy with 177Lu-DOTATATE,	insomnia,	appetite	 loss	and	
diarrhea	improved	significantly	(15,16).	Besides	these	symptoms,	the	global	health	status/
QOL improved significantly as well. Especially patients with bone metastasis had a relief 
of pain. A similar effect was seen in a small group of 13 patients treated with 90Y-DOTA-
TOC or 90Y-DOTA-lanreotide (90Y-DOTALAN) (17). Despite 9 out of the 13 patients had 
metastasized	NETs,	 patients	 with	 SD	 experienced	 an	 improvement	 in	weight,	 appetite,	
Karnofsky score and general wellbeing.
Side-effects
Acute side-effects
In	general,	PRRT	is	well	tolerated.	Acute	side-effects	with	177Lu-DOTATATE as reported in 
the study by Kwekkeboom et al. (14) are mild and include nausea (in a minority of patients 
accompanied with vomiting) and mild abdominal pain. These effects are probably caused by 
the concomitant infusion of amino-acids and occur mostly in the first 24-hours after therapy. 
Often these side effects are selflimiting or can be treated with anti-emetics. An other sub-
acute	side-effect	is	increased	hair	loss	(WHO	toxicity	grade	1).	This	was	noticed	in	64%	of	
the patients treated with 177Lu-DOTATATE. It has not been reported for 90Y-DOTATOC. An 
other	severe	but	rare	complication	is	a	carcinoid	crisis.	This	can	be	caused	by	the	excessive	
release of metabolically active amines or peptides. De Keizer et al. [18] described a hormon-
al crisis in 6 of 479 patients (1%) after treatment with 177Lu-DOTATATE.	Three	of	the	six	
patients developed the crises during or directly after infusion. The other three patients devel-
oped the crisis 48 h after infusion. All patients eventually recovered after adequate treatment.
Sub-acute and long-term side-effects
The	kidneys	and	bone	marrow	are	the	critical	or	dose	limiting	organs	due	to	sub-acute	and/
or	long-term	radiation	toxicity	(Table	3).	Radiation-induced	bone	marrow	suppression	is	
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observed	frequently	at	4-6	weeks	after	PRRT.	This	sub-acute	hematological	toxicity	caus-
ing	a	decrease	of	the	platelet	count,	white	blood	cell	(WBC)	count	and	hemoglobin	(Hb),	
is usually mild and reversible. Most susceptible for the radiation-induced decrease of cell 
count	are	the	platelets,	followed	by	the	white	blood	cells	and	Hb	level	(12).	WHO	Grade	
3/4	toxicity	in	any	of	the	blood	counts	occurred	in	<15%	of	the	treated	patients	(Table	3).	
Furthermore,	Sierra	et	al.	 (19)	 reported	a	mild	 transient	 toxicity	 in	WBC	count	 in	63%.	
Grade	 2-3	 lymphocyte	 reduction	was	 observed	 in	 88%	 of	 treated	 patients.	 Fortunately,	
all	toxicity	was	resolved	after	60	days.	Although	the	blood	count	will	recover	in	the	first	
months	of	therapy	in	the	majority	of	patients,	some	patients	will	have	more	severe	hema-
tological side-effects resulting in cessation of further cycles of PRRT. Lutetium-177 has 
a	shorter	tissue	penetration	than	Yttrium-90	and	may	therefore,	cause	less	toxicity	on	the	
bone marrow (19).
Indeed,	 different	 studies	 showed	 less	 severe	 hematological	 toxicity	 with	 PRRT	 using	
177Lu-DOTATATE	(Table	3).	Grade	3/4	toxicity	is	reported	in	approximately	12%	of	the	pa-
tients treated with 90Y-DOTATOC,	whereas	this	was	observed	in	4%	of	the	patients	treated	
with 177Lu-DOTATATE. Serious long-term hematological side-effects are myelodysplastic 
syndrome (MDS) and acute leukemia (AL). MDS is reported in 1-2% and AL in less than 
1% of the patients. A risk factor for the development of MDS is prior treatment with che-
motherapy,	tumor	invasion	in	the	bone	marrow	and	previous	use	of	myelotoxic	therapies	
(20).	Also,	chemotherapy	can	cause	hematological	toxicity	and	it	is	impossible	to	relate	the	
MDS	in	some	patients	directly	to	one	of	the	therapies,	since	they	were	treated	with	multiple	
cytoreductive	 therapies.	Another	 risk	 factor	 for	 developing	hematological	 toxicity	 is	 an	
impaired	renal	function	at	baseline.	Such	patients	were	exposed	to	a	higher	renal	dose	and	
subsequently	were	more	likely	to	develop	a	higher	grade	of	hematological	toxicity	(14,21).
Reference
No. of  
patients
Median Follow- 
up(months)
Severe renal 
(%)
Hematological 
Grade 3/4 MDS AL
[90Y-DOTA0,Tyr3]octreotide
Imhof et al 2011 (9) 1,109 31 9.2 11.3 <1 <1
Bodei et al 2015 (20) 360 30 2.8 14.1 2.35* 1.1*
[177Lu-DOTA0,Tyr3]octreotate
Kwekkeboom et al. 
2008 (14) 504 19 <1 3.6 <1 N/A
Gupta et al 2012 (57) 47 6 N/A 4.3 N/A N/A
Sabet et al 2013 (58) 203 31 0 11.3 1.4 0
Bodei et al 2015 (20) 290 30 0 3.1 2.35* 1.1*
Table 3. Toxicity	of	PRRT
*	in	the	total	group	patients	treated	with	Y	and/or	Lu.
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Another	potential	clinical	problem	to	take	into	account	is	renal	toxicity.	To	decrease	the	
radiation dose on the kidney specific amino-acids are co-administered. Infusion of these 
positively charged amino acids can reduce the kidney dose up to 40% via the inhibition of 
tubular reabsorption of the radiopeptide (22-24). Despite the absorbed dose to the kidneys 
in	each	patient	the	development	of	renal	failure	after	PRRT	is	extremely	rare.	However,	
a	retrospective	study	in	807	patients	demonstrated	renal	 toxicity	 in	35%	of	 the	patients.	
Severe	 (Grade	 3/4)	 occurred	 in	 1.5%	 (20).	 Similar	 to	 hematological	 side-effects,	 renal	
toxicity	is	observed	more	frequently	after	therapy	with	Yttrium-90	and	after	therapy	with	
the combination of Yttrium-90 and Lutetium-177 than after treatment with Lutetium-177 
labeled somatostatin analogs. Especially patients that have a poor renal function before 
therapy	are	at	risk	for	severe	renal	toxicity	or	renal	failure.	Other	established	risk	factors	
include	hypertension,	diabetes,	age	(>60	years),	renal	morphological	abnormalities,	tran-
sarterial	chemoembolization	and	previous	chemotherapy	with	nephrotoxic	agents	(25).
Alternative PRRT strategies
Despite	the	fact	that	the	results	of	PRRT	in	a	monotherapeutic	setting	are	very	promising,	
several groups tried to improve the results by combining PRRT with chemotherapy or us-
ing two different radionuclides. The possible synergistic effect of combining two or more 
therapies to increase the efficacy is supported by the evidence of the successful integration 
of capecitabine in chemoradiation regimens (26). 
Combination of different radionuclides
A combination of 177Lu- and 90Y-labeled somatostatin analogs might be more effective than 
PRRT with Lutetium-177 or Yttrium-90 alone. The rationale for the usage of the combi-
nation	is	the	relatively	short	pathlength	of	the	medium	energy	β-emission	of	Lutetium-177	
and	the	longer	pathlength	of	the	high	energy	of	β-emission	of	Yttrium-90,	which	may	have	
a	maximal	impact	on	small	and	large	tumors,	respectively.	The	first	proof	of	concept	was	
demonstrated in PRRT animal studies in which the combination was superior compared to 
PRRT	with	one	of	the	radionuclides	(7).	Villard	et	al.	(27)	treated	a	large	group	of	486	pa-
tients either with 90Y-DOTATOC monotherapy or with the combination of 90Y-DOTATOC 
and 177Lu-DOTATOC. Patients who were able to complete three or more treatment cy-
cles of the combination therapy had a significantly longer survival than patients receiving 
90Y-DOTATOC	alone.	However,	as	it	was	not	a	randomized	clinical	trial,	evidence	of	a	
real advantage with the combinationtherapy remains to be elucidated (28). Reported severe 
hematological	and	renal	toxicity	were	comparable	in	the	two	groups.
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Combination with chemotherapy
External	beam	radiotherapy	can	be	combined	with	5-fluorouracil	(5-FU).	In	patients	with	
rectal cancer this combination of radiotherapy and 5-FU (or with the prodrug capecitabine) 
has shown improvement of survival rates (26). It seems obvious that radiosensitising che-
motherapy	has	the	potential	to	enhance	the	effect	of	PRRT	as	well.	Increased	toxicity	could	
be	 the	major	 limitation	 for	 this	 combination	of	PRRT	and	 chemotherapy.	However,	 the	
first	 small	clinical	studies	did	not	show	an	 increase	of	serious	side-effects	 (29,30).	Fur-
thermore,	these	preliminary	studies	demonstrated	a	better	response	rate	compared	to	PRRT	
alone.	Still,	the	results	of	randomized	studies	have	to	be	awaited	before	this	approach	can	
be adapted as a standard treatment for our patients. Such a study is currently running at 
Erasmus MC.
Other	non-PRRT,	combinational	therapies	have	been	studied.	The	combination	of	capecit-
abine and temozolomide is used as a first line chemotherapy for metastatic neuroendocrine 
tumors with reasonable effects (31). In patients with pancreatic NETs an objective response 
was	found	in	21	patients	(70%).	There	is	not	much	experience	for	the	combination	of	these	
two chemotherapeutic agents and PRRT. Only one study demonstrated a favorable result 
with	a	complete	response	rate	in	15%,	a	partial	response	in	38%	and	stable	disease	in	38%.	
This study was conducted in a small group of 34 patients and no serious side-effects were 
reported	 (32).	Nonetheless,	 these	were	 promising	 results,	 but	more	 substantial	 research	
is	 necessary.	A	potential	 problem	could	 be	 an	 increased	hematological	 toxicity,	 as	 both	
therapies	can	induce	suppression	of	bone	marrow.	However,	Kesavan	et	al.	(33)	monitored	
patients who were treated with 177Lu-DOTATATE in combination with capecitabine and 
temozolomide	 for	 five	years.	No	 significant	 increased	hematological	 toxicity,	 including	
MDS	and/or	AL,	was	observed.
Neoadjuvant PRRT
Neoadjuvant PRRT is used mainly for inoperable pancreatic neuroendocrine tumors. Cur-
rently,	surgery	is	the	only	potential	curative	option	for	neuroendocrine	tumors	of	the	pan-
creas. Due to metastases or vascular involvement many patients are inoperable at time of 
diagnosis. If the tumor can be reduced in size by PRRT or limited tumor-load in the liver 
can	be	 resolved,	 a	 curative	 treatment	with	 surgery	might	 become	 feasible.	There	 is	 not	
much	experience	with	 this	 specific	 indication	 for	PRRT.	However,	 the	 few	case	 reports	
available	show	promising	results	(34,35),	even	in	patients	with	limited	metastatic	disease.	
Data	from	Van	Vliet	et	al.	(36)	showed	successful	surgery	in	9	of	29	patients	treated	with	
neoadjuvant PRRT.
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PRRT intra-arterial/loco-regional liver
It is not uncommon for patients with neuroendocrine tumors to have metastases predom-
inantly or solely located in the liver. The disadvantage of ‘normal’ PRRT administered 
intravenously	 is	 the	high	radiation	dose	delivered	 to	healthy	 tissue	or	organs.	 In	 theory,	
administration of the radiopharmaceutical directly into the hepatic artery should enable 
an increase of uptake of the radiolabeled peptide in the liver (the so called “first-pass” 
effect),	and	thereby	reduce	the	dose	to	the	remainder	of	the	body.	Pool	et	al.	(37)	demon-
strated a two-fold higher tumor uptake of 111In-DTPA-octreotide after intraarterial (i.a.) 
administration	than	after	intravenous	(i.v.)	administration.	The	renal	dose,	however,	was	
not significantly lowered. A small group of 17 patients from Greece (38) were treated with 
111In-DTPA-octreotide i.a. as well. Complete response was achieved in one patient (5.9%) 
and partial response in eight (47%). These results are much better than was published 
with the first PRRT studies with 111In-DTPA-octreotide	administrated	i.v.	(2,3).	The	next	
logical step was to use beta-emitting radionuclides to treat this category NET patients 
intra-arterially. McStay et al. (39) treated 23 patients with 90Y-DOTA-Lanreotide i.a. Par-
tial responses were achieved in three (16%) and stable disease in 12 (63%) of 19 patients. 
Hematological	 toxicity	occurred	in	three	patients,	but	was	reversible.	Furthermore,	Kra-
tochwil et al. (40) treated a small group of patients with intra-arterial 90Y-DOTATOC or 
177Lu-DOTATOC and found a complete response in one patient (7%) and a partial response 
in	8	(53%).	Overall,	the	results	of	i.a.	administration	are	promising,	but	only	pilot	studies	
with limited number of patients have been published. More research in larger groups of 
patients and in a randomized setting is warranted before this alternative option in this spe-
cific group of NET patients to introduce this novel approach into the standard of clinical 
care.
PRRT salvage therapy
Unfortunately most patients will become progressive after a favorable response induced by 
the	initial	series	of	cycles	of	PRRT.	Currently,	when	progressive	disease	becomes	evident	
only few proven effective therapeutic options are available. One alternative treatment op-
tion	may	be	treatment	with	additional	cycles	of	PRRT,	if	initial	PRRT	showed	benefit	in	a	
patient. Reports on studies with only a limited number of retreated patients showed that it 
is	not	only	feasible	to	retreat	these	patients	with	PRRT	in	terms	of	safety	and	toxicity,	but	
is a serious option to consider when better alternatives are not available. In this ‘salvage’ 
therapy	setting,	Forrer	et	al.	(41)	retreated	27	patients	after	an	initial	favorable	response	to	
therapy with 90Y-DOTATOC with 177Lu-DOTATOC. Patients received only one additional 
cycle of 7.4 GBq of 177Lu-DOTATOC. Only 8 (30%) patients had PD 8-12 weeks after ther-
apy.	No	significant	changes	in	hemoglobin	and	creatinine	were	observed.	Van	Essen	et	al.	
(42) reported the results in 33 patients who had PD and were retreated with two additional 
cycles of 177Lu-DOTATATE (7.4-14.8 GBq). After a median follow-up of 16 months 18 
(55%) patients had a response or stable disease. Sabet et al. (43) found comparable results 
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in a group of 33 patients treated with a median two treatment courses per patient. In 67% 
of patients the salvage therapy resulted in a response or stable disease of after a median fol-
low-up	of	27	months	from	the	start	of	salvage	PRRT.	Overall,	the	response	rate	was	not	as	
good	as	after	the	initial	cycles	of	PRRT.	However,	to	compare	the	response	rates	mentioned	
within these PRRT salvage studies to the PRRT studies reporting the outcome of initial 
PRRT cycles is not appropriate. Differences can be found in the number of patients who 
had	PD,	since	all	included	patients	in	the	salvage	setting	had	PD	at	the	time	of	inclusion.	
Furthermore,	patients	were	treated	with	less	cycles	of	PRRT.	In	the	initial	treatment,	the	
majority of patients received either two or three cycles of 90Y-DOTATOC and either three 
or four cycles of 177Lu-DOTATATE. These differences might be responsible for the fact that 
the results of additional cycles of PRRT are not as encouraging as the initial series of PRRT 
cycles	in	terms	of	objective	tumor	response	and	PFS.	Nonetheless,	as	there	are	no	good	
alternative	treatments,	PRRT	as	a	salvage	therapy	should	be	considered	in	patients	who	are	
progressive and responded well to the initial cycles of PRRT.
Future developments
More research is necessary to improve PRRT further with the goal of higher response rates 
and more durable response. An important goal to achieve this is to induce higher uptake of 
the radiopharmaceutical and thereby a higher absorbed dose in the tumors. Studies with the 
previously mentioned method of i.a. administration of the radiopharmaceutical are prom-
ising,	although	no	randomized	studies	are	available.
A new strategy to increase the tumor dose is the use of somatostatin antagonists. Since the 
introduction of PRRT it was generally accepted that an ideal peptide for PRRT has to be 
internalized	 to	 increase	 its	 residence	 time.	However,	 surprisingly,	Ginj	et	al.	 (44)	 found	
significant higher doses of radioactivity in vivo in tumors in mice with the somatostatin an-
tagonists 111In-DOTA-sst3-ODN-8 and 111In-DOTA-sst2-ANT	compared	to	agonists.	Also,	
when	coupled	to	Lutetium-177	a	higher	dose	could	be	accomplished	in	vitro	in	SST2R-ex-
pressing human tumor samples (45). A recent pilot study in 4 patients showed a 1.7-10.6 
times higher tumor dose using the antagonist 177Lu-DOTA-JR11 compared to 177Lu-DO-
TATATE. Only minor reversible adverse effects were observed.
A different promising new technique is the use of alpha emitting radiolabeled somatostatin 
analogs. Alpha emitting radionuclides such as Bismuth-213 have a shorter tissue path-
length	in	comparison	with	β-emitting	radionuclides.	The	path-range	of	an	alpha	particle	is	
approximately	50-100	mm,	about	two	or	three	cell	diameters.	Within	this	short	path	range	
all energy is absorbed by the tissue and more DNA damage will be induced compared to 
beta-emitters.	Another	 advantage	 is	 a	 limited	 absorbed	 dose	 on	 other,	 healthy	 tissue.	A	
pilot study was conducted in seven patients who had PD after initial 90Y/177Lu-DOTATOC 
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therapy and who were treated with intra-arterial infusion of 213Bi-DOTATOC (46). One 
patient was treated with 213Bi-DOTATOC intravenously. The results of this study are very 
promising with an objective response or stable disease in all patients after a follow-up 
of	at	least	12	months.	Acute	hematotoxicity	was	even	less	pronounced	than	PRRT	using	
β-emitting	radionuclides.	The	alkylating	agent	temozolomide	followed	by	PRRT	is	also	an	
interesting therapeutic approach. Preclinical studies by Bison et al. (47) demonstrated that 
a pre-treatment for 14 days with temozolomide resulted in an increase in tumor perfusion 
as	measured	 by	MRI.	 Subsequently,	 this	 increase	 in	 perfusion	 resulted	 in	 a	 significant	
higher	uptake	in	the	tumor.	Therefore,	temozolomide	treatment	prior	to	PRRT	might	be	a	
good option to increase the tumor response in NET patients. 
In	 the	 last	decade,	new	 targeted	 therapies	 such	as	 sunitinib	 (a	 tyrosine	kinase	 inhibitor)	
and everolimus (an inhibitor of mammalian target of rapamycin (mTOR)) were registered 
for (metastatic) neuroendocrine tumors of the pancreas. In a recent systematic review the 
different	non-surgical	treatments	for	pancreatic	NETs	were	evaluated	(48).	Unfortunately,	
there are only a few randomized clinical trials (RCT’s) and the included group of pa-
tients	within	 these	 trials	are	very	heterogeneous.	Therefore,	 it	 is	 impossible	 to	compare	
the	 results	 of	different	 studies.	Overall,	 the	 targeted	 therapies	 result	 in	 a	 longer	PFS	of	
11.4 months compared to placebo 5.5 months for sunitinib and 11.0 versus 4.6 months for 
everolimus	(49,50).	In	the	future	it	is	important	to	compare	targeted	therapies	to	PRRT	in	
a	RCT.	Besides	a	direct	comparison,	a	combination	of	PRRT	with	one	of	these	compounds	
is also an interesting topic for future research.
Summary
PRRT is a good treatment option for patients with metastasized neuroendocrine tumors. 
Reported	response	rates	for	the	different	β-emitting	radionuclides	Lutetium-177	and	Yttri-
um-90	are	similar,	but	a	slightly	higher	toxicity	is	reported	in	patients	treated	with	Yttri-
um-90.	Beside	the	reported	favorable	responses	and	increased	survival	rate,	PRRT	increas-
es the quality of life of patients. In the last decade variants have been proposed to optimize 
the treatment and increase the response and survival rates. The combination of PRRT and 
radiosensitising chemotherapy may be very promising. For patients with a predominance 
of	 liver	metastases,	 the	possibility	 to	administer	 the	 radioactivity	directly	 in	 the	hepatic	
artery in an attempt to optimize dose-delivery has been studied. This localized procedure 
increases the tumor uptake in the liver metastases and therefore may show better results in 
terms	of	tumor	response.	Large,	randomized	studies	are	necessary	to	compare	PRRT	to	the	
new	targeted	therapies,	such	as	sunitinib	and	everolimus	for	NET	patients.	Meanwhile,	re-
search is on-going to develop PRRT that is superior to the current PRRT available in terms 
of	objective	response	and	survival,	such	as	PRRT	with	the	use	of	somatostatin	agonists,	
with	alpha	emitting	radionuclides,	or	radiolabeled	somatostatin	antagonists.	For	patients	
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who	had	a	favorable	response	after	the	initial	cycles	of	PRRT	but	progressed,	salvage	ther-
apy is a feasible option in terms of therapeutic efficacy and safety.
PRACTICE POINTS
• PRRT	using	somatostatin	analogs	labeled	with	β-emitting	radionuclides,	such	as	
Yttrium-90 or Lutetium-177 can induce tumor shrinkage.
• Radiation-induced	toxicity	is	rare;	severe	hematological	toxicity	and	kidney	fail-
ure is seen in less than 5% of patients.
• Patients with a favorable outcome after PRRT are likely to have their quality of 
life improved 
• PRRT can be applied successfully in the neo-adjuvant setting. 
• Patients with PD after a good initial response can benefit from salvage therapy 
with additional cycles of PRRT.
RESEARCH AGENDA
• Use of somatostatin analogs labeled with alpha emitting radionuclides.
• Increasing the tumor uptake by replacing the somatostatin agonists with antago-
nists.
• Intra-arterial administration of radiolabeled somatostatin analogs for patients with 
a predominance of liver metastases.
• The	 combination	 of	 targeted	 therapies,	 such	 as	 sunitinib	 and	 everolimus,	 and	
PRRT.
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Abstract
Purpose
Bronchial and gastroenteropancreatic neuroendocrine tumors (NETs) are slow-growing 
tumors,	which	frequently	express	somatostatin	receptors	on	their	cell	membranes.	These	
receptors are targets for therapy with Lutetium-177-labeled somatostatin analogs. We have 
treated over 1200 patients with peptide receptor radionuclide therapy (PRRT) with 177Lu-
DOTA0,Tyr3]octreotate (177Lu-DOTATATE) since the year 2000 and present the results on 
efficacy,	survival	and	toxicity	of	this	therapy.	
Patients and methods
For	safety	analysis,	610	patients	treated	with	a	cumulative	dose	of	at	least	100	mCi	(3.7	
GBq) 177Lu-DOTATATE were included. A subgroup of 443 Dutch patients who were treat-
ed with a cumulative dose of at least 600 mCi (22.2 GBq) 177Lu-DOTATATE before 2013 
was further analyzed for efficacy and survival.
Results
The objective response rate (ORR) of the total group of patients was 39%. Stable disease 
(SD) was reached in 43% of patients. Progression free survival (PFS) and overall survival 
(OS) for all NET patients were 29 months (95% CI 26-33 months) and 63 months (95% CI 
55-72	months).	Long-term	toxicity	included	acute	leukemia	in	4	patients	(0.7%)	and	my-
elodysplastic syndrome in 9 patients (1.5%). No therapy-related long-term renal or hepatic 
failure occurred.
Conclusion 
PRRT with 177Lu-DOTATATE is a favorable therapeutic option in patients with metastat-
ic	bronchial	and	gastroenteropancreatic	NETs	that	express	somatostatin	receptors.	PRRT	
with 177Lu-DOTATATE is safe with few side-effects and shows a good response rates with 
PFS of 29 months and OS of 63 months.
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Introduction
Neuroendocrine tumors (NETs) are a heterogeneous group of tumors. A subset of this 
slow-growing tumor type are the gastroenteropancreatic neuroendocrine tumors (GEP-
NETs)	 and	 bronchial	NETs	 (1).	Unfortunately,	 the	majority	 of	GEP-NET	patients	 have	
metastatic	disease	at	time	of	presentation	(2).	Over	the	past	decades,	the	incidence	of	GEP-
NETs	is	 rising.	After	 the	 introduction	of	new	therapies,	 the	5-years	survival	has	signifi-
cantly improved (3). This improvement is partly due to first-line therapy with long-acting 
somatostatin	 analogs	 (Octreotide	LAR,	Lanreotide	Autogel)	 and	 targeted	 therapies	 (e.g.	
everolimus	and	sunitinib),	which	are	approved	second-line	therapies	for	patients	with	pro-
gressive	inoperable	GEP	NETs	(sunitinib	only	being	approved	in	pancreatic	NET)	(4,5).	For	
gastroenteropancreatic	and	bronchial	NETs,	Peptide	receptor	radionuclide	therapy	(PRRT)	
with [177Lu-DOTA0,Tyr3]octreotate (177Lu-DOTATATE) has yielded very promising results. 
This	therapy	is	based	on	the	fact	that	the	majority	of	these	NETs	express	a	high	number	
of high affinity somatostatin receptors on their cell membranes. These receptors can be 
used	for	both	imaging	and	therapy	with	radiolabeled	somatostatin	analogs	(6).	For	therapy,	
the	beta-emitting	radionuclide	Lutetium-177,	with	a	half-life	of	6.7	days	and	a	maximum	
beta	range	of	2	mm	in	tissue,	can	be	used.	These	parameters	makes	Lutetium-177	the	ideal	
radionuclide for PRRT. Treatment with beta-emitting radiolabeled somatostatin analogs 
results	in	impressive	percentages	of	tumor	regression	(7–10).	Also,	success	monitored	as	
time	to	progression	(TTP),	progression	free	survival	(PFS)	and	overall	survival	(OS)	has	
been	reported	in	uncontrolled	studies	(8,11).	With	the	recent	publication	of	the	promising	
results	of	the	NETTER-1	trial	(12),	the	first	phase	III	trial	comparing	177Lu-DOTATATE 
to	high	dose	Octreotide	LAR	therapy	in	patients	with	inoperable	metastatic	midgut	NETs,	
it	may	be	expected	that	the	use	of	this	therapy	will	increase	in	the	coming	years.	We	have	
previously reported on the treatment with the radiolabeled somatostatin analog 177Lu-DO-
TATATE	(8),	and	have	compared	the	side-effects	and	the	results	of	this	treatment	with	other	
treatment	modalities	and	historical	controls.	Righteously,	critical	commentary	arose,	as	to	
the	validity	of	the	comparisons	with	historical	controls.	Also,	the	high	number	of	foreign	
patients	 that	we	have	 treated,	 and	of	whom	a	 significant	 number	was	 lost	 to	 follow-up	
might	bias	the	percentage	of	reported	severe	adverse	events.	We,	therefore,	present	now	
the	long-term	results	of	efficacy,	survival	and	toxicity	of	PRRT	with	177Lu-DOTATATE in 
a	cohort	of	more	than	500	Dutch	patients	with	metastastic	GEP-NETs	and	bronchial	NETs,	
who all had their follow-up at our institution. 
Chapter 5
86
Patients and methods 
Patients
A total of 1214 patients were treated with 177Lu-DOTATATE from January 2000 to January 
2015	in	our	institution.	We	selected	only	Dutch	patients	with	NETs	of	the	midgut,	foregut,	
hindgut	and	unknown	primary	that	were	treated	according	to	a	standard	protocol,	because	
of	the	very	limited	loss	in	follow-up	in	this	subgroup.	For	safety	evaluation,	all	patients	
who received at least 100 mCi (3.7 GBq) 177Lu-DOTATATE were selected. For the evalua-
tion	of	efficacy,	patients	who	received	at	least	600	mCi	(22.2	GBq)	177Lu-DOTATATE be-
fore 2013 were investigated. Patients treated after 2013 returned to their referring specialist 
in	a	different	institute	after	therapy,	and	imaging	was	not	performed	according	to	our	study	
protocol. For safety analysis 610 patients were available and 443 patients for efficacy and 
survival	analysis	(Figure	1).	For	analysis	of	efficacy,	NET	types	were	divided	into	bronchi-
al,	pancreatic,	(other)	foregut,	hindgut,	midgut	and	NET	of	unknown	origin.	Other	foregut	
NETs	included:	5	NETs	of	the	stomach,	5	NETs	of	the	proximal	duodenum	and	2	NETs	of	
the thymus. For comparison with the NETTER-1 study (12) 106 patients with progressive 
midgut	NETs	who	received	a	cumulative	dose	of	≥100	mCi	(3.7	GBq)	177Lu-DOTATATE 
were selected. Patients were treated with 177Lu-DOTATATE if the tumor uptake was at least 
as high as the uptake in the normal parenchyma of the liver on 111In-DTPA-octreotide scin-
tigraphy (OctreoScan) prior to the therapy. Other inclusion criteria were serum hemoglobin 
≥	6.0	mmol/L	(≥	9.7	g/dL),	total	white	blood	cell	(WBC)	count	≥	2·109/L,	platelet	count	≥	
75·109/L,	serum	creatinine	concentration	≤	150	umol/L	(≤	1.7	mg/dL)	-	or	creatinine	clear-
ance	≥	40	mL/min	until	2007	or	50	mL/min	from	2007,	serum	albumin	>30	g/L,	Karnofsky	
performance	status	(KPS)	≥	50	and	no	prior	treatment	with	other	radiolabeled	somatostatin	
analogs. Preliminary results in a subgroup of these patients with GEP-NETs were reported 
previously	(8).	All	patients	gave	written	informed	consent	to	participate	in	the	study,	which	
was approved by the medical ethical committee of our hospital. 
Methods 
[DOTA0,Tyr3]octreotate	was	obtained	from	BioSynthema,	St	Louis,	MO.	177LuCl3 was dis-
tributed	by	IDB-Holland,	Baarle-Nassau,	the	Netherlands.	177Lu-DOTATATE was locally 
prepared	 as	 described	 previously	 (13).	 Before	 the	 infusion	 of	 the	 radiopharmaceutical,	
Granisetron 3 mg or Ondansetron 8 mg was injected intravenously (iv). To reduce the ra-
diation	dose	to	the	kidneys,	an	iv	infusion	of	amino	acids	(2.5%	arginine	and	2.5%	lysine	
in 1L 0.9% NaCl) was started 30 min before the administration of the radiopharmaceutical 
and lasted for 4 h. The radiopharmaceutical was co-administered iv using a second pump 
system over 30 min. The intended interval between treatments was 6–10 weeks. The treat-
ment	interval	could	be	extended	to	16	weeks	in	patients	with	longer	continuing	subacute	
hematological	toxicity.	Patients	were	treated	up	to	a	cumulative	intended	dose	of	750	to	
800 mCi (27.8–29.6 GBq) 177Lu-DOTATATE. 
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Routine	hematology,	 liver,	 and	kidney	 function	 tests	were	performed	after	each	 therapy	
cycle	and	at	follow-up	visits	at	6	weeks,	3	months	and	6	months	after	the	last	treatment	
cycle,	and	thereafter	at	6	month	intervals.	Computed	tomography	(CT),	or	magnetic	reso-
nance	imaging	(MRI)	was	performed	within	3	months	before	the	first	therapy,	and	at	every	
follow-up visit. Every patient was seen at the outpatient clinic by one of the investigators 
and a research nurse. A case report form (CRF) was completed at every follow-up visit. 
Figure 1. Flowchart for the selection of patients. 
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In Vivo Measurements 
Tumor response was assessed on CT or MRI according to the Response Evaluation Criteria 
in Solid Tumors 1.1 (RECIST 1.1) criteria (14). Radiological disease control was defined 
as all patients achieving objective response (OR) or stable disease (SD) in patients with 
progressive disease (PD) at baseline. Uptake on the OctreoScan was scored on planar im-
ages using a 4-point scale; grade 1: less than the uptake in the normal parenchyma of the 
liver,	grade	2:	equal	to	the	liver,	grade	3:	greater	uptake	than	the	liver,	grade	4:	higher	than	
the	uptake	in	the	normal	spleen	or	kidneys.	The	whole	body	extent	of	disease	was	scored	by	
experienced	nuclear	medicine	physicians	as:	limited,	moderate	or	extensive	on	OctreoScan	
as described previously (15). 
Outcomes
PFS was defined as the time from first day of treatment until day of ascertainment of ob-
jective progression or death from any cause. The TTP was calculated from the first day of 
treatment to the day of documented progression. Deaths were censored in the TTP analyses. 
OS	was	calculated	from	the	first	day	of	treatment	until	the	day	of	death,	or	until	the	last	date	
of	follow-up	for	patients	who	were	lost	to	follow-up	(16).	Toxicity	was	scored	according	to	
the Common Terminology Criteria for Adverse Events 4.0 (CTCAE) scoring system (17).
Statistics 
For	survival	analysis,	 log-rank	tests	and	Cox	regression	models	were	used.	PFS	and	OS	
analyzes were performed using the Kaplan-Meier method. Comparison between subgroups 
was	made	using	χ2-test	(or	if	applicable	Fisher	exact	test),	ANOVA	or	paired	t-tests.	P-val-
ues lower than 0.05 were considered to be significant. 
Results
For	 safety	 outcome	 610	 patients	who	 received	 ≥100	mCi	 (3.7	GBq)	 177Lu-DOTATATE 
were analyzed. Median follow-up time was 64 months (95% CI 58-70 months). Mean age 
was 60.4 years (range 23-88). The median TTP was 35 months (95% CI 32-39 months) and 
the median OS was 58 months (95% CI 52-64 months). 
CTCAE	grade	3/4	toxicity	of	the	combination	of	the	following	hematologic	parameters	oc-
curred	in	61/582	patients	(10%(95%CI	8-13%)),	grade	3/4	toxicity	of	platelets	occurred	in	
30/582	patients	(5%(95%CI	4-7%)),	total	WBC	count	grade	3/4	toxicity	in	32/582	patients	
(5%(95%CI	4-8%),	hemoglobin	grade	3	toxicity	in	22/582	patients	(4%	(95%CI	2-6%))	
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and	no	grade	4	hemoglobin	toxicity	was	observed.	No	data	are	available	on	the	remaining	
28	 patients.	At	 first	 follow-up	 visit	 after	 3	months,	 these	 values	 normalized	 in	 77%	of	
patients.	CTCAE	grade	3/4	of	 the	 lymphocytes	was	observed	 in	288/581	patients	 (50%	
(95%CI	 46-54%)).	At	 3	months	 follow-up	 74/287	 patients	 and	 at	 30	months	 follow-up	
6/108	patients	had	persistent	grade	3/4	lymphocyte	toxicity	and	53/108	patients	had	grade	
1/2	lymphocyte	toxicity.	
Characteristic
Yes No Unknown
No of  
patients %
No of  
patients %
No of  
patients %
Male 230 (52) 213 (48)
Median age (range) 60 years (30-83)
Pretreatment
 surgery 190 (43) 252 (57) 1 (0)
 chemotherapy* 28 (6) 415 (94) 0 (0)
 radiotherapy 30 (7) 412 (93) 1 (0)
 somatostatin analogs 271 (61) 172 (39) 0 (0)
Bone metastases 70 (16) 367 (83)
Liver metastases 346 (78) 93 (21)
Functional pancreatic NET** 21 (5)
Median time since diagnosis (range) 14 months (0-371)
Baseline progression 239 (54) 69 (16) 135 (30)
Extent	of	disease
 Limited 62 (14)
 Moderate 314 (71)
	 Extensive 67 (15)
Uptake on Octreoscan
 Grade 2 35 (8)
 Grade 3 278 (63)
 Grade 4 130 (29)
* Including alkylating chemotherapy in 16 patients 
**	Including	Vasoactive	Intestinal	Peptide-secreting	tumor	(VIPoma),	insulinoma,	gastrinoma	and	
glucagonoma.
Table 1. Patient,	treatment	and	tumor	characteristics	in	patients	with	gastroenteropancreatic	and	
bronchial	NETs	(n=443).
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An	 increase	 of	 aminotransferases	 (aspartate	 transaminase	 and/or	 alanine	 transaminase)	
grade	3/4	was	observed	in	20/581	patients	(3%	(95%CI	2-5%)).	After	3	months	follow-up,	
there	were	3	patients	with	persistent	grade	3/4	toxicity	of	the	aminotransferases.	Creatinine	
grade	3/4	 toxicity	 occurred	 in	 2/581	patients	 (0.3%	 (95%CI	<1-1%)).	Serum	creatinine	
levels normalized in all patients at 3 months follow-up. 
Acute leukemia (AL) occurred during follow-up in 4 patients (0.7%) after a median 
follow-up of 55 months after first therapy (range 32-125 months). Three of these patients 
died after a median follow-up of 7 months after diagnosis of AL. Myelodysplastic syn-
drome (MDS) occurred in 9 patients (1.5%) after a median follow-up of 28 months (range 
9-41 months) after first therapy. Five of these patients died after a median follow-up of 
7	months	after	diagnosis	of	MDS.	Of	the	remaining	patients,	no	date	of	death	is	known,	
since	these	patients	were	referred	back	to	their	own	local	hospital	after	the	diagnosis	AL/
MDS was made. None of these patients were treated with alkylating chemotherapy prior 
to PRRT. 
Renal failure occurred in 6 patients (1%) during follow-up. The most probable cause of 
the renal failure was post-renal in one patient (hydronephrosis) and pre-renal in the other 
patients (hypotension after gastrointestinal bleeding in one patient and in four patients de-
hydration caused by severe vomiting and diarrhea). No hepatic failure was observed during 
or after therapy.  
Patient	characteristics	of	the	443	patients	who	received	≥600	mCi	(22.2	GBq)	177Lu-DO-
TATATE and who were evaluated for efficacy and survival are presented in table 1. Median 
follow-up was 78 months from the first day of treatment. The majority of all patients (61%) 
were treated with somatostatin analogs at referral.
Best objective response rate (ORR) was defined as the proportion of patients achieving 
CR and PR at follow-up according to the RECIST 1.1 criteria. Best response rates are pre-
sented in table 2. The ORR in the entire patient group was 39%. SD was found in 43% of 
patients. PD as treatment outcome was observed in 12% of patients and 5% of patients had 
non-evaluable treatment outcome. In patients with midgut NETs and pancreatic NETs with 
PD	at	baseline,	radiological	disease	control	was	observed	in	84%	and	81%,	respectively.	
For	the	entire	group	of	443	NET	patients,	the	median	OS	was	63	months	(95%	CI	55-72	
months). The median PFS was 29 months (95% CI 26-33 months). The median TTP was 
36 months (95% CI 32-40 months) (table 2). Patients with a primary NET in the pancreas 
had the longest OS (figure 2). We identified several risk factors associated with shorter OS 
(table 3). The OS was significantly shorter in patients with liver or bone metastases at base-
line.	Also,	patients	with	increased	alkaline	phosphatase	(ALP)	levels	(>120	IU/L)	and	pa-
tients	with	extensive	disease	as	scored	with	the	OctreoScan	had	a	worse	prognosis	(table	3).	 
For the group of 239 NET patients with objective PD at baseline the median PFS was 30 
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months	(95%CI	27-33	months),	the	median	TTP	36	months	(95%CI	32-41	months)	and	the	
median OS was 58 months (95%CI 52-64 months). 
Characteristics of patients with NETs of the midgut and PD at baseline are presented in 
Table	4.	For	comparison	with	 the	NETTER-1	study,	patients	 that	 received	a	cumulative	
dose	of	≥100	mCi	(3.7	GBq)	177Lu-DOTATATE were selected. The PFS of patients with 
progressive midgut NETs was 24 months (95% CI 18-30 months). OS was 46 months (95% 
CI 32-60 months). The OS was significantly worse for patients with PD at baseline as com-
pared to patients without PD at baseline.
Discussion
The results of this study demonstrate that PRRT with 177Lu-DOTATATE	 is	 an	 ex-
cellent therapeutic option for patients with advanced grade 1-2 gastroenteropancre-
atic and bronchial NETs. This treatment has limited side-effects and is relatively safe. 
In the last decade various types of targeted therapies have been introduced. After the pre-
sentation	of	the	PROMID	study	(18)	in	2009	and	the	CLARINET	study	in	2014	(19),	the	
use	of	somatostatin	analogs	for	progressive,	 inoperable	grade	1-2	GEP-NETs	was	regis-
tered. Rinke and colleagues (18) demonstrated that the median TTP in patients with met-
astatic midgut tumors is longer (14.3 months) with the use of 30 mg Octreotide LAR per 
4	weeks	as	compared	to	placebo	(6.0	months),	although	there	seemed	to	be	no	significant	
Figure 2. Median overall survival in 419 NET patients treated with 177Lu-DOTATATE according 
to	location	of	the	primary	tumor.	Not	shown	are	patients	with	primary	tumor	of	the	hindgut	(n=12)	
and	other	foregut	(n=12)	due	to	the	small	number	of	patients.
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effect of Octreotide LAR on the overall survival (20). Also for Lanreotide Autogel 120 mg 
per	4	weeks,	Caplin	and	colleagues	have	demonstrated	that	the	PFS	in	GEP-NETs	with	a	
Ki67	index	<	10%	was	better	(32.8	months)	as	compared	to	placebo	(18	months)	(19,21).	
Recently,	the	first	results	of	the	NETTER-1	study	were	published	(12).	This	is	the	first	ran-
domized phase III study comparing 177Lu-DOTATATE to high dose octreotide LAR therapy 
in	patients	with	inoperable,	progressive	midgut	NETs.	The	dosing	protocol	was	compara-
ble to our protocol with 4 administrations of 200 mCi (7.4 GBq) 177Lu-DOTATATE every 8 
weeks. The PFS for the control group receiving 60 mg Octreotide LAR per 4 weeks was 8.4 
Factor
No of  
patients*
Median OS 
(months)
Hazard ratio
(95% CI) p-value
ALP
 <120
 >120
248
189
83
47
0.45 (0.35-0.59) p<0.01
Liver metastases
 Yes
 No
346
93
57
119
0.46 (0.34-0.62) p<0.01
Bone metastases
 Yes
 No
70
367
47
69
0.56 (0.38-0.83) p<0.01
Extent	of	disease
 Limited
 Moderate
	 Extensive
62
314
67
123
62
46
p<0.01
KPS
	 ≤70
 80
 90
 100
35
103
160
138
27
49
65
81
p<0.01
Best response
 CR
 PR
 SD
 PD
9
165
192
53
Undefined
82
61
24
p<0.01
Table 3. Factors predicting median overall survival in patients with bronchial and gastroenteropan-
creatic NETs. 
Abbreviations: NET neuroendocrine tumor; OS overall survival; ALP alkaline phosphatase; KPS 
Karnofsky performance status; CR complete response; PR partial response; SD stable disease; PD 
progressive disease. 
*Number of patients may vary due to missing data. 
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months and the PFS was not reached for the patients receiving 177Lu-DOTATATE plus 30 
mg	Octreotide	LAR	per	4	weeks.	For	comparison	with	the	NETTER-1	study,	we	selected	
patients	with	progressive	midgut	NETs,	who	received	at	least	the	same	minimum	cumula-
tive	dose	of	≥100	mCi	(3.7	GBq)	of	177Lu-DOTATATE. Most patient characteristics were 
not	significantly	different	from	patients	in	the	NETTER-1	study	(Table	4).	However,	tumor	
regional distribution seemed to be higher and tumor uptake on OctreoScan lower in our 
patients. The latter may be affected in the NETTER-1 study by the high dose Octreotide 
LAR pre-treatment (22). 
The	proliferation	marker	Ki67	 is	used	for	 the	grading	of	NETs	(23–25).	 In	our	study,	 the	
results	 of	 the	Ki67	 index	 labeling	was	 not	 available	 in	 all	 tumors,	 because	we	 started	 to	
routinely	use	the	Ki67	index	for	grading	of	NETs	in	2007.	In	order	to	have	an	estimation	of	
the	presence	of	high-grade	NETs	in	our	patient	cohort,	we	took	a	sample	of	230	GEP-NET	
patients	who	were	 treated	after	2006.	Of	 these	230	patients,	88	patients	 (38%)	had	WHO	
grade	1	NETs,	131	patients	(57%)	had	grade	2	NETs	and	11	patients	(5%)	had	grade	3	NETs	
(23–25).	Since	mainly	grade	1-2	NETs	were	treated,	we	can	conclude	that	PRRT	is	especially	
a	therapeutic	option	for	these	tumors.	Moreover,	the	majority	of	grade	3	tumors	are	negative	
on OctreoScan (26) and therefore cannot be treated with PRRT with 177Lu-DOTATATE. 
For	progressive,	metastatic	grade	1-2	pancreatic	NETs,	both	Everolimus	and	Sunitinib	are	
approved	therapies.	In	the	RADIANT-3	study	(27),	comparing	10	mg	Everolimus	orally	
daily	to	placebo,	the	PFS	was	11.0	months	for	Everolimus.	In	the	study	comparing	Suni-
tinib	37.5	mg	orally	daily	 to	placebo	 (28),	 the	PFS	 for	Sunitinib	was	11.4	months.	The	
PFS for pancreatic NETs with radiological progression at baseline (table 2) after therapy 
with 177Lu-DOTATATE was 31 months and suggests being longer than with the currently 
available targeted therapies. 
Recently,	the	results	of	the	RADIANT-4	study	(29)	have	also	been	published.	This	study	
compared everolimus 10 mg orally daily to placebo in patients with advanced grade 1-2 
NETs of the lung and gastrointestinal origin. The PFS for Everolimus was 11.0 months 
and thus comparable to the PFS for Everolimus in the RADIANT-3 study. We found a PFS 
after PRRT with 177Lu-DOTATATE of 29 months in the total group of patients with primary 
NETs in the lung or gastrointestinal tract. Although our patients were not randomized at 
inclusion,	the	present	results	can	be	compared	to	other	studies	due	to	the	large	number	of	
patients	and	very	long	follow-up	period.	Therefore,	not	only	in	patients	with	pancreatic,	
but	also	in	patients	with	bronchial	and	gastrointestinal	NETs,	the	PFS	seems	to	be	better	
after 177Lu-DOTATATE than the current targeted therapies which are registered for these 
indications. 
A	disadvantage	of	PRRT	 in	general	 is	 the	potential	 side-effects,	 especially	on	 the	bone	
marrow	and	kidneys.	Due	to	co-infusion	of	lysine	and	arginine	starting	just	before	therapy,	
the	radiation	dose	to	the	kidneys	can	be	lowered	and,	therefore,	the	kidney	is	no	longer	the	
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Progressive Midgut  
Carcinoids Characteristic
NETTER 1 
(N = 116)
Erasmus MC 
(N = 106) P-value
Sex—	no.	(%)
 Female 53 (46) 52 (49) NS
 Male 63 (54) 54 (51)
Mean	age	(±SD)	—	yr 63 (±9) 62 (±10) NS
Mean	BMI	(±SD)	—	kg/m2 25 (±5) 26 (±4) NS
Mean KPS (±SD) 88.6 (±9.3) 85.8 (±10.2) p<0.05
Site	of	metastasis	—	no.	(%)
 Liver 97 (84) 97 (92) NS
 Bone 13 (11) 14 (13) NS
SRS,	uptake	scale	—	no.	(%)
 Grade 2 11 (10) 7 (7) NS
 Grade 3 34 (29) 74 (70) p<0.01
 Grade 4 71 (61) 25 (23) p<0.01
Extent	of	disease	-	no.	(%)	
 Limited 99 (85) 4 (4) p<0.01
 Moderate 13 (11) 82 (77) p<0.01
	 Extensive 4 (3) 20 (19) p<0.01
Previous	treatments—no.	(%)
 Surgery 93 (80) 60 (57) p<0.01
 Chemotherapy 11 (9) 6 (6) NS
 Radiotherapy 4 (3) 3 (3) NS
Previous Somatostatin analog therapy (%) 116 (100) 89 (84) p<0.01
ORR-no.(%) 18 (16) 29 (27)* p<0.05
PFS rate at 20 months (%) 65 58 NS
Median OS-months NR 46
Table 4. Comparison between NETTER-1 study and patients with progressive midgut NETs receiv-
ing	≥100	mCi	(3.7	GBq)	177Lu-DOTATATE.
* Best response used for Erasmus MC patients
Abbreviations:	BMI	body	mass	index;	KPS	Karnofsky	performance	status;	CTCAE	Common	Ter-
minology Criteria for Adverse Events; WBC white blood cell count; ORR objective response rate; 
PFS progression free survival; OS overall survival; NR not reached.
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dose-limiting organ (13). We have observed renal failure in 6 patients during follow-up af-
ter	this	therapy.	The	cause	of	this	renal	failure	was	probably	not	related	to	PRRT,	since	we	
found other more plausible causes in all patients. AL and MDS are severe complications 
related to PRRT and occurred after a median of 28 months after the first cycle of PRRT 
with 177Lu-DOTATATE for MDS and after a median of 55 months for AL. Although none 
of	our	patients	who	were	diagnosed	with	AL/MDS	 received	prior	 chemotherapy,	 recent	
reports	suggest	that	there	might	be	a	higher	risk	of	MDS/AL	after	alkylating	chemotherapy	
(30–32). 
Other therapy-related side-effects are hormone related problems. In this study we did not 
focus	on	hormonal	crises	after	PRRT.	In	a	previous	study,	we	have	reported	on	6/479	pa-
tients (1%) with GEP-NETs and pheochromocytomas who developed severe symptoms 
after PRRT due to a release of bioactive substances (33). When treating patients with hor-
mone-producing	tumors,	these	side-effects	should	be	taken	into	account	as	well.	
Various	 centers	 in	 Europe	 use	 [90Y-DOTA0,Tyr3]-octreotide (90Y-DOTATOC) for PRRT. 
The	results	of	therapy	with	this	radiopharmaceutical	have	been	extensively	reported	in	the	
last	decade	(7,11,34–36).	Due	to	the	higher	energy	of	Yttrium-90,	as	compared	to	Lute-
tium-177,	more	side-effects	have	been	reported.	Imhof	et	al	(36)	reported	transient	grade	
3/4	hematological	toxicity	in	12,8%	of	patients	and	permanent	grade	4/5	renal	toxicity	in	
9.2% with 90Y-DOTATOC.	In	our	opinion,	177Lu is therefore the radionuclide of first choice 
for	treating	patients	with	NETs	with	PRRT	because	of	less	renal	toxicity.	
In	2008,	we	reported	on	310	GEP-NET	patients	who	were	treated	with	177Lu-DOTATATE 
(8). Although part of the patients reported in the present paper was included in the 2008 
study,	we	believe	that	the	current	results	are	more	distinctive	and	more	unique.	In	contrast	
to	the	former	report,	in	this	cohort	only	Dutch	patients	with	a	very	long	follow-up	in	our	
institution were included and results of various subtypes of GEP-NETs are reported. The 
relative low loss to follow-up makes the present results more solid. 
For this study no intention-to-treat analysis was made. We believe that an analysis of all 
1214 patients is not reliable. This group includes patients from different countries who 
were only treated at our institute and all follow-up was conducted in their own country. 
No data about this follow-up is available. This group also includes patients with different 
kind	of	malignancies,	e.g.	thyroid	cancers,	paragangliomas	and	lymphomas.	This	hetero-
geneity will make an analysis not reliable and not representative for the investigated group 
of bronchial and GEPNET patients. The main limitation of this study is the fact that it is a 
non-randomized	study.	However,	with	the	selection	of	patients	that	were	all	treated	strictly	
according to the inclusion criteria and an active follow-up during many years make the 
results very reliable. Also the inclusion of patients with stable disease at baseline is a lim-
itation compared to other studies reporting on NETs. Patients with a very large tumor load 
or	many	symptoms	of	the	tumor	or	its	produced	hormones	were	treated,	because	PRRT	was	
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the	best	available	treatment	option	at	that	point	in	time.	However,	analysis	of	the	patients	
with	PD	at	baseline	demonstrated	only	small	differences	in	PFS,	TTP	and	OS	compared	to	
all GEPNET patients. 
Conclusion
PRRT with 177Lu-DOTATATE produces good tumor response rates for patients with grade 
1-2 GEP-NETs and bronchial NETs. The side-effects are limited and in the vast majority 
of	patients	reversible	on	short	term.	Severe	long-term	toxicities	are	AL	or	MDS,	occurring	
in 2% of patients. No therapy-related long-term renal or hepatic failure was observed. 
Although	 this	was	a	non-randomized	study,	 the	PFS	and	TTP	 for	 177Lu-DOTATATE are 
favorable to all other registered medical options that are currently available for patients 
with advanced or metastasized G1-G2 GEP-NETs and bronchial NETs. 
Chapter 5
98
References
1.		 Fraenkel	M,	Kim	M,	Faggiano	A,	de	Herder	WW,	Valk	GD,	On	behalf	of	the	Knowledge	NET-
work. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the 
literature. Endocr Relat Cancer. 2014;21:R153–63. 
2.		 Korse	CM,	Taal	BG,	van	Velthuysen	M-LF,	Visser	O.	Incidence	and	survival	of	neuroendocrine	
tumours	in	the	Netherlands	according	to	histological	grade:	Experience	of	two	decades	of	can-
cer registry. Eur J Cancer. 2013;49:1975–83. 
3.		 Yao	JC,	Hassan	M,	Phan	A,	Dagohoy	C,	Leary	C,	Mares	JE,	et	al.	One	Hundred	Years	After	
“Carcinoid”:	Epidemiology	of	and	Prognostic	Factors	for	Neuroendocrine	Tumors	in	35,825	
Cases in the United States. J Clin Oncol. 2008;26:3063–72. 
4.		 Kulke	MH,	Benson	AB,	Bergsland	E,	Berlin	JD,	Blaszkowsky	LS,	Choti	MA,	et	al.	Neuroen-
docrine tumors. J Natl Compr Canc Netw. 2012;10:724–64. 
5.		 Pavel	M,	O’Toole	D,	Costa	F,	Capdevila	J,	Gross	D,	Kianmanesh	R,	et	al.	ENETS	Consensus	
Guidelines	Update	for	the	Management	of	Distant	Metastatic	Disease	of	Intestinal,	Pancreatic,	
Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendo-
crinology. 2016;103:172–85. 
6.		 Krenning	EP,	Breeman	WAP,	Kooij	PPM,	Lameris	JS,	Bakker	WH,	Koper	JW,	et	al.	Localisa-
tion of endocrine-related tumours with radioiodinated analogue of somatostatin. The Lancet. 
1989;Pages 242–4. 
7.		 Forrer	 F,	 Waldherr	 C,	 Maecke	 HR,	 Mueller-Brand	 J.	 Targeted	 radionuclide	 therapy	 with	
90Y-DOTATOC in patients with neuroendocrine tumors. Anticancer Res. 2006;26:703–7. 
8.		 Kwekkeboom	DJ,	de	Herder	WW,	Kam	BL,	van	Eijck	CH,	van	Essen	M,	Kooij	PP,	et	al.	Treat-
ment	With	 the	Radiolabeled	Somatostatin	Analog	[177Lu-DOTA0,Tyr3]Octreotate:	Toxicity,	
Efficacy,	and	Survival.	J	Clin	Oncol.	2008;26:2124–30.	
9.		 Bodei	L,	Cremonesi	M,	Grana	CM,	Fazio	N,	Iodice	S,	Baio	SM,	et	al.	Peptide	receptor	radionu-
clide therapy with 177Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 
2011;38:2125–35. 
10.		 Sabet	A,	Dautzenberg	K,	Haslerud	T,	Aouf	A,	Sabet	A,	Simon	B,	et	al.	Specific	efficacy	of	
peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tu-
mours of the small intestine. Eur J Nucl Med Mol Imaging. 2015;42:1238-1246. 
11.		 Bushnell	DL,	O’Dorisio	TM,	O’Dorisio	MS,	Menda	Y,	Hicks	RJ,	Van	Cutsem	E,	et	al.	90Y-Edo-
treotide for Metastatic Carcinoid Refractory to Octreotide. J Clin Oncol. 2010;28:1652–9. 
12.		 Strosberg	 JR,	El-Haddad	G,	Wolin	E,	Hendifar	A,	Yao	 J,	Chasen	B,	 et	 al.	 Phase	 3	Trial	 of	
177-Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med 2017;376:125-35.  
13.		 Kwekkeboom	DJ,	Bakker	WH,	Kooij	PP,	Konijnenberg	MW,	Srinivasan	A,	Erion	 JL,	 et	 al.	
[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur J 
Nucl Med. 2001;28:1319–25. 
14.		 Eisenhauer	EA,	Therasse	P,	Bogaerts	J,	Schwartz	LH,	Sargent	D,	Ford	R,	et	al.	New	response	
evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 
2009;45:228–47. 
99
Efficacy, survival and safety of 177Lu-DOTATATE in GEPNETs
5
15.		 Kwekkeboom	DJ.	Radiolabeled	Somatostatin	Analog	[177Lu-DOTA0,Tyr3]Octreotate	in	Pa-
tients With Endocrine Gastroenteropancreatic Tumors. J Clin Oncol. 2005;23:2754–62. 
16.  Pazdur R. Endpoints for assessing drug activity in clinical trials. The oncologist. 2008;13:19–
21. 
17.		 US	Department	of	Health	and	Human	Services,	National	Institute	of	Health,	National	Cancer	
Institute.	Common	Terminology	Criteria	for	Adverse	Events	(CTCAE).	Version	4.0.	2010;	
18.		 Rinke	A,	Muller	H-H,	Schade-Brittinger	C,	Klose	K-J,	Barth	P,	Wied	M,	et	al.	Placebo-Con-
trolled,	 Double-Blind,	 Prospective,	 Randomized	 Study	 on	 the	 Effect	 of	 Octreotide	 LAR	 in	
the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A 
Report From the PROMID Study Group. J Clin Oncol. 2009;27:4656–63. 
19.		 Caplin	ME,	Pavel	M,	Ćwikła	JB,	Phan	AT,	Raderer	M,	Sedláčková	E,	et	al.	Lanreotide	in	Met-
astatic Enteropancreatic Neuroendocrine Tumors. N Engl J Med. 2014;371:224–33. 
20.		 Rinke	A,	Wittenberg	M,	Schade-Brittinger	C,	Aminossadati	B,	Ronicke	E,	Gress	TM,	et	 al.	
Placebo	Controlled,	Double	Blind,	Prospective,	Randomized	Study	on	the	Effect	of	Octreotide	
LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tu-
mors (PROMID): Results on Long Term Survival. Neuroendocrinology [Internet]. 2016 [cited 
2016	Jun	8];	Available	from:	http://www.karger.com/?doi=10.1159/000443612
21.		 Caplin	ME,	Pavel	M,	Ćwikła	JB,	Phan	AT,	Raderer	M,	Sedláčková	E,	et	al.	Anti-tumour	effects	
of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label 
extension	study.	Endocr	Relat	Cancer.	2016;23:191–9.	
22.		 Dörr	U,	Räth	U,	Sautter-Bihl	M-L,	Guzman	G,	Bach	G,	Adrian	H-J,	et	al.	Improved	visualiza-
tion of carcinoid liver metastases by indium-111 pentetreotide scintigraphy following treatment 
with cold somatostatin analogue. Eur J Nucl Med. 1993;20:431–3. 
23.		 Rindi	G,	Klöppel	G,	Alhman	H,	Caplin	M,	Couvelard	A,	de	Herder	WW,	et	al.	TNM	staging	of	
foregut	(neuro)endocrine	tumors:	a	consensus	proposal	including	a	grading	system.	Virchows	
Arch. 2006;449:395–401. 
24.		 Rindi	G,	Klöppel	G,	Couvelard	A,	Komminoth	P,	Körner	M,	Lopes	JM,	et	al.	TNM	staging	of	
midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading sys-
tem.	Virchows	Arch.	2007;451:757–62.	
25.		 Bosman,	F	T,	World	Health	Organization,	International	Agency	for	Research	on	Cancer.	WHO	
classification	of	tumours	of	the	digestive	system.	4th	ed.	Lyon	:	IARC	Press,	2010;	
26.		 Sorbye	H,	Welin	S,	Langer	SW,	Vestermark	LW,	Holt	N,	Osterlund	P,	et	al.	Predictive	and	prog-
nostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuro-
endocrine carcinoma (WHO G3): The NORDIC NEC study. Ann Oncol. 2013;24:152–60. 
27.		 Yao	JC,	Shah	MH,	Ito	T,	Bohas	CL,	Wolin	EM,	Van	Cutsem	E,	et	al.	Everolimus	for	advanced	
pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514–23. 
28.		 Raymond	E,	Dahan	L,	Raoul	J-L,	Bang	Y-J,	Borbath	I,	Lombard-Bohas	C,	et	al.	Sunitinib	Ma-
late for the Treatment of Pancreatic Neuroendocrine Tumors. N Engl J Med. 2011;364:501–13. 
29.		 Yao	JC,	Fazio	N,	Singh	S,	Buzzoni	R,	Carnaghi	C,	Wolin	E,	et	al.	Everolimus	for	the	treatment	
of	advanced,	non-functional	neuroendocrine	tumours	of	the	lung	or	gastrointestinal	tract	(RA-
DIANT-4):	a	randomised,	placebo-controlled,	phase	3	study.	The	Lancet.	2015;968–77.	
Chapter 5
100
30.		 Bodei	L,	Kidd	M,	Paganelli	G,	Grana	CM,	Drozdov	I,	Cremonesi	M,	et	al.	Long-term	tolerabil-
ity of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical 
factors. Eur J Nucl Med Mol Imaging. 2015;42:5–19. 
31.		 Brieau	B,	Hentic	O,	Lebtahi	R,	Palazzo	M,	Ben	Reguiga	M,	Rebours	V,	et	al.	High	risk	of	myel-
odysplastic syndrome and acute myeloid leukemia after 177 Lu-octreotate PRRT in NET patients 
heavily pretreated with alkylating chemotherapy. Endocr Relat Cancer. 2016;23:L17–23. 
32.		 Bodei	L,	Modlin	IM,	Luster	M,	Forrer	F,	Cremonesi	M,	Hicks	RJ,	et	al.	Myeloid	neoplasms	
after chemotherapy and PRRT: myth and reality. Endocr Relat Cancer. 2016;23:C1–7. 
33.		 de	Keizer	B,	 van	Aken	MO,	Feelders	RA,	 de	Herder	WW,	Kam	BLR,	 van	Essen	M,	 et	 al.	
Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin 
analogue	[177Lu-DOTA0,Tyr3]octreotate.	Eur	J	Nucl	Med	Mol	Imaging.	2008;35:749–55.	
34.		 Waldherr	 C,	 Pless	 M,	 Maecke	 HR,	 Haldemann	A,	 Mueller-Brand	 J.	 The	 clinical	 value	 of	
[90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine 
tumours: a clinical phase II study. Ann Oncol. 2001;12:941–5. 
35.		 Valkema	R,	Pauwels	S,	Kvols	L,	Barone	R,	Jamar	F,	Bakker	W,	et	al.	Survival	and	Response	
After	 Peptide	 Receptor	 Radionuclide	 Therapy	 With	 [90Y-DOTA0,Tyr3]Octreotide	 in	 Pa-
tients With Advanced Gastroenteropancreatic Neuroendocrine Tumors. Semin Nucl Med. 
2006;36:147–56. 
36.		 Imhof	A,	Brunner	P,	Marincek	N,	Briel	M,	Schindler	C,	Rasch	H,	 et	 al.	Response,	 Surviv-
al,	 and	 Long-Term	 Toxicity	 After	 Therapy	 With	 the	 Radiolabeled	 Somatostatin	 Analogue	
[90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers. J Clin Oncol. 2011;29:2416–23. 
101
Efficacy, survival and safety of 177Lu-DOTATATE in GEPNETs
5

Pitfalls in the response evaluation after 
peptide receptor radionuclide therapy 
with [177Lu-DOTA0,Tyr3]octreotate
Tessa Brabander1,	Wouter	A	van	der	Zwan1,	Jaap	JM	Teunissen1,	Boen	L	Kam1,	Wouter	
W de Herder2,	Richard	A	Feelders2,	Eric	P	Krenning1,		Dik	J	Kwekkeboom1 
1Department	of	Radiology	&	Nuclear	Medicine,	Erasmus	MC,	Rotterdam,	The	Netherlands	
2Department	of	Internal	medicine,	Sector	of	Endocrinology,	
Erasmus	MC,	Rotterdam,	The	Netherlands	
Endocrine-Related Cancer (2017), vol 24, pp 243-251. 
Chapter 6
Chapter 6
104
Abstract
Peptide receptor radionuclide therapy (PRRT) with [177Lu-DOTA0,Tyr3]octreotate 
(177Lu-DOTATATE) is a treatment with good results in patients with metastatic gastroen-
teropancreatic	neuroendocrine	tumors	(GEPNETs).	However,	there	are	some	pitfalls	that	
should be taken into consideration when evaluating the treatment response after PRRT. 354 
Dutch patients with GEPNETs who were treated with 177Lu-DOTATATE between March 
2000 and December 2011 were retrospectively selected. Liver function parameters and 
chromogranin A were measured before each therapy and in follow-up. Anatomical imaging 
was	performed	before	therapy	and	in	follow-up.	An	increase	in	aminotransferases	by	≥20%	
compared to baseline was observed in 83 of 351 patients (24%). In patients with an ob-
jective	response	(OR)	and	stable	disease	(SD)	this	increase	was	observed	in	71/297	(24%)	
and	in	patients	with	progressive	disease	(PD)	it	was	observed	in	12/54	patients	(22%).	An	
increase	in	chromogranin	A	by	≥20%	compared	to	baseline	was	observed	in	76	patients	
(29%). This was present in 34% of patients who eventually had PD and 27% of patients 
who	had	OR/SD.	 In	70%	of	patients	 this	 tumor	marker	 returned	 to	baseline	 levels	after	
therapy. An increase in liver enzymes and chromogranin A is not uncommon after PRRT. 
In the vast majority of patients this will resolve in follow-up. Clinicians should be aware 
that these changes may occur due to radiation-induced inflammation or disease progression 
and that repeated measurements over time are necessary to differentiate between the two.
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Introduction
Neuroendocrine tumors (NETs) are a rare type of cancer. The overall incidence rate for 
NETs	has	 increased	 in	 the	 last	 few	decades	 (1).	Unfortunately,	 the	majority	 of	 patients	
have metastatic disease at the time of presentation (2). In the past decade a promising new 
treatment modality has been developed for inoperable or metastasized NETs. This peptide 
receptor radionuclide therapy (PRRT) uses radiolabeled somatostatin analogs. Since the 
majority	of	NETs	express	a	high	number	of	the	somatostatin	receptors	on	their	cell	mem-
brane,	this	receptor	can	be	used	both	for	imaging	and	therapy	of	NETs	with	radiolabeled	
somatostatin analogs.
The	most	 frequently	 used	 β-emitting	 radionuclides	 for	 PRRT	 are	Yttrium-90	 and	Lute-
tium-177,	linked	to	[DOTA0,Tyr3]octreotide	(90Y-DOTATOC)	or	[DOTA0,Tyr3]octreotate	
(177Lu-DOTATATE),	 respectively.	The	objective	 response	 rate	 in	patients	with	gastroen-
teropancreatic	neuroendocrine	tumors	(GEPNETs)	is	15–35%	(3-8).	Recently,	the	results	
of the multicentre randomized phase III NETTER-1 trial in patients with advanced midgut 
NETs	(9),	comparing	177Lu-DOTATATE to high dose octreotide LAR therapy were present-
ed. The progression free survival (PFS) in the group receiving octreotide LAR 60 mg was 
8.4 months and was not reached for the group receiving 177Lu-DOTATATE plus 30 mg oc-
treotide	LAR	(Hazard	ratio	0.21;	95%	CI	0.13–	0.34).	It	may	be	expected	that	the	number	
of patients treated with 177Lu-DOTATATE will increase in the coming years. Awareness of 
possible side-effects is important when treating patients with PRRT. The most frequent-
ly	reported	subacute	side-effect	is	hematologic	toxicity	(4,10,11).	This	toxicity	is	mostly	
mild	and	reversible.	Late	severe	side-effects	are	myelodysplastic	syndrome	(MDS)	/	acute	
leukemia (AL). Although 70–90% of patients with disseminated disease have metastases 
in	 the	 liver,	 reported	 hepatotoxicity	 is	 rare.	 Between	 treatment	 cycles	 patients	 undergo	
different	blood	tests	to	detect	possible	side-effects.	These	blood	tests	include	hematology,	
renal	 and	 liver	 function	 parameters,	 and	measurement	 of	 tumor	markers.	 For	 response	
evaluation	after	therapy,	imaging	is	done	in	addition	to	these	blood	tests.	In	2013	van	Vliet	
and coworkers demonstrated that there are no differences in the different response methods 
used in the follow-up of NET patients (12). When interpreting the blood tests and imag-
ing	during	and	directly	after	therapy	some	remarkable	changes	may	occur,	which	are	not	
in	line	with	the	final	treatment	response	to	therapy.	Here,	we	present	several	pitfalls	that	
might occur in the response evaluation during treatment and follow-up after PRRT with 
177Lu-DOTATATE that the treating physicians should be aware of. 
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Materials and methods 
Patients 
354 Dutch patients with GEPNETs who were treated with 177Lu-DOTATATE between 
March 2000 and December 2011 were selected. Follow-up data was available until 2014. 
After	2011	most	new	patients	returned	to	their	referring	specialist	after	therapy,	so	infor-
mation about follow-up at our institute in these patients was limited. Inclusion criteria for 
therapy	were:	histologically	proven	metastatic	or	 inoperable	GEPNETs,	 tumor	uptake	at	
least equal to liver uptake on 111In-DTPA-octreotide	scintigraphy,	Karnofsky	performance	
score	(KPS)	of	at	least	50,	creatinine	clearance	≥40	mL/min	until	2007	or	50	mL/min	from	
2007,	a	platelet	level	of	at	least	75.109/L,	a	hemoglobin	level	of	at	least	6.0	mmol/L	(9.7	g/
dL),	and	a	white	blood	cell	count	of	at	least	2.0.109/L.	Only	Dutch	patients	were	selected,	
because of the limited loss in follow-up in this patient group. This study was part of the 
ongoing prospectively designed study in patients with NETs at our department and was 
approved by the local medical ethical committee. All patients gave their written informed 
consent to participate in the study.
Treatment 
[DOTA0,Tyr3]octreotate	 was	 obtained	 from	 BioSynthema.	 177LuCl
3 
was distributed by 
IDB-Holland. 177Lu-DOTATATE was locally prepared as described previously (13). 30 min 
before the infusion of 177Lu-DOTATATE	was	started,	Granisetron	3	mg	or	Ondansetron	8	
mg	was	injected	intravenously.	An	infusion	of	amino	acids	(2.5%	arginine	and	2.5%	lysine,	
1 L) was started 30 min before the administration of the radiopharmaceutical as well and 
lasted	for	4	h.	The	radiopharmaceutical	was	co-administered,	using	a	second	pump	system.	
Cycle	doses	were	3.7	or	7.4	GBq	(100	or	200	mCi),	depending	on	short-term	toxicity,	in-
jected	over	30	min.	The	intended	interval	between	treatments	was	6–10	weeks.	Normally,	
patients undergo 4 treatment cycles. Patients were treated up to an intended cumulative 
dose of 22.2–29.6 GBq (600–800 mCi).
Anatomical imaging 
Computed tomography (CT) or magnetic resonance imaging (MRI) was performed at least 
3	months	prior	to	therapy.	In	follow-up,	CT	or	MRI	was	performed	6	weeks,	3	months	and	
6 months after the last treatment and thereafter every 6 months. Tumor response was scored 
according	to	the	Southwest	Oncology	Group	(SWOG)	solid	tumor	response	criteria	(14),	
modified	by	adding	a	minor	response	(MR),	pertaining	to	a	decrease	of	25–50%	of	the	sum	
of measurable lesions. Patients were categorized according to confirmative tumor response 
3 months after the last therapy.
107
Pitfalls after PRRT
6
Groups	of	patients	with	limited	or	extensive	metastases	in	the	liver	were	defined.	Extensive	
liver disease was defined as diffuse metastases throughout the whole liver with hepatomega-
ly.	Examples	of	patients	with	limited	and	extensive	disease	in	the	liver	are	presented	in	Fig.	1.	
Blood examinations
Routine	hematology,	liver	and	kidney	function	parameters	and	chromogranin	A	were	deter-
mined	before	each	therapy,	and	at	fixed	follow-up	visits.	An	increase	of	≥20%	compared	to	
baseline	after	the	first	therapy	in	alanine	aminotransferase	(ALT),	aspartate	aminotransfer-
ase	(AST),	gamma-glutamyl	transpeptidase	(GGT),	lactate	dehydrogenase	(LDH),	alkaline	
phosphatase (ALP) or chromogranin A (CgA) was considered clinically significant. ALP 
was measured as a total of all fractions (including bone and liver fractions). 
Adverse events were assessed according to the National Cancer Institute Common Termi-
nology	Criteria	 for	Adverse	Events	 (CTCAE),	version	4.0	 (https://evs.	 nci.nih.gov/ftp1/
CTCAE/CTCAE_4.03_2010-06-14_	QuickReference_5x7.pdf).	
Figure 1. Axial	slices	of	CT’s	of	the	upper	abdomen	in	the	arterial	contrast	phase.	A	and	B	are	
examples	of	patients	with	limited	metastases	in	the	liver.	C	and	D	are	examples	of	patients	with	
extensive	metastases	and	enlargement	of	the	liver.	
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Statistics 
Statistical	analysis	of	the	data	was	performed	using	Fisher’s	exact	test	or	chi-square	test.	A	
p-value <0.05 was considered to be statistically significant. 
Results 
354 Dutch patients with GEPNETs were evaluated. Baseline characteristics are presented 
in	Table	1.	The	most	 common	primary	 tumor	was	 located	 in	 the	 small	 intestine	 (46%),	
followed by the pancreas (31%). The vast majority of patients (86%) had metastases in the 
liver.	Sixty-one	patients	(17%)	had	bone	metastases.	The	mean	age	was	59	years	(range	
23–84 years). 
Characteristic Number of patients %
Male 180 51
Female 174 49
Age 59 (range 23-84)
Primary tumor
Pancreatic NET 110 31
   Non-functional 99 28
   Functional 11 3
Small intestine 163 46
Colorectal 14 4
Stomach 7 2
Duodenum 3 1
Unknown primary 57 16
Total 354
Liver metastases 306 86
   Limited 223 63
			Extensive	 83 23
Bone metastases 61 17
Table 1. Baseline characteristics of 354 Dutch patients with a gastroenteropancreatic neuroendo-
crine tumor.
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A significant (p <0.05) higher baseline level of the cholestatic liver enzymes GGT and ALP 
was	observed	in	patients	with	extensive	liver	disease	compared	to	patients	with	limited/
no	liver	metastases.	An	increase	of	≥20%	in	GGT	compared	to	baseline	was	observed	in	
a total of 87 patients (25%) (Fig. 2 and Table 2). In patients with an objective response 
(OR)	or	stable	disease	(SD)	this	increase	was	seen	in	72/293	patients	(25%)	and	in	patients	
with	progressive	disease	(PD)	it	was	seen	in	15/54	patients	(28%).	Of	the	87	patients	with	
an	increase	of	GGT,	an	increase	of	1	CTCAE	grade	was	seen	in	33	patients	(38%)	and	an	
increase of 2 grades was seen in 13 patients (15%). 
Figure 2. Evolution of liver enzymes after an 
initial	increase	of	≥20%	after	first	therapy	cate-
gorized	by	extent	of	liver	metastases.	Presented	
as	mean	levels,	bars	represent	upper	limit	of	
95%CI.
*:	p<0.05	from	limited/no	liver	metastases.	
Abbreviations: 
GGT:	gamma-glutamyl	transpeptidase,	ALP:	
alkaline	phosphatase,	AST:	aspartate	amino-
transferase,	ALT:	alanine	aminotransferase,	
LDH: lactate dehydrogenase.
PRRT: peptide receptor radionuclide therapy.
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An	increase	of	≥20%	in	ALP	compared	to	baseline	was	observed	in	36/350	patients	(10%).	
Of	these	36	patients,	5	had	bone	metastases.	The	incidence	of	elevation	was	not	significant-
ly different from patients without bone metastases. 
An	increase	 in	 the	aminotransferases	(AST	and/or	ALT)	by	≥20%	compared	 to	baseline	
was	observed	in	83	of	351	patients	(24%)	(Table	2).	In	patients	with	OR/SD	this	increase	
was	observed	in	71/297	(24%)	and	in	patients	with	PD	in	12/54	patients	(22%).	This	in-
crease	was	mild	to	moderate	in	all	patients,	with	a	maximum	of	537	U/L.	After	an	initial	
increase,	the	liver	enzymes	declined	and	eventually	returned	to	baseline	levels	in	the	ma-
jority	of	patients	during	follow-up.	In	patients	with	OR/SD	this	increase	was	permanent	in	
9%,	whereas	in	patients	with	PD	a	permanent	increase	was	observed	in	43%	of	patients.	
The	albumin	levels	of	these	patients	did	not	change	significantly	during	therapy,	bilirubin	
levels	increased	≥20%	compared	to	baseline	in	20/83	of	these	patients	(24%).	Both	patients	
with and without metastases in the liver showed a similar increase (Fig. 2). In patients 
without	metastases	 an	 initial	 increase	 in	 aminotransferases	was	 found	 in	 17/43	patients	
(40%).	This	was	permanent	in	4/17	patients	(24%).	In	70%	of	patients	with	limited	or	no	
metastases	in	the	liver,	the	mean	enzyme	level	declined	after	the	initial	increase.	In	patients	
with	extensive	tumor	load	in	the	liver	this	decline	was	observed	after	the	second	therapy	
(Fig.	2).	Of	the	66	patients	with	an	increase	in	AST,	35	(53%)	had	an	increase	of	CTCAE	of	
1	grade,	2	patients	(3%)	had	an	increase	of	2	grades	and	3	patients	(5%)	had	an	increase	of	
3	grades.	Of	the	82	patients	with	an	increase	of	ALT,	33	(40%)	had	an	increase	of	1	grade,	
4 patients (5%) had an increase of 2 grades and 3 patients (4%) had an increase of 3 grades. 
No	CTCAE	grade	4	toxicity	of	AST/ALT	was	observed.	
OR SD PD
n Increase (%*)
Permanent 
(%**) n
Increase 
(%*)
Permanent 
(%**) n
Increase 
(%*)
Permanent 
(%**)
ALP 94 6 (6) 1 (17) 202 22 (11) 4 (18) 54 8 (15) 4(50)
GGT 92 16 (17) 2 (13) 205 56 (27) 9 (16) 54 15 (28) 7 (47)
AST 91 16 (18) 1 (6) 205 39 (19) 3 (8) 54 11 (20) 5 (45)
ALT 88 24 (27) 2 (8) 205 46 (22) 5 (11) 54 12 (22) 5 (42)
LDH 88 10 (11) 1 (10) 200 13 (7) 2 (15) 54 5 (9) 1 (20)
CgA 68 14 (21) 1 (7) 147 45(31) 10(22) 50 17(34) 12 (71)
Table 2. Number	of	patients	with	an	increase	of	biochemical	markers	≥20%	after	first	therapy	
compared to baseline value.
Abbreviations: 
ALP:	alkaline	phosphatase,	GGT:	gamma-glutamyl	transpeptidase,	AST:	aspartate	aminotransfer-
ase,	ALT:	alanine	aminotransferase,	LDH:	lactate	dehydrogenase,	CgA:	chromogranin	A.	
*Increase:	%	of	n	(OR/SD/PD);	**Permanent:	%	of	increased	n.
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An increase of LDH was observed in 28 patients (8%). The baseline level of LDH was 
significantly	higher	in	patients	with	extensive	disease	(p<0.05).	The	hemoglobin	levels	of	
these 28 patients did not changed significantly after PRRT. Mean baseline level was 7.6 
mmol/L	and	12	weeks	after	PRRT	the	mean	level	was	7.3	mmol/L.	
CgA	was	elevated	in	265/354	patients.	An	increase	of	≥20%	after	first	therapy	compared	to	
baseline	was	observed	in	76/265	patients	(29%).	This	was	present	in	59/215	patients	(27%)	
who	had	OR/SD	and	in	17/50	patients	(34%)	who	eventually	had	PD.	During	the	treatment	
cycles no differences of CgA between the response groups was found (Fig. 3). Twelve 
weeks	after	the	last	therapy	the	mean	levels	of	CgA	in	patients	with	an	OR/SD	continued	
to	decline,	whereas	the	level	of	CgA	in	patients	with	PD	showed	a	strong	increase.	In	19%	
of	patients	with	OR/SD	and	71%	of	patients	with	PD,	the	initial	increase	of	CgA	did	not	
return to baseline levels. 
In the group of patients with a complete response (CR) and partial response (PR) at 3 
months	follow-up,	no	increase	in	the	tumor	size	was	observed	on	the	first	CT	in	follow-up	
at	 6	weeks	 after	 the	 last	 PRRT	cycle.	Of	 the	 206	patients	with	SD	 (including	MR),	 18	
patients	(9%)	had	an	increase	of	≥10%	in	size	at	the	first	follow-up	visit	at	6	weeks	after	
the	last	cycle	of	PRRT.	The	median	increase	in	size	was	18%	(range	10–71%).	In	16/18	
patients	this	increase	was	below	50%	and	in	2/18	patients	there	was	an	increase	of	≥50%.	
An	example	is	given	in	Fig.	4.	During	follow-up	the	sum	diameter	of	lesions	eventually	
declined in 50% of patients at 6 months follow-up with a median decrease of 27%. PD as 
outcome at 3 months follow-up and based solely on an increase in size of measureable le-
sions of more than 50% occurred in 3 patients out of 54 patients with PD. In the remaining 
51/54	patients	 (94%)	new	lesions	or	clear	deterioration	 in	clinical	condition	determined	
permanent PD.
Figure 3. Evolution of chromogranin A after 
an	initial	increase	of	≥20%	after	first	thera-
py. Presented as mean levels of CgA.
Abbreviations:
CgA: chromogranin A.
CR:	complete	remission,	PR:	partial	re-
mission,	MR:	minor	response,	SD:	stable	
disease,	PD:	progressive	disease.	
PRRT: peptide receptor radionuclide therapy.
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Discussion 
In	 this	 study,	 we	 identified	 several	 pitfalls	 that	 should	 be	 taken	 in	 consideration	when	
evaluating the response to treatment in patients treated with 177Lu-DOTATATE. These tem-
porary changes during and directly after therapy have not been described previously. There 
are	many	 reports	 about	 hematologic	 and	 renal	 toxicity	 (10,	 15-17),	while	 reports	 about	
hepatotoxicity	after	PRRT	are	rare	(18-19).	From	experience	with	external	beam	radiation	
therapy it is known that radiation-induced liver disease or radiation hepatitis can be a 
serious	problem,	which	can	result	in	liver	failure	and	even	death.	Radiation-induced	liver	
disease	typically	presents	4–8	weeks	after	therapy	(20),	especially	as	increased	ALP,	but	
aminotransferases can be elevated as well. The whole liver can recover from a radiation 
dose of 30 Gy without permanent damage. During treatment with 177Lu-DOTATATE the 
radiation	dose	to	the	liver	remains	well	below	30	Gy	(13),	explaining	the	very	low	radi-
ation-induced liver disease after PRRT. Liver failure after PRRT with 90Y	 and/or	 177Lu 
labeled	somatostatin	analogs	is	reported	rarely,	and	is	most	commonly	due	to	progressive	
disease. In patients treated with 90Y	microsphere	 radioembolization,	a	 radiation-induced	
liver disease grade 2–3 is reported in 0–4% of patients (21). A report from Ezziddin and 
coworkers	 found	mostly	minor	 (no	grade	4)	 liver	 toxicity	 in	23	patients	 after	 treatment	
with 90Y microspheres as a salvage therapy after failed PRRT with 177Lu-DOTATATE (22). 
We found a mild to moderate (CTCAE grade 1–3) increase in aminotransferases in 24% of 
patients,	which	was	reversible	in	most	patients.	Since	the	level	of	albumin	did	not	change,	
the	hepatocyte	function	seems	not	 to	be	affected.	Both	 in	patients	with	OR/SD	and	PD,	
there was an increase in aminotransferases that was not different between these response 
groups. Also an increase of serum ALP was observed after the first therapy. An elevated 
ALP	can	be	indicative	of	liver	toxicity	or	obstruction,	but	can	also	be	due	to	a	high	bone	
turnover,	 caused	by	bone	metastases.	However,	no	differences	 in	ALP	between	patients	
with and without bone metastases were found. Also an increase of LDH can have dif-
ferent	causes.	The	hemoglobin	 level	of	 these	patients	did	not	change	during	 therapy,	so	
hemolysis is probably not the cause of this increase. A recent report of Jimenez- Fonseca 
and coworkers demonstrated that an elevated LDH is associated with a worse prognosis 
compared to patients with a normal LDH (23). The present results show that patients with 
extensive	metastases	in	the	liver	had	a	higher	baseline	level	of	LDH.	In	2008	we	demon-
strated	that	patients	with	extensive	liver	involvement	have	a	shorter	survival	than	patients	
with limited or no metastases in the liver (4). These findings are concordant with the report 
by Jimenez-Fonseca and coworkers. 
The	published	reports	about	hepatotoxicity	after	PRRT	are	not	consistent.	A	recent	report	
from	Riff	and	coworkers	showed	an	episode	of	hepatotoxicity	in	59%	of	patients	treated	
with 90Y-DOTATOC	and/or	in	combination	with	177Lu-DOTATOC (19). Besides radiophar-
maceuticals,	 patient	 features	 also	 differ	 from	our	 study	 and	may	 explain	 the	 difference	
between	the	reported	hepatotoxicity.	A	number	of	patients	in	the	report	from	Riff	and	co-
workers	were	treated	with	radioembolization	or	other	liver-directed	therapies	before	PRRT,	
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whereas	in	our	study	no	patient	underwent	previous	radioembolization.	Furthermore,	the	
hepatotoxicity	in	our	study	was	temporary	and	reversible	in	91%	of	patients	with	OR/SD	
and 57% of patients with PD.
Bushnell and coworkers (18) found an increase of one WHO grade in at least one liver 
enzyme in 9 of 15 patients with liver metastases after the first treatment of 90Y-DOTATOC. 
In only 4 patients this increase was still present 4–6 weeks after the third and last therapy. 
In	patients	without	liver	metastases	one	of	six	patients	had	an	increase	after	three	therapies.	
No	significant	relation	was	found	between	the	extent	of	hepatic	metastases	and	the	increase	
in liver enzymes. The results from this small study are more consistent with our data than 
the above-mentioned study from Riff and coworkers (19). None of the patients from the 
study of Bushnell and coworkers had prior liver-directed therapy. 
The pattern of an initial increase followed by normalization in follow-up has also been 
described	for	hematologic	toxicity	after	PRRT.	Sierra	and	coworkers	reported	a	grade	2–3	
B-cell	lymphocyte	toxicity	after	each	cycle	in	14	of	16	patients	(24).	All	types	of	lympho-
cyte	toxicity	eventually	resolved	after	90	days.	Kulkarni	and	coworkers	described	mildly	
elevated	serum	creatinine	in	5/22	patients	directly	after	PRRT	(25).	However,	serious	renal	
toxicity	is	very	rare	after	treatment	with	177Lu-DOTATATE and occurs in less than 1% of 
patients	(26,27),	provided	that	appropriate	renal	protection	by	lysine/arginine	infusion	is	
applied. 
CgA is a protein that is present in the secretory granules of most neuroendocrine cells (28). 
In	patients	with	NETs	it	can	be	used	as	a	tumor	marker,	since	it	is	excreted	together	with	the	
peptide	hormones	in	the	neurosecretory	granules	(29,30).	Although	CgA	is	a	nonspecific	
marker	for	NETs,	well-differentiated	NETs	often	have	an	elevated	level	of	CgA,	which	is	
positively	correlated	with	a	tumor	burden.	If	elevated,	it	is	a	useful	marker	to	evaluate	bio-
chemical response to therapy or progression. After the first cycle with 177Lu-DOTATATE an 
increase	of	≥20%	in	CgA	was	observed	in	29%	of	our	patients.	No	differences	were	found	
between	the	different	response	groups.	Therefore,	this	increase	did	not	indicate	progression	
in	most	patients	and	may	be	explained	by	a	release	of	CgA	due	to	radiation-induced	cell	
damage or lysis. The decline of CgA after the initial peak supports this hypothesis. Also in 
patients	with	PD	the	CgA	declined	after	an	initial	peak.	In	follow-up,	not	until	12	weeks	af-
ter	the	last	cycle	of	PRRT,	a	difference	in	CgA	between	PD	and	non-PD	patients	occurs.	To	
avoid	undertreatment,	patients	should,	therefore,	not	be	considered	as	progressive	based	on	
an increase of CgA during or shortly after PRRT. In a small number of patients the increase 
in liver enzyme and CgA levels did not return to baseline levels during follow-up. This was 
seen	more	often	in	patients	with	PD	compared	to	those	with	OR/SD	and	this	increase	is,	
therefore,	more	likely	to	be	tumor	progression	related.	
This phenomenon is not unique: in patients with well-differentiated thyroid carcinoma 
treated	with	radioactive	iodine	therapy,	a	transient	increase	in	the	biochemical	marker	thy-
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roglobulin (Tg) directly after radioactive iodine ablation has been described. Similar to 
PRRT	in	NETs,	it	was	suggested	that	this	increase	is	due	to	tissue	destruction/inflamma-
tion.	During	follow-up,	the	Tg	levels	fall	below	baseline	levels	after	6	months	(31).	This	
transient increase of Tg is even considered as a prognostic indicator of the success of the 
radioactive iodine treatments (32). 
A change in CgA may also occur after the start and during the use of proton pump inhib-
itors	(PPI),	and	during	the	use	of	somatostatin	analogs.	A	total	of	16/76	patients	with	an	
increase	of	CgA	used	PPIs	during	PRRT	and	33/76	of	patients	used	somatostatin	analogs.	
Three	patients	started	PPIs	during	therapy,	this	may	have	an	influence	on	the	evolution	of	
CgA	during	therapy.	Although	due	to	the	small	number	of	patients,	the	potential	effect	on	
the	increase	of	CgA	is,	therefore,	limited.	
The	proliferation	marker	Ki-67	can	be	used	for	the	grading	of	NETs	(33,34).	In	2007	we	
started to use Ki-67 routinely for all NETs. This study included patients treated from 2000 
and	therefore	the	Ki-67	is	not	available	for	all	patients.	It	is,	therefore,	not	possible	to	cor-
relate the grading to the incidence of increase of CgA and liver enzymes. 
An increase of the diameter of lesions of 10% or more on imaging was seen in 9% of pa-
tients with SD at 6 weeks post PRRT and was reversible at 6 months follow-up in 50% of 
patients. This transient increase was probably caused by inflammation causing localized 
edematous tissue at the site of the metastases and not based on progression. This radio-
genic	oedema	has	been	described	previously	for	PRRT	of	brain	tumors	and	external	beam	
radiation	 (35,36).	 In	studies	with	cytokines,	cancer	vaccines	and	monoclonal	antibodies	
Figure 4. Axial	slices	of	a	contrast	enhanced	CT	of	the	liver	before	PRRT,	6	weeks,	6	and	36	
months after therapy. This 64 year-old patient presented with a NET of the small intestine and 
metastases	in	the	liver.	A	well-defi	ned	metastasis	was	visible	in	segment	7	of	the	liver	(red	arrow).	
Directly	after	therapy,	the	metastasis	had	increase	in	size	and	was	less	demarcated.	In	follow-up,	
after	6	and	36	months,	the	metastasis	further	decreased	in	size.	Response	evaluation	after	3	months	
resulted in a SD.
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an	 increase	 in	 tumor	 burden	 has	 been	 demonstrated	 in	 patients	with	CR,	 PR	 or	 SD	 as	
treatment outcome. This phenomenon was described as pseudo-progression and resulted 
in	a	new	response	method,	the	immune-related	response	criteria	(irRC)	(37).	This	increase	
in the tumor size after immunotherapy is probably related to infusion of lymphocytes and 
macrophages	in	the	tumor	and	new	lesions	are	not	always	considered	as	PD.	In	our	study,	a	
temporary increase in tumor size was only observed in NET patients with SD as treatment 
outcome.	Furthermore,	it	is	notable	that	in	51/54	of	the	PRRT	patients	who	eventually	had	
PD	as	treatment	outcome,	it	was	based	on	the	finding	of	new	lesions	on	imaging	or	clinical	
deterioration.	In	3	of	54	patients	who	had	PD	as	treatment	outcome,	it	was	based	solely	
on	an	increase	of	the	diameter	of	the	lesions	according	to	SWOG	criteria.	The	irRC	are,	
therefore,	not	applicable	for	NET	patients.	Also,	due	to	the	low	frequency	of	radiation-in-
duced	inflammation	after	PRRT,	it	seems	that	a	new	response	method	for	NET	patients	is	
not	 required.	However,	clinicians	should	be	aware	 that	an	 increase	 in	size	directly	after	
PRRT is more frequently due to radiation-induced inflammation than to permanent disease 
progression.
Conclusion 
In this study we found that a temporary increase in liver function parameters and CgA level 
is	not	uncommon	after	treatment	with	PRRT,	and	it	is	not	related	to	the	final	response	to	
therapy	at	3	months	post	PRRT.	Since	CgA	may	be	released	during	cell	damage,	this	in-
crease does not pertain to progression in most patients. No differences were found between 
patients	with	an	OR/SD	and	PD.	Therefore,	both	liver	function	parameters	and	CgA	should	
be	 interpreted	with	caution	during	 therapy.	Lastly,	a	 temporary	 increase	of	≥10%	in	 the	
size of metastases is not uncommon after the intended cycles of PRRT. Our observations 
reported in this study indicate that initial permanent progression based on imaging is virtu-
ally always reflected by the finding of new lesions and rarely by an increase in tumor size 
alone. Clinicians should be aware that initial diameter increases are more frequently due to 
temporary	radiation-induced	inflammation	than	due	to	permanent	disease	progression,	and	
that repeated imaging over time is necessary to differentiate between the two.
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Abstract
Purpose
Peptide receptor radionuclide therapy (PRRT) is a good therapeutic option for patients with 
inoperable or metastasized neuroendocrine tumors. In follow-up after PRRT patients un-
dergo	routine	blood	tests,	anatomical	and	molecular	imaging	to	detect	progressive	disease	
(PD). We compared the different methods and tried to determine the best diagnostic test to 
detect PD.  
Patients and methods
Seventy-one patients with PD after therapy with [177Lu-DOTA0,Tyr3]octreotate who all had 
a CT and somatostatin receptor scintigraphy (SRS) at the moment of PD were retrospec-
tively selected. Chromogranin A (CgA) was elevated in 50 patients and the cholestatic liv-
er enzymes gamma-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP) were 
available	 in	63	and	65	patients,	 respectively.	Results	of	CT,	SRS	and	biochemical	 tests	
were compared to determine the best diagnostic test to detect progressive disease. 
Results
Progression	was	demonstrated	by	CT	and	SRS	at	the	same	follow-up	visit	in	54/71	patients	
(76%). In 9 patients (13%) SRS detected PD before CT and in 8 patients (11%) CT was 
the	first	imaging	modality	to	detect	PD.	Overall,	an	increase	of	≥25%	of	CgA	level	com-
pared	to	previous	measurements	as	an	indication	of	PD	was	demonstrated	in	37/50	patients	
(74%),	of	ALP	in	24/65	(37%)	and	of	GGT	in	32/63	(51%).	An	increase	of	CgA	level	was	
observed	before	imaging	in	21/50	(42%)	patients.	
Conclusion 
CT and SRS are complementary in the detection of PD after therapy with 177Lu-DOTATATE. 
Also	biochemical	markers	are	able	to	detect	PD	in	the	majority	of	patients.	However,	none	
of the used diagnostic tests is clearly superior compared to the other and therefore a combi-
nation	of	different	diagnostic	tests,	including	imaging,	is	necessary	in	every	patient.	
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Introduction
Neuroendocrine tumors (NETs) are a rare and heterogeneous group of tumors. The majority 
of	grade	1-2	tumors	express	the	somatostatin	receptor,	especially	subtype	2	(1).	This	recep-
tor	is	a	target	for	somatostatin	analogs,	which	can	be	labeled	with	radionuclides	for	both	
imaging	and	therapy.	Currently,	the	most	frequently	used	imaging	modalities	for	NETs	are	
computed	tomography	(CT),	magnetic	resonance	imaging	(MRI)	and	somatostatin	receptor	
scintigraphy (SRS) with 111In-DTPA-octreotide	(Octreoscan,	Petten,	The	Netherlands).	For	
low-grade	tumors,	SRS	is	more	sensitive	for	the	detection	of	metastases	than	CT	(2,3).	For	
therapy,	the	radionuclide	Lutetium-177	can	be	used.	This	is	a	β-emitting	radionuclide	with	
a half-life of 6.7 days. Linked to the somatostatin analog octreotate ([177Lu-DOTA0,Tyr3]
octreotate),	it	 is	used	for	the	treatment	of	metastasized	or	inoperable	neuroendocrine	tu-
mors. Treatment with these radiolabeled somatostatin analogs results in good tumor re-
sponse rates and a long time to progression (TTP) and overall survival (OS) (4). 
NETs	may	excrete	the	tumor	marker	chromogranin	A	(CgA)	(5).	This	tumor	marker	can	
be	elevated	in	the	blood	samples	of	patients	with	NETs,	but	is	not	specific	for	the	disease.	
Moreover,	not	every	patient	with	a	NET	has	an	elevation	of	CgA.	Especially	well-differen-
tiated	NETs	excrete	CgA,	while	in	patients	with	a	poorly	differentiated	tumor	the	level	of	
CgA	is	often	not	elevated.	The	level	of	serum	CgA	correlates	positively	with	the	extent	of	
disease	and	can	also	predict	the	response	to	therapy	(6,7).	If	a	patient	has	an	elevated	CgA,	
this marker can be useful especially in the follow-up after peptide receptor radionuclide 
therapy	(PRRT).	Also	the	metabolite	of	serotonin,	5-hydroxyindoleacetic	acid	(5-HIAA),	
which	is	excreted	in	the	urine	of	patients	with	neuroendocrine	tumors,	may	be	helpful	in	
the diagnosis and follow-up of patients. The complete response rate in the group of pa-
tients	 treated	with	PRRT	is	approximately	2%,	so	most	patients	will	eventually	become	
progressive during follow-up (4). It is important to confirm progressive disease (PD) in an 
early	stage,	since	other	therapeutic	options	may	be	effective	and	should	be	started	shortly	
after	the	detection	of	PD.	In	our	institute	patients	undergo	CT,	SRS	and	blood	sampling	in	
follow-up. We retrospectively selected patients from our department who all had a CT and 
SRS with PD in the follow-up after PRRT with [177Lu-DOTA0,Tyr3]octreotate (177Lu-DO-
TATATE) and tried to determine the best way to detect progression of disease.  
Patients and methods 
Patients
Dutch patients with a histologically proven neuroendocrine tumor that were treated at our 
institute with 177Lu-DOTATATE between July 2000 and March 2007 were retrospectively 
selected. Patients were included if they have had PD and at least 3 CT scans and one SRS 
in	follow-up.	For	comparison	between	CT	and	SRS,	patients	should	have	had	at	least	one	
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SRS.	Therefore,	 the	follow-up	period	must	be	at	 least	12	months	and	only	patients	with	
a therapy date before March 2007 were included. Since we previously reported a median 
TTP of 40 months (4) and patients were referred back to their own referring specialist af-
ter	2011,	only	a	limited	number	of	patients	treated	before	March	2007	could	be	included.	
Moreover,	only	Dutch	patients	were	selected,	because	of	the	limited	loss	to	follow-up	in	
this patient group. 
Inclusion criteria for therapy with 177Lu-DOTATATE were: tumor uptake at least as high 
as the uptake in the normal parenchyma of the liver on 111In-DTPA-octreotide scintigra-
phy	(Octreoscan,	Mallinckrodt,	Petten,	the	Netherlands)	prior	to	the	therapy	and	no	previ-
ous treatment with other radiolabeled somatostatin analogs. Other inclusion criteria were: 
serum	hemoglobin	 ≥	 6.0	mmol/L	 (≥	 9.7	 g/dL),	WBC	count	 ≥	 2·109/L,	 platelet	 count	 ≥	
75·109/L,	serum	creatinine	concentration	≤	150	umol/L	(≤	1.7	mg/dL)	or	creatinine	clear-
ance	≥	40-50	mL/min	and	Karnofsky	performance	status	(KPS)	≥	50.
SRS was performed in the follow-up at 12 months after therapy and thereafter every 18 
months.	CT	or	MRI	was	done	in	follow-up	at	6	weeks,	3	months,	6	months	and	thereafter	
every	6	months.	Routine	blood	samples	including	hematology,	liver	and	kidney	function	
tests and CgA were taken after each therapy cycle and at every follow-up visit. 
This study was part of an on-going prospectively designed study on patients with neuroen-
docrine tumors treated with 177Lu-DOTATATE at our department. The local medical ethical 
committee approved this study. All patients gave written informed consent to participate 
in the study. 
Methods 
[DOTA0,Tyr3]octreotate	was	obtained	from	BioSynthema,	St	Louis,	MO.	177LuCl3 was dis-
tributed	by	 IDB-Holland,	Baarle-Nassau,	 the	Netherlands.	 177Lu-DOTATATE was local-
ly prepared as described previously (8)Tyr3]octreotate has a nine-fold higher affinity for 
the	 somatostatin	 receptor	 subtype	 2	 as	 compared	with	 [DOTA0,	 Tyr3]octreotide.	Also,	
labeled	with	the	beta-	and	gamma-emitting	radionuclide	lutetium-177,	this	compound	has	
been shown to have a very favorable impact on tumor regression and animal survival in 
a rat model. Because of these reported advantages over the analogs currently used for so-
matostatin	receptor-mediated	radiotherapy,	we	decided	to	compare	[177Lu-DOTA0,Tyr3]
octreotate	(177Lu-octreotate.	Before	the	infusion	of	the	radiopharmaceutical,	Granisetron	
or	Ondansetron	was	injected	intravenously.	To	reduce	the	radiation	dose	to	the	kidneys,	an	
infusion of amino acids (2.5% arginine and 2.5% lysine in 1L 0.9% NaCl) was started 30 
min before the administration of the radiopharmaceutical and lasted 4 h. The radiopharma-
ceutical was coadministered using a second pump system over 30 min. The intended in-
terval between treatments was 6–10 wk. Patients were treated up to a cumulative intended 
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dose of 750 to 800 mCi (27.8–29.6 GBq). 
Imaging
Contrast	enhanced	CT	of	the	abdomen	and	if	applicable	also	a	CT	of	the	thorax	were	made	
at every follow-up visit. Additional scanning of the liver in the arterial phase was done if 
a patient had (suspicion of) liver metastases. SRS was done 24 hours after injection of 220 
MBq (± 22 MBq). Planar imaging of the whole body was acquired by spot views of 15 
min.	Additional	SPECT(/CT)	of	the	upper	abdomen	was	done	if	a	patient	had	a	tumor	or	
metastases in the liver or upper abdomen. 
Determination of progressive disease
Progressive	disease	on	CT	was	defined	according	to	the	SWOG	criteria	(9)	as	≥50%	in-
crease or an increase of 10 cm2 in the sum of products of all measurable lesions over the 
smallest	sum	observed	(over	baseline	if	no	decrease),	or	clear	worsening	of	any	evaluable	
disease,	 or	 reappearance	 of	 any	 lesion	 that	 had	 disappeared,	 or	 appearance	 of	 any	 new	
lesion. Progressive disease on SRS was defined as reappearance of any lesion that had 
disappeared,	or	appearance	of	any	new	lesion.	Progressive	disease	based	on	serum	CgA,	
alkaline phosphatase (ALP) or gamma-glutamyl transpeptidase (GGT) was defined as an 
increase	in	serum	≥25%	compared	to	the	previous	measurement,	which	was	confirmed	by	
a second measurement within 6 months. This second measurement was necessary to avoid 
any	false-positive	results.	5-Hydroxyindoleacetic	acid	(5-HIAA)	excretion	was	 tested	 in	
24-hour	urine	samples.	An	increase	of	≥25%	compared	to	the	previous	measurement	was	
considered as an indication of PD. 
Results 
A	total	of	71	patients	were	progressive	at	the	time	of	CT/SRS	and	available	for	evaluation.	
CgA was elevated in 50 patients. Baseline characteristics are presented in table 1. There 
were 33 men and 38 women. Mean age was 57.2 years (range 32-79). Imaging was done 
with CT in 70 patients and with MRI in one patient. The median TTP was 37 months (range 
22-119 months).  
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Progression was confirmed on anatomical imaging and SRS at the same follow-up visit 
in	54/71	patients	(76%)	(Figure	1).	In	9	patients	(13%)	SRS	demonstrated	PD	before	CT.	
In all patients this was based on new lesions that were not yet visible on CT. In 8 patients 
(11%) CT was the first imaging modality to detect PD (Figure 1). This was based solely 
on an increase in size of metastases in one patient and in seven patients based also on new 
lesions.
CgA	was	elevated	in	50/71	(70%)	of	the	selected	patients.	Overall,	CgA	indicated	PD	in	
74%	of	these	patients.	An	increase	of	≥25%	compared	to	the	previous	measurement	con-
firmed	PD	at	 the	 same	 follow-up	visit	 as	 imaging	 in	16/50	patients	 (32%).	An	 increase	
in	CgA	was	observed	before	 imaging	 in	21/50	 (42%)	patients	 (Figure	2).	This	 increase	
was	detected	an	average	of	8	months	before	PD	on	imaging.	In	13/50	(26%)	patients	no	
increase of CgA was observed at the moment of PD on imaging. 
5-HIAA	was	elevated	 in	27	patients.	At	 the	 time	of	progression	on	 imaging	8/27	(30%)	
patients	had	an	 increase	of	5-HIAA.	In	9/27	(33%)	patients	an	 increase	of	5-HIAA	was	
observed before the confirmation of PD on imaging. This resulted in a sensitivity for the 
detection of PD with 5-HIAA of 63%. 
No patients %
Male 33 47
Female 38 54
Age 57.2 (range 32-79)
Primary tumor site
  Small intestine
  Pancreas
  Rectum
  Bronchus
  Stomach
  Kidney
  Unknown 
37
20
5
3
2
1
3
53
29
7
4
3
1
4
Liver metastases
  Limited
		Extensive	
66
54
12
94
77
17
Bone metastases 9 13
No. of cycles PRRT 3.9 (range 3-5)
Median cumulative administered 
activity
800 mCi
(range 600-900)
Median time to progression 37 months
(range 22-119)
Table 1. Patient and tumor characteristics.
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The cholestatic liver enzymes gamma-glutamyl transpeptidase (GGT) and alkaline phos-
phatase (ALP) were available in 63 and 65 patients respectively. ALP was able to indicate 
PD in 37% and GGT in 51% of patients. An increase ≥25%	of GGT compared to the pre-
vious measurement was	observed	 in	16/63	(25%)	of	patients	and	an	 increase	of	ALP	 in	
15/65	(23%)	of	patients	at	time	of	PD	on	imaging.	The	cholestatic	liver	enzymes	and	CgA	
showed an increase of ≥25%	in the same part of patients at time of PD on imaging (figure 
2).	An	increase	of	ALP	and	GGT	was	observed	before	imaging	in	9/65	(14%)	and	16/63	
(25%) of patients respectively. 
The body weight was measured at every follow-up visit in 59 patients. A decrease of body 
weight	of	3	kg	or	more	was	observed	in	20/59	patients	(34%)	at	the	time	of	PD	(figure	3).	
The	mean	weight	loss	was	6	kg	(range	3-19	kg).	In	4/59	(7%)	patients	an	increase	of	body	
weight of 3 kg or more was found (range 3-6 kg). 
Figure 1. Progression based on 
different imaging modalities
Figure 2. Percentages of patients 
with PD in relation to the change 
in biochemical markers.
*: p<0.05 
**: p<0.01
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In none of these patients the development of ascites or edemas was the cause for the in-
crease	in	body	weight.	In	the	remaining	35/59	patients	the	body	weight	was	stable.	
Discussion 
In	 this	 study,	we	demonstrated	 that	 in	 the	majority	of	patients	 (76%)	both	CT	and	SRS	
could detect progressive disease after PRRT with 177Lu-DOTATATE at the same follow-up 
visit. The tumor marker CgA was able to indicate PD in 74% of patients. In 42% of patients 
CgA was increased before there was any evidence of PD on imaging. Cholestatic liver en-
zymes were not very helpful as a method for the detection of PD.
Progressive disease can present as either a deterioration of the clinical condition or an 
increase	of	biochemical	markers,	but	 the	gold	standard	remains	 imaging.	For	 low-grade	
(grade	1	and	2)	NET,	SRS	has	a	better	sensitivity	than	CT,	therefore	it	 is	not	surprising	
that	new	metastases	can	be	detected	on	SRS	at	an	earlier	stage	than	on	CT.	However,	PD	
based	solely	on	an	increase	of	size	can	only	be	detected	with	CT.	Besides,	due	to	the	better	
spatial	resolution	of	CT,	small	metastases	can	be	detected	before	these	are	visible	on	SRS.	
Our results demonstrated that both CT and SRS can detect new lesions before these are 
recognized	on	the	other	imaging	modality.	Therefore,	anatomical	and	molecular	imaging	
are complementary to each other and not one modality is superior. A disadvantage when 
frequently imaging is performed is the radiation dose. Both CT and SRS give the patients a 
significant	radiation	dose.	However,	for	this	specific	group	of	patients	this	is	less	relevant,	
since they receive a significant higher radiation dose during PRRT than with imaging.  
With the introduction of somatostatin analogs bound to the positron emitting radionuclide 
Gallium-68,	 the	 sensitivity	 for	 the	 detection	 of	metastases	 is	 even	 better	 than	 for	 SRS	
Figure 3. Change in body weight 
at time of PD
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and CT. More metastases can be detected and also a change in clinical management was 
demonstrated	with	these	new	radiopharmaceuticals	(10).	Due	to	a	higher	spatial	resolution,	
it	is	expected	that	imaging	with	68Ga labeled somatostatin analogs can detect metastases 
before these are visible on SRS. This imaging modality may be able to detect PD at an 
earlier	stage	than	CT.	Unfortunately,	since	this	technique	is	only	recently	introduced	in	the	
daily	practice,	no	data	is	available	about	results	in	the	follow-up	after	PRRT	in	our	group	
of patients.  
An	increase	of	CgA	is	seen	in	42%	of	patients	before	PD	on	imaging.	Although,	in	a	few	
of	these	patients	there	was	an	increase	in	size	of	the	metastases	on	CT,	it	did	not	fulfil	the	
criteria of PD according to the SWOG criteria. Different studies demonstrated that SRS 
is more sensitive for the detection of NETs than CgA (11–14). A report from Rossi et al 
demonstrated that CgA can detect PD earlier than radiological imaging (15). This is con-
cordant	with	our	findings.	However,	the	main	disadvantage	of	this	tumor	marker	is	the	fact	
that not all tumors produce CgA and in a substantial part of patients there is no increase 
at	the	moment	of	PD	on	imaging.	Moreover,	the	use	of	proton	pomp	inhibitors	and	soma-
tostatin	analogs	may	cause	a	fluctuation	in	the	levels	of	CgA,	making	it	less	reliable.	To	
avoid	these	false-positive	results,	the	confirmation	by	a	second	measurement	is	mandatory.	
A main advantage of CgA is the low cost compared to imaging. 
Other biochemical markers that can be used for detection and follow-up of neuroendocrine 
tumors	 are	 neuron-specific	 enolase	 (NSE)	 and	 the	 α-subunit	 of	 glycoprotein	 hormones	
(α-SU).	Unfortunately,	 the	 sensitivity	 for	 the	 detection	 of	 neuroendocrine	 tumors	 is	 far	
lower	for	these	markers	than	for	CgA	(16).	Therefore,	these	are	not	frequently	used	in	daily	
practice.  
5-HIAA is a metabolite of serotonin and is typically elevated in patients with a carcinoid 
syndrome. An increase of this marker may indicate more production of serotonin and thus 
more	tumor	activity.	Unfortunately,	5-HIAA	may	show	an	increase	due	to	other	conditions,	
such	as	changes	in	diet.	We	tried	to	exclude	the	false	positive	results	with	a	confirmation	
by a second measurement. With these additional measurements a sensitivity of 63% for the 
detection	of	PD	can	be	accomplished,	which	is	lower	than	for	CgA.	
The cholestatic liver enzymes ALP and GGT may also rise at the time of PD. If a tumor in-
creases	in	size,	it	is	expected	that	there	will	be	more	obstruction	of	bile	ducts	and	therefore	
higher	levels	of	these	liver	enzymes.	Unfortunately,	ALP	and	GGT	were	only	able	to	pre-
dict	PD	in	37%	and	51%,	respectively.	Besides,	the	tumor	marker	CgA	was	better	than	the	
liver	enzymes	for	the	overall	detection	of	PD	after	PRRT.	Therefore,	these	liver	enzymes	
are not very useful for the detection of PD in follow-up.
The most simple and cheapest way to detect PD is body weight. If the body weight is 
measured	at	every	follow-up	visit	with	the	same	method,	patients	with	PD	had	a	decrease	
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in	 body	weight	 of	 ≥	 3	 kg	 in	 34%	of	 patients.	 Since	 this	measurement	 is	 a	 very	 simple	
and	cheap	procedure,	it	should	be	done	at	every	follow-up	visit.	Although	the	sensitivity	
of	body	weight	for	the	detection	of	PD	is	not	very	high,	an	unintended	decrease	in	body	
weight should always be an indication for further investigations. 
Recently,	the	NETest	has	been	developed	(17).	This	test	uses	a	circulating	transcript	anal-
ysis in NETs and can predict the response after treatment with somatostatin analogs (18). 
Also,	this	test	can	predict	the	efficacy	of	PRRT	(19).	Besides,	Bodei	et	al	reported	that	CgA	
was non-informative after PRRT compared to NETest.  In the near future this might be a 
promising method to predict response before PRRT and detect progression in follow-up. 
Unfortunately,	this	new	method	is	currently	used	only	in	studies	and	not	widely	performed	
during and after PRRT.  
A limitation of this study is the small number of included patients. Although we analysed 
more	than	300	patients,	only	71	patients	were	suitable	for	analysis.	For	a	good	comparison	
between	SRS	and	CT,	patients	were	only	selected	if	PD	was	confirmed	at	the	time	of	the	
less	frequently	performed	SRS.	Moreover,	due	to	a	relative	low	frequency	of	imaging	with	
SRS	(every	18	months)	and	long	time	to	progression	many	patients	had	to	be	excluded.	
Conclusion 
Both CT and SRS are able to detect PD after PRRT with 177Lu-DOTATATE and are com-
plementary to each other. In a relative large part of patients (42%) the tumor marker CgA 
can	detect	PD	before	imaging,	however	in	a	substantial	part	of	patients	(26%)	no	increase	
of this tumor marker was observed at the time of PD. The cholestatic liver enzymes ALP 
and	GGT	can	detect	PD	as	well,	but	only	in	less	than	half	of	patients	and	are	therefore	not	
very	helpful	in	the	detection	of	PD	after	PRRT.	In	conclusion,	there	is	not	one	ideal	method	
that	can	demonstrate	PD	before	the	other.	Biochemical	markers	may	give	an	indication,	but	
cannot be leading in the follow-up. The combination of different imaging modalities and 
biochemical makers is necessary in all patients. 
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NETs	are	a	heterogeneous	group	of	 tumors,	but	 they	generally	express	high	numbers	of	
high affinity somatostatin receptors on their cell membranes. These receptors are a target 
for	SSAs,	which	can	be	labeled	with	radionuclides	for	both	imaging	and	therapy.	Treat-
ment with “cold” long-acting SSAs is now widely used for suppression of NET-related 
symptoms,	 but	 also	 for	 inhibition	 of	 tumor	 growth	 (1,2).	 The	 expression	 of	 the	 soma-
tostatin receptor subtypes can be used for imaging by SSAs labeled to different radionu-
clides.	Currently,	the	most	frequently	used	radiopharmaceutical	is	 111In-DTPA-octreotide 
(OctreoScan).	However,	recently	developed	PET	tracers	will	replace	OctreoScan.	For	PET	
imaging,	three	different	combinations	of	SSAs	and	Gallium-68	are	used;	68Ga-DOTATOC,	
68Ga-DOTANOC and 68Ga-DOTATATE. These Gallium-68 labeled SSAs all have different 
affinity	profiles	for	the	different	subtypes	of	the	somatostatin	receptor,	but	have	in	common	
that each SSA has a high affinity to the somatostatin receptor subtype 2. Despite their dif-
ferent	affinities,	there	are	no	big	differences	in	the	sensitivity	for	the	detection	of	NETs	(3).	
For	therapy,	SSAs	can	be	labeled	to	the	beta-emitting	radionuclides	Yttrium-90	or	Lute-
tium-177.	Although	no	direct	 comparison	between	 these	 two	 radionuclides	 is	 available,	
reports	about	PFS/OS	are	more	or	less	the	same	(4).	The	main	disadvantage	of	Yttrium-90	
labeled SSAs is the more frequently reported and more severe side-effects due to the high 
energy	of	this	radionuclide,	specifically	related	to	the	renal	function.	
In	this	thesis,	several	aspects	regarding	the	imaging	and	therapy	of	NETs	with	radiolabeled	
SSAs are discussed. 
Chapter 1 is a general introduction on NETs and gives an overview about the different 
imaging	and	treatment	options,	which	are	currently	available	for	NETs.	
Chapter 2 is a review of the literature on nuclear imaging techniques of NETs. The different 
results	of	imaging	with	radiolabeled	SSAs	are	discussed.	Currently,	111In-DTPA-octreotide 
and 68Ga-labeled	SSAs	are	most	frequently	used.	Besides	these	tracers,	also	other	PET	targets	
like 11C-5-HTP and 18F-DOPA	were	developed.	For	the	localization	of	insulinomas,	gluca-
gon-like	peptide-1	receptor	(Exendin-4)	imaging	is	a	promising	new	sensitive	technique.
In	chapter	3,	incidence	and	mechanism	of	physiological	uptake	in	the	pancreatic	head	on	
111In-DTPA-octreotide	scintigraphy	is	described.	178	scans	with	a	SPECT/CT	of	the	upper	
abdomen were analyzed. Uptake in the pancreatic head (uncinate process) was seen in 
46/178	patients	on	SPECT/CT	and	in	12	patients	uptake	was	seen	on	planar	imaging.	In	
patients	with	diabetes	mellitus,	the	incidence	of	uptake	in	the	pancreatic	head	was	doubled.	
Since previous case reports showed uptake in the pancreatic head due to histology proven 
PP	cell	hyperplasia	and	90%	of	these	cells	are	located	in	the	pancreatic	head,	PP	cell	hy-
perplasia	is	the	most	likely	explanation	for	this	visualization.	Also,	patients	with	diabetes	
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mellitus	may	 have	 elevated	 serum	 PP	 concentrations,	 explaining	 the	 high	 incidence	 of	
uptake in the pancreatic head in these patients. 
Chapter 4 is a review of the literature on PRRT. The results and side-effects of the differ-
ent radiolabeled SSAs are discussed. The ORRs that are reported vary between 15-35%. 
The results may differ for different radionuclides and type of primary tumor. Compared to 
historical controls and other currently available therapeutic options for metastasized and 
inoperable	NETs,	the	PFS,	TTP	and	OS	are	favorable	for	PRRT.	Severe	long-term	side-ef-
fects are rare and the incidence of side-effects differ between the radionuclides. Especially 
for	Yttrium-90	severe	long-term	renal	toxicity	is	reported	in	up	to	9%	of	all	patients.	Other	
long-term	side-effects	are	MDS	and	AL.	These	occur	in	approximately	2-3%	of	all	patients.	
In	chapter	5,	the	long-term	efficacy,	survival	and	side	effect	of	treatment	with	177Lu-DO-
TATATE	in	patients	with	GEP	and	bronchial	NETs	is	described.	Since	2000,	a	large	group	
of more than 1200 patients were treated and followed at our department. ORR in 443 
patients	receiving	≥	600	mCi	 177Lu-DOTATATE was 39% and SD was observed in 43% 
of	patients.	PFS	was	29	months,	TTP	was	36	months	and	OS	was	63	months.	Long-term	
toxicity	included	AL	in	4	patients	(0.7%)	and	MDS	in	9	patients	(1.5%).	No	therapy-related	
renal or hepatic failure was observed. Compared to studies with the other therapeutic op-
tions	that	are	currently	registered	for	patients	with	inoperable	or	metastasized	NETs,	PRRT	
with 177Lu-DOTATATE has a better PFS and TTP. 
Chapter 6 describes the pitfalls in the response evaluation after PRRT with 177Lu-DO-
TATATE.	An	increase	of	the	aminotransferases	was	observed	in	24%	of	all	patients.	Also,	
an increase of CgA was observed in 29% of patients. There was no difference in the tumor 
marker	increase	between	patients	with	an	OR	or	PD	as	treatment	outcomes.	On	imaging,	
patients	with	SD	as	treatment	outcome	can	have	a	temporary	increase	in	tumor	size,	which	
is	not	related	to	progression.	An	increase	in	tumor	size	of	≥10%	was	observed	in	9%	of	
patients with SD. Clinicians should be aware that these changes are probably due to radi-
ation-induced inflammation and not related to the treatment response. Repeated measure-
ments are necessary to differentiate between these two and to confirm progression.
In	chapter	7,	the	best	ways	to	detect	progression	after	therapy	with	177Lu-DOTATATE are 
described.	Patients	underwent	biochemical	markers	tests,	molecular	and	anatomical	imag-
ing	at	follow-up.		A	definite	answer	to	the	question,	which	is	best	way	to	detect	progres-
sive disease cannot be given. If we compare the different biochemical tumor markers and 
cholestatic	 liver	 enzymes,	CgA	has	 the	 best	 sensitivity	 for	 the	 detection	 of	 progressive	
disease.	Unfortunately,	a	subgroup	of	patients	didn’t	show	any	increase	of	this	biochemical	
marker	at	the	time	of	progression	on	imaging.	Therefore,	the	combination	of	biochemical	
markers and imaging is the only way to not miss any patients with progressive disease. 
It	can	be	expected	that	tests	using	molecular	markers	(like	the	NETest)	in	the	future	will	
provide better sensitivities.
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With	the	recent	publication	of	the	excellent	results	of	the	NETTER-1	trial	in	patients	with	
advanced	midgut	NETs,	 it	 is	 expected	 that	 177Lu-DOTATATE will become available for 
the treatment of more NET patients around the world. The NETTER-1 study demonstrated 
a longer PFS and higher response rates for 177Lu-DOTATATE combined with octreotide 
LAR in a direct comparison to high-dose octreotide LAR treatment alone (5). The targeted 
therapies that are currently registered for pancreatic NETs are everolimus and sunitinib. A 
direct comparison between one of these targeted therapies and 177Lu-DOTATOC is current-
ly being studied for both drugs. 
To	improve	the	efficacy	of	PRRT,	the	combination	of	PRRT	with	chemotherapy	has	been	
investigated by different research groups (6–9). These reports have shown better response 
rates	with	combined	 therapies	 than	PRRT	alone,	but	unfortunately	no	 randomized	stud-
ies are available at this moment. The results of a randomized trial comparing 177Lu-DO-
TATATE with 177Lu-DOTATATE	in	combination	with	capecitabine	(Xeloda,)	are	currently	
being analyzed in our institute. 
NETs of the pancreas may be inoperable due to involvement of the vascular structures. In 
our study we found the best ORR of 48% in patients with pancreatic NETs. After a signif-
icant reduction of tumor size after therapy with 177Lu-DOTATATE,	some	pancreatic	NET	
patients	can	become	eligible	 for	 surgery.	Therefore,	 therapy	with	 177Lu-DOTATATE can 
be	used	in	a	neo-adjuvant	setting.	A	publication	by	van	Vliet	and	colleagues	(10)	indeed	
demonstrated successful pancreatic surgery after therapy with 177Lu-DOTATATE	in	9/29	
patients (31%) with inoperable pancreatic NETs at baseline. 
Since	the	majority	of	NET	metastases	are	located	in	the	liver,	intra-arterial/loco-regional	
administration of PRRT in the liver via the hepatic artery may result in a higher response 
rates as compared to systemic PRRT (11-13). Pool et al (13) demonstrated a two-fold 
higher uptake in the liver after intra-arterial administration of 177Lu-DOTATATE via the 
hepatic	artery	as	compared	to	intravenous	administration	in	a	preclinical	model.	Also,	im-
aging studies with 68Ga-DOTATOC	PET	demonstrated	an	average	3.75	fold	higher	SUV	
in liver metastases after intraarterial injection via the hepatic artery than after systemic 
administration of this radiopharmaceutical (14). Other clinical studies demonstrated bet-
ter therapeutic results after loco-regional therapy than after systemic therapy in NET pa-
tients	with	dominant	metastases	in	the	liver.	However,	randomized	studies	are	still	lacking	
(11,12).
Unfortunately,	most	NET	patients	will	become	progressive	again	after	 initial	 successful	
therapy with 177Lu-DOTATATE.  If patients tolerated the first PRRT cycles well and if 
there	was	an	objective	response	or	clinical	improvement	to	the	initial	PRRT,	it	is	feasible	to	
retreat patients with additional cycles of 177Lu-DOTATATE. PRRT as a salvage therapy has 
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been described with reasonable results and limited side-effects (15–17). Results of larger 
studies with a long follow-up are necessary to demonstrate long-term safety. 
A different strategy to improve uptake of PRRT in the tumor is the use of somatostatin 
receptor	antagonists	instead	of	agonists.	In	the	past,	it	was	widely	accepted	that	a	radiola-
beled peptide should internalize into the cell to increase the residence time. The antagonists 
do	not	internalize	into	the	cell,	but	only	bind	to	the	receptors	on	the	cell	surface.	Surpris-
ingly,	in	a	preclinical	model	comparing	the	effects	of	one	of	these	somatostatin	receptor	
antagonists,	177Lu-DOTA-JR11,	and	177Lu-DOTA-octreotate a five-times higher uptake of 
the antagonist as compared to the receptor agonist was demonstrated (18). The first human 
study with 177Lu-DOTA-JR11 demonstrated that this treatment is feasible in patients and 
showed a 1.7-10.6 higher tumor uptake than 177Lu-DOTATATE	(19).	However,	no	 large	
studies,	or	direct	comparisons	with	somatostatin	receptor	agonists	are	currently	available	
and	the	(long-term)	toxicity	of	these	antagonists	is	currently	unknown.	
A different approach to improve the response of PRRT is the use of alpha-emitting radio-
nuclides. Alpha-emitting radionuclides have a shorter tissue path-length than beta-emitting 
radionuclides.	However,	all	energy	is	absorbed	in	the	tissue	and	therefore	more	DNA-dam-
age	will	be	induced	by	these	alpha-emitting	radionuclides.	Also,	the	absorbed	dose	in	other	
(healthy) organs will be limited due to the shorter path-length. The first study in NET 
patients using 213Bi-DOTATOC was promising with an objective response or stable disease 
obtained 12 months after therapy in all 7 patients (20). 
A new way to predict the response after PRRT is the NETest (21). This test uses a circulat-
ing	transcript	analysis	in	NETs	and	can	predict	the	efficacy	of	PRRT	(22,23).	In	the	near	
future,	this	test	might	prove	to	be	promising	with	regard	to	predict	response	at	baseline	or	
to	detect	progression	at	follow-up.	Unfortunately,	 this	new	test	 is	currently	only	used	in	
clinical studies and not routinely performed during and after PRRT.  
In	conclusion,	PRRT	with	radiolabeled	SSAs	is	an	effective	and	safe	therapy	for	NETs.	The	
response rates are high and PFS is longer than with the other currently available therapies. 
With	new	developments	in	the	fields	of	imaging	and	PRRT,	hopefully	more	patients	will	
receive the most appropriate treatment at the best moment (theranostics) and in the end 
more patients will achieve disease control. 
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Neuro-endocriene	tumoren	(NETs)	zijn	een	heterogene	groep	tumoren,	maar	over	het	al-
gemeen brengen ze een groot aantal somatostatine receptoren met een hoge affiniteit tot 
expressie	op	hun	celmembraan.	Deze	receptoren	kunnen	somatostatine	analogen	(SSAs)	
binden. Deze SSAs kunnen worden gelabeld met radionucliden voor beeldvorming en ther-
apie. Behandeling met ongelabelde langwerkenden SSAs wordt gebruikt voor het onder-
drukken	van	symptomen,	maar	ook	voor	het	remmen	van	tumorgroei	(1,2).	De	expressie	
van de somatostatine receptoren wordt gebruikt voor beeldvorming door SSAs te label-
en met verschillende radionucliden. Op dit moment is het meest gebruikte radiofarmacon 
111In-DTPA-octreotide (OctreoScan). Het is echter de verwachting dat dit binnenkort wordt 
vervangen	door	radionucliden	die	positronen	uitzenden.	Voor	beeldvorming	met	positron	
emissie tomografie (PET) zijn op dit moment drie verschillende combinaties van SSA en 
Gallium-68 beschikbaar; 68Ga-DOTATOC,	 68Ga-DOTANOC en 68Ga-DOTATATE. Deze 
SSAs gelabeld met Gallium-68 hebben allemaal een andere affiniteit voor de verschil-
lende	subtypen	van	de	somatostatine	receptor,	maar	ze	hebben	overeenkomstig	allemaal	
een goede affiniteit voor receptor subtype 2. Ondanks hun verschillende affiniteiten is de 
sensitiviteit voor de detectie van NETs min of meer gelijk (3). 
Voor	 therapie	kunnen	SSAs	worden	gelabeld	met	de	 radionucliden	Yttrium-90	en	Lute-
tium-177,	welke	bèta	straling	uitzenden.	Hoewel	er	geen	directe	vergelijking	beschikbaar	
is	tussen	deze	twee	radionucliden,	zijn	de	PFS	en	OS	min	of	meer	hetzelfde	(4).	Het	grote	
nadeel van Yttrium-90 is het optreden van bijwerkingen door de hogere energie van dit 
radionuclide en dit heeft met name betrekking op de nierfunctie.
In dit proefschrift worden verschillende aspecten van de beeldvorming en therapie van 
NETs met radioactief gelabelde SSAs besproken. 
Hoofdstuk 1 is een algemene introductie over NETs en het geeft een overzicht van de ver-
schillende beeldvorming en therapeutische opties welke op dit moment beschikbaar zijn 
voor NETs.
Hoofdstuk 2 is een review van de literatuur over beeldvorming van NETs met nucleaire 
technieken. De verschillende resultaten van beeldvorming met radioactief gelabelde SSAs 
worden besproken. Op dit moment worden 111In-DTPA-octreotide en Gallium-68 gelabelde 
SSAs	het	meest	gebruikt.	Naast	deze	tracers,	zijn	er	ook	andere	PET-tracers	zoals	11C-5-
HTP en 18F-DOPA	 ontwikkeld.	 Voor	 het	 lokaliseren	 van	 insulinomen	 is	 beeldvorming	
gericht	 op	 de	 glucagon-like	 peptide-1	 receptor	 (Exendine-4)	 een	 veelbelovende	 nieuwe	
techniek. 
In hoofdstuk 3 worden de incidentie en de mechanismen voor fysiologische uptake in de 
pancreaskop op 111In-DTPA-octreotide scans beschreven. 178 scans met een single foton 
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emissie	 tomografie	(SPECT)/CT	van	de	bovenbuik	werden	geanalyseerd.	Opname	in	de	
pancreaskop	 (processus	uncinatus)	werd	gezien	bij	46/178	patiënten	met	SPECT/CT	en	
bij	 12	 patiënten	 werd	 uptake	 gezien	 in	 de	 pancreaskop	met	 de	 planaire	 beeldvorming.	
Bij	patiënten	met	diabetes	mellitus	(DM)	werd	dit	 twee	keer	zo	vaak	gezien.	Aangezien	
eerdere casuïstische beschrijvingen uptake in de pancreaskop hebben aangetoond bij PP-
cel	 hyperplasie	 en	90%	van	deze	 cellen	 in	de	pancreaskop	gelokaliseerd	 zijn,	 is	PP-cel	
hyperplasie	de	meest	waarschijnlijke	verklaring	voor	deze	opname.	Ook	kunnen	patiënten	
met	DM	een	verhoogd	serum	PP	hebben,	wat	de	verhoogde	incidentie	bij	deze	patiënten	
zou kunnen verklaren. 
Hoofdstuk 4 is een review van de literatuur over PPRT. De resultaten en bijwerkingen 
van de verschillende gelabelde SSAs worden besproken. De objectieve respons cijfers 
die worden gerapporteerd voor PRRT liggen tussen 15-35%. De resultaten kunnen ver-
schillen	voor	de	verschillende	radionucliden	en	soorten	primaire	tumoren.	Vergeleken	met	
historische controlegroepen en de andere beschikbare therapeutische opties voor gemetas-
taseerde	en	inoperabele	NETs,	zijn	de	PFS,	TTP	en	OS	in	het	algemeen	beter	voor	PRRT.	
Ernstige lange termijn bijwerkingen zijn zeldzaam en de incidentie hiervan verschilt per 
radionuclide.	Bij	Yttrium-90	wordt	niertoxiciteit	gerapporteerd	tot	in	9%	van	de	patiënten.	
Andere ernstige bijwerkingen op de lange termijn zijn het myelodysplatisch syndroom 
(MDS)	en	acute	leukemie	(AL).	Dit	komt	voor	bij	ongeveer	2-3%	van	patiënten.	
In	hoofdstuk	5	wordt	de	effectiviteit	op	de	lange	termijn,	overleving	en	bijwerkingen	van	
de behandeling met 177Lu-DOTATATE	van	patiënten	met	gastroenteropancreatische	(GEP)	
en	bronchiale	NETs	beschreven.	Vanaf	2000	werd	een	grote	groep	van	ruim	1200	patiënten	
behandeld en gevolgd op onze afdeling. De objectieve respons bij 443 Nederlandse pa-
tiënten	welke	minimaal	600	mCi	177Lu-DOTATATE hebben toegediend gekregen was 39% 
en	stabiele	ziekte	werd	gevonden	bij	43%	van	alle	patiënten.	PFS	was	29	maanden,	TTP	36	
maanden	en	overleving	63	maanden.	Toxiciteit	op	de	lange	termijn	omvat	AL	in	4	patiënten	
(0.7%)	en	MDS	bij	9	patiënten	(1.5%).	Therapie-gerelateerd	nier-	of	lever	falen	werd	niet	
gevonden.	Vergeleken	met	alle	andere	therapeutische	opties,	welke	op	dit	moment	beschik-
baar	zijn	voor	de	behandeling	voor	inoperabele	en	gemetastaseerde	NETs,	is	bij	PRRT	met	
177Lu-DOTATATE de PFS en TTP beter. 
Hoofdstuk 6 beschrijft de valkuilen waarmee rekening moet worden gehouden bij de re-
spons evaluatie na PRRT met 177Lu-DOTATATE. Een verhoging van de serum transami-
nasen	wordt	gezien	bij	24%	van	alle	patiënten.	Ook	een	verhoging	van	de	de	tumor	marker	
chromogranine	A	(CgA)	werd	gezien	bij	29%	van	de	patiënten.	Er	was	geen	verschil	in	de	
stijging	van	tumormerkstoffen	tussen	patiënten	met	een	objectieve	respons	en	progressieve	
ziekte	als	uitkomst	na	therapie.	Op	beeldvorming	kunnen	patiënten	met	stabiele	ziekte	een	
tijdelijke	toename	van	de	tumorgrootte	krijgen,	welke	niet	is	gerelateerd	aan	de	uitkomst	
na therapie. Een toename van de tumorgrootte van minimaal 10% werd gezien bij 9% van 
de	patiënten	met	stabiele	ziekte.	Clinici	moeten	derhalve	rekening	houden	met	het	feit	dat	
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deze veranderingen waarschijnlijk door stralingsgerelateerde inflammatie veroorzaakt zijn 
en niet gerelateerd zijn aan de uiteindelijke uitkomst van deze therapie. Meerdere tumor 
metingen zijn daarom nodig om een onderscheid te maken en om progressie te bevestigen.
In hoofdstuk 7 wordt de beste manier om progressie te bevestigen na therapie met 177Lu-DO-
TATATE	beschreven.	In	de	follow-up	krijgen	patiënten	bloedtesten,	nucleaire	en	radiolo-
gische beeldvorming. Een duidelijk antwoord op de vraag wat de beste methode is om 
progressie te detecteren kan niet worden gegeven. Als we de verschillende biochemische 
markers	en	de	cholestatische	leverenzymen	vergelijken,	heeft	het	CgA	de	hoogste	sensiti-
viteit	voor	de	detectie	van	progressie.	Helaas	is	bij	een	deel	van	de	patiënten	geen	stijging	
van de biochemische markers zichtbaar op het moment van progressie. Het is daarvoor 
noodzakelijk om een combinatie van biochemische markers en beeldvorming te maken bij 
alle	patiënten	om	geen	patiënten	met	progressieve	ziekte	te	missen.	Misschien	lukt	het	in	
de	toekomst	om	hiervoor	moleculaire	markers,	zoals	bijvoorbeeld	de	NETest	te	gebruiken.	
Toekomstvisie 
Met de recente publicatie van de uitstekende resultaten van de NETTER-1 studie bij pa-
tiënten	met	 vergevorderde	middendarm	NETs,	 is	 het	 de	 verwachting	 dat	 het	 177Lu-DO-
TATAAT	binnenkort	wereldwijd	beschikbaar	komt	voor	alle	patiënten	met	NETs.	De	NET-
TER-1 studie heeft aangetoond dat 177Lu-DOTATAAT gecombineerd met octreotide LAR 
een langere PFS en een betere tumorrespons geeft dan alleen behandeling met een hoge 
dosis	octreotide	LAR	(5).	De	doelgerichte	therapieën	die	op	dit	moment	zijn	geregistreerd	
voor NET van het pancreas zijn everolimus en sunitinib. Een directe vergelijking tussen 
deze	doelgerichte	therapieën	en	177Lu-DOTATOC wordt op dit moment uitgevoerd. 
Om de effectiviteit van PRRT te vergroten is door verschillende onderzoeksgroepen de 
combinatie met chemotherapie onderzocht (6-9). De studies laten een betere tumorrespons 
zien	dan	PRRT	alleen,	echter	op	dit	moment	zijn	er	nog	geen	directe	vergelijkende	studies	
beschikbaar. De resultaten van een directe vergelijking tussen 177Lu-DOTATAAT en de 
combinatie	van	dit	middel	met	capecitabine	(Xeloda)	worden	op	dit	moment	geëvalueerd	
in ons centrum.
NETs van het pancreas kunnen inoperabel zijn door ingroei in de bloedvaten. In onze 
studie hebben we gevonden dat tumoren van het pancreas de beste tumorrespons van 
48% laten zien op PRRT. Na een significante verkleining van de tumor met therapie met 
177Lu-DOTATAAT,	 kunnen	 sommige	 tumoren	 operabel	worden.	Daarom	wordt	 therapie	
met 177Lu-DOTATAAT ook wel gebruikt in de neoadjuvante setting. Een publicatie van van 
Vliet	en	collegae	(10)	laat	zien	dat	succesvolle	chirurgie	na	PRRT	mogelijk	werd	bij	9/29	
patiënten	(31%)	met	aanvankelijk	inoperabele	tumoren	van	het	pancreas.	
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Aangezien	de	meeste	metastasen	van	NETs	gelokaliseerd	zijn	in	de	lever,	is	het	mogelijk	
dat	intra-arteriële,	danwel	locoregionale	toediening	van	177Lu-DOTATAAT direct in lever-
slagader (arteria hepatica) een betere tumorrespons kan geven dan systemische therapie 
(11-13). Pool en collegae (13) toonden aan dat een twee keer hogere dosis in de lever kon 
worden bereikt dan na intraveneuze toediening. Ook studies met PET beeldvorming met 
het 68Ga-DOTATOC	 liet	 een	3,75	keer	hogere	SUV	 in	 levermetastasen	zien	na	 intra-ar-
teriële	 toediening	 in	 the	 arterie	 hepatica	 ten	 opzichte	 van	 systemische	 toediening	 (14).	
Andere klinische studies hebben betere therapeutische resultaten na locoregionale ther-
apie	laten	zien	dan	na	systemische	therapie	bij	patiënten	met	levermetastasering.	Directe	
vergelijkende	studies	zijn	echter	niet	beschikbaar	(11,12).	
Helaas	wordt	de	NET	ziekte	bij	het	merendeel	van	de	patiënten	uiteindelijk	weer	progressief	
ondanks	een	initiële	goede	reactie	op	therapie	met	177Lu-DOTATAAT.	Wanneer	patiënten	
de eerste PRRT cycli goed hebben verdragen en wanneer er een objectieve respons danwel 
klinische	verbetering	was,	dan	is	het	goed	mogelijk	om	patiënten	opnieuw	te	behandelen	
met	extra	cycli	met	het	177Lu-DOTATAAT. PRRT als herbehandeling geeft redelijk goede 
resultaten en heeft beperkte bijwerkingen (15-17). Met behulp van grotere studies zal het 
mogelijk worden om de bijwerkingen op de lange termijn in kaart te brengen.
Een andere strategie om de uptake in de tumoren te verhogen is het gebruik van somatosta-
tine antagonisten in plaats van agonisten. In het verleden werd aangenomen dat radioactief 
gelabelde peptiden moeten worden geïnternaliseerd in de cel om het effect te vergroten. De 
antagonisten	internaliseren	niet	in	de	cel,	maar	binden	alleen	aan	de	receptor	op	het	opper-
vlak	van	de	cel.	Verrassend	genoeg	bleek	bij	preklinisch	onderzoek	dat	de	somatostatine	
antagonist 177Lu-DOTA-JR11 een vijf keer hogere uptake had dan het 177Lu-DOTATAAT 
(18).	De	eerste	studie	bij	patiënten	met	177Lu-DOTA-JR11 liet zien dat het eveneens mo-
gelijk	is	om	dit	preparaat	toe	te	dienen	bij	NET	patiënten	en	dat	de	opname	in	de	tumor	
1,7-10,6	keer	hoger	was	dan	met	het	177Lu-DOTATAAT (19). Er zijn echter nog geen grote 
studies of directe vergelijkingen met agonisten verricht en de (lange termijn) bijwerkingen 
van deze antagonisten zijn nog niet bekend. 
Een andere aanpak om de respons op PRRT te verbeteren is het gebruik van alfa emitters. 
Radionucliden die alfastraling uitzenden hebben een korter cel doordringend vermogen 
dan	bèta	emitters.	Echter,	alle	energie	wordt	geabsorbeerd	in	het	weefsel	en	daardoor	kan	
er	meer	DNA-schade	plaatsvinden.	De	geabsorbeerde	dosis	op	andere,	gezonde	organen	is	
lager	door	het	kortere	doordringend	vermogen.	De	eerste	studie	bij	NET	patiënten	waarbij	
gebruik gemaakt werd van het 213Bi-DOTATOC liet veelbelovende resultaten zien met een 
objectieve	respons	of	stabiele	ziekte	na	12	maanden	bij	alle	7	patiënten	(20).	
Een nieuwe diagnostische methode om de respons op PRRT te voorspellen is de NETest 
(21). Deze test maakt gebruik van circulerende transcript analyses in NETs en kan de ef-
fectiviteit	van	PRRT	voorspellen	(22,23).	In	de	toekomst	is	dit	een	veelbelovende	optie	om	
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de respons te voorspellen voor aanvang van de PRRT en om progressie te detecteren. Op 
dit moment wordt deze test alleen gebruikt in studieverband en nog niet in de dagelijkse 
praktijk. 
Concluderend is PRRT met radioactief gelabelde somatostatine analogen een effectieve 
en veilige therapie voor NETs. De tumorrespons is goed en de PFS is langer dan met de 
andere	therapieën	die	momenteel	beschikbaar	zijn.	Met	de	nieuwe	ontwikkelingen	op	het	
gebied	van	beeldvorming	zullen	hopelijk	meer	patiënten	de	juiste	behandeling	op	het	juiste	
moment	krijgen	en	kunnen	we	bij	meer	patiënten	hun	ziekte	onder	controle	krijgen.	
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Summary of PhD training and teaching
Erasmus MC department:  Radiology & Nuclear Medicine 
PhD period:  2013-2017
Promotoren:		 Prof.dr.	D.J.	Kwekkeboom,	Prof.dr.	W.W.	de	Herder
PhD training
Course	‘Radiation	safety,	level	5B’		 2011	 1,5
Course	‘Radiation	safety,	level	3’		 2013	 12
Journal club meetings Nuclear medicine  2011-2017 1 
Research	meetings,	dept	Nuclear	medicine		 2011-2017	 1	
Presentations / posters at conferences
Annual Congress of the European Association of Nuclear Medicine  
(EANM) Birmingham 2011 (poster) 2011 2
Annual Congress Radiological Society of North America  
(RSNA) Chicago 2011 (poster)  2011 2
NVNG	Najaarsbijeenkomst	2014	(oral)	 2014	 2
Annual meeting of the North American Neuroendocrine Tumor Society  
(NANETS) Jackson 2016 (oral and 2 posters) 2016 2
Annual Congress of the European Association of Nuclear Medicine 
(EANM) Barcelona 2016 (poster) 2016 2
Annual Congress of the European Neuroendocrine Tumor Society 
(ENETS) Barcelona 2017 (oral and poster) 2017 2
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Teaching activities
Supervising	practicals	medical	students	2th	year		 2011-2016	 0,5
Education nuclear medicine at start internships  2011-2016 1
In-hospital	teaching	for	nuclear	medicine	technologists		 2014-2016	 0,5
Continuing	education	for	technicians	(NVMBR)	 2016	 2	

List of abbreviations
166
α-SU	 α-subunit	of	glycoprotein	hormones
AADC	 aromatic	amino	acid	decarboxylase
ACTH adrenocorticotrophic hormone
AJCC American Joint Committee on Cancer
AL acute leukemia
ALP alkaline phosphatase
ALT alanine aminotransferase
AST aspartate aminotransferase
11C-5-HTTP	 β-[11C]-5-hydroxy-L-tryptophan	
CgA chromogranin-A
CI	 confidence	interval
Ci Curie
CR complete response
CRF case report form
CT computed tomography 
CTCAE Common Terminology Criteria for Adverse Events
DM  diabetes mellitus
DOTA	 1,4,7,10-tetraazacyclotetradecane-1,4,7,10-tetraacetic	acid
DTPA diethylenetriaminepentaacetic acid
EANM European Association of Nuclear Medicine 
EBRT	 external	beam	radiotherapy
EMA European Medicines Agency
ENETS European Neuroendocrine Tumor Society
EUS endoscopic ultrasound 
18F-DOPA	 6-18F-L-3,4-dihydroxyphenylalanine
18F-FDG	 18-F-fluordeoxyglucose
FDA Food and Drug Administration (USA)
5-FU	 5-fluorouracil
68Ga Gallium-68
68Ga-DOTANOC	 [68Ga-DOTA,1-nal3]octreotide
68Ga-DOTATATE	 [68Ga-DOTA0,	Tyr3]octreotate
68Ga-DOTATOC	 [68Ga-DOTA0,	Tyr3]octreotide
68Ga-SSA 68-Gallium labeled somatostatin analogs
G grade
GBq gigabequerel
GEP gastroenteropancreatic 
GEPNET gastroenteropancreatic neuroendocrine tumor
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GGT gamma-glutamyl transpeptidase
GLP-1R glucagon-like peptide-1 receptor
Gy Gray
5-HIAA	 5-hydroxyindole	acetic	acid
Hb hemoglobin
HPF	 high-power	field
123I Iodine-123
131I Iodine-131
111In Indium-111
i.a. intra-arterial
IFN-alpha interferon-alpha 
irRC immune-related Response Criteria
i.v. intra-venous
KPS Karnofsky performance score
177Lu Lutetium-177
177Lu-DOTATATE	 [177Lu-DOTA0,Tyr3]Octreotate	
LDH lactate dehydrogenase
MC mitotic count
mCi millicurie
MDS myelodysplastic syndrome
MEN multiple endocrine neoplasia
MIBG metaiodobenzylguanidine
min minutes
MIP	 maximum	intensity	projection
MR minor response
MRI magnetic resonance imaging
mTOR mammalian target of rapamcycin
NEC neuroendocrine carcinoma
NET neuroendocrine tumor
NSE	 neuron-specific	enolase
OR objective response
ORR objective response rate
OS overall survival
PD progressive disease
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PET positron emission tomography
PFS progression free survival
pNET pancreatic neuroendocrine tumor
PP pancreatic polypeptide
PPI proton pomp inhibitors
PR partial response
PRRT peptide receptor radionuclide therapy
QOL quality of life
RCT randomized controlled trial
RECIST Response Evaluation Criteria in Solid Tumors
RFA radiofrequency ablation
RTK receptor tyrosine kinase 
SD stable disease
SNM Society of Nuclear Medicine
SPECT single photon emission computed tomography
SRS somatostatin receptor scintigraphy
SSA somatostatin analog
SSTR somatostatin receptor
STZ streptozotocin
SUV	 standardized	uptake	value
SWOG Southwest Oncology Group
99mTc Technetium-99m
99mTc-HYNIC-TOC	 99m-Tc-EDDA/HYNIC-Tyr3-octreotide	
T/nT	 tumor-to-nontumor	ratio
TC thyroid carcinoma
Tg thyroglobulin
TTP time to progression
Tyr tyrosine
VIP	 vasoactive	intestinal	polypeptide
WBC white blood cell
WHO World Health Organization
90Y Yttrium-90
90Y-DOTALAN 90Y-DOTA-lanreotide 
90Y-DOTATOC	 [90Y-DOTA0,Tyr3]octreotide
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Graag wil ik een aantal personen bedanken die hebben bijgedragen aan het tot stand komen 
van dit proefschrift. 
Mijn	promotor,	Prof.dr.	D.J.	Kwekkeboom,	Beste	Dik,	helaas	kan	je	niet	bij	deze	dag	aan-
wezig	zijn.	Vanaf	het	eerste	moment	dat	ik	op	de	afdeling	kwam,	heb	je	mij	gesteund	en	
geholpen met het onderzoek en de opleiding. Ik had mij geen betere promotor en opleider 
kunnen	wensen,	dank	voor	alles.
Mijn	tweede	promotor,	Prof.dr.	W.W.	de	Herder,	Beste	Wouter,	ik	waardeer	het	enorm	dat	
jij direct na het uitvallen van Dik de promovendi heb geholpen en bijgestaan. Je kennis van 
neuro-endocrine tumoren is zeer groot en alle manuscripten werden ontzettend snel voor-
zien van zeer nuttig commentaar teruggestuurd. Je hebt dit proefschrift zeker van betere 
kwaliteit	gemaakt,	dank	hiervoor.	
Graag wil ik de overige leden van de commissie bedanken:
Prof.dr.	M.G.E.H.	Lam,	Prof.dr.	A.	van	der	Lugt	en	Prof.dr.	G.P.	Krestin,	hartelijk	dank	
voor het lezen en beoordelen van mijn proefschrift en voor het plaatsnemen in de commis-
sie. Daarnaast wil ik graag Prof.dr. G.P. Krestin ook bedanken voor alle mogelijkheden en 
kansen die mij zijn geboden op de afdeling Radiologie & Nucleaire geneeskunde. 
De	overige	leden	van	de	grote	commissie,	Prof.dr.	C.H.J.	van	Eijck,	Prof.dr.	L.F.	de	Geus-
Oei	en	Prof.dr.	E.P.	Krenning,	hartelijk	dank	voor	het	plaatsnemen	in	de	commissie.	
Prof.dr.	E.P.	Krenning,	Beste	Eric,	dank	voor	alle	hulp	bij	mijn	artikelen	en	presentaties.	
Het is een voorrecht om samen te werken met de persoon die aan de wieg stond van de 
somatostatine receptor scintigrafie en de peptide receptor radionuclide therapie. 
Uiteraard wil ik ook alle medewerkers van de afdeling Radiologie & Nucleaire genee-
skunde	bedanken	voor	hun	hulp.	Met	name	mijn	mede-AIOS,	stafleden	en	kamergenootjes	
op	Na-25	waren	er	altijd	voor	bijstand	in	onderzoek	en	de	opleiding,	maar	zeker	ook	voor	
veel gezelligheid en een borrel. 
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